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Abstract
CLC anion transporters are found in all phylae and form a gene family of eight members in 
mammals. Two CLC proteins, each of which completely contains an ion translocation parthway, 
assemble to homo- or heteromeric dimers that sometimes require accessory β-subunits for 
function. CLC proteins come in two flavors: Anion channels and anion/proton exchangers. 
Structures of these two CLC protein classes are surprisingly similar. Extensive structure-function 
analysis identified residues involved in ion permeation, anion-proton coupling and gating and 
led to attractive biophysical models. In mammals, ClC-1, -2, -Ka/-Kb are plasma membrane Cl- 
channels, whereas ClC-3 through ClC-7 are 2Cl-/H+-exchangers in endo-lysosomal membranes. 
Biological roles of CLCs were mostly studied in mammals, but also in plants and model 
organisms like yeast and C. elegans. CLC Cl- channels have roles in the control of electrical 
excitability, extra- and intracellular ion homeostasis and transepithelial transport, whereas 
anion/proton exchangers influence vesicular ion composition and impinge on endocytosis and 
lysosomal function. The surprisingly diverse roles of CLCs are highlighted by human and mouse 
disorders elicited by mutations in their genes. These pathologies include neurodegeneration, 
leukodystophy, mental retardation, deafness, blindness, myotonia, hyperaldosteronism, renal 
salt loss, proteinuria, kidney stones, male infertility and osteopetrosis. In this review, emphasis 
is laid on biophysical structure-function analysis and on the cell biological and organismal roles 
of mammalian CLCs and their role in disease.  
I. INTRODUCTION
II. BIOPHYSICAL PROPERTIES OF CLC PROTEINS
III. CELL BIOLOGY, PHYSIOLOGY AND PATHOLOGY OF MAMMALIAN CLC PROTEINS
IV. CLC PLASMA MEMBRANE CHLORIDE CHANNELS
V. ClC-1 – THE SKELETAL MUSCLE CL- CHANNEL MUTATED IN MYOTONIA
VI. ClC-2 – A WIDELY EXPRESSED CL- CHANNEL INVOLVED IN VARIOUS PROCESSES
VII. ClC-KA/KB-BARTTIN CHANNELS – HIGHLY CELL-SPECIFIC CL- CHANNELS MUTATED IN
CERTAIN FORMS OF KIDNEY DISEASE AND DEAFNESS
VIII. VESICULAR 2CL-/H+ EXCHANGERS
IX. ClC-3 – A WIDELY EXPRESSED, MAINLY ENDOSOMAL CL-/H+ EXCHANGER
X. ClC-4 – A VESICULAR CL-/H+ EXCHANGER WITH SLOWLY EMERGING ROLES
XI. ClC-5 – A KIDNEY-SPECIFIC CL-/H+ ANTIPORTER INVOLVED IN RENAL ENDOCYTOSIS
XII. ClC-6 – A LATE ENDOSOMAL CL-/H+ EXCHANGER OF NEURONS
XIII. ClC-7 – A LYSOSOMAL CL-/H+ ANTIPORTER MUTATED IN OSTEOPETROSIS AND
NEURODEGENERATION




Chloride is the most abundant anion and serves many different biological roles. As a counterion 
for Na+ and K+, chloride ensures electroneutrality both under steady state and during transport 
across cellular membranes, as exemplified by transepithelial transport and acidification of 
intracellular vesicles. Owed to its high concentration, it serves, together with positively charged 
counterions, as important osmolyte to drive water across cellular membranes in cell volume 
regulation and transepithelial secretion or absorption of water. Chloride may also have 
‘chemical’ roles by binding to proteins and thereby modifying their function. Examples are given 
by the lysosomal enzyme cathepsin C, the activity of which is modulated by the binding of 
chloride to the protein (138) and WNK protein kinases (616, 646, 830), but many other proteins 
are known to be chloride-sensitive (207). Chloride transport across cellular membranes 
generates electrical currents if its transport is not strictly coupled to that of other ions, such as 
in ‘electroneutral’ K+Cl- or Na+K+2Cl- cotransporters or Cl-/HCO3- exchangers. Cl- channels can 
therefore change the voltage across the plasma membrane and thereby influence the electrical 
excitability of neurons, muscle, and endocrine cells (310, 423, 477, 572, 702). Cl- channels might 
also influence the voltage of intracellular organelles, but most likely the main Cl- transporters of 
endosomes and lysosomes are 2Cl-/H+-exchangers of the CLC gene family, which encompasses 
both these exchangers and Cl- channels. These exchangers also generate currents (are 
‘electrogenic’), but, as discussed below, coupling of Cl- to H+ transport has additional important 
implications for their biological roles. 
The direction of Cl- transport through channels is entirely determined by the transmembrane 
gradient of the electrochemical potential, which is given by the difference in Cl- concentration 
and the transmembrane voltage according to the Nernst equation. Whereas in mammals the 
serum concentration of Cl- is universally high (~120 mM) and intracellular chloride 
concentration ([Cl-]int) much lower, different cell types display a wide range of  [Cl-]int (from ~5-
10 mM in most mature neurons up to ~40 mM in epithelial cells). This large difference in [Cl-]int 
is mainly due to differential expression of secondarily active Cl- transporters that either increase 
(e.g. Na+K+2Cl- cotransporters or Cl-/HCO3- exchangers) or decrease (like K+Cl- cotransporters)  
[Cl-]int (201, 889). Hence opening of Cl- channels may either hyperpolarize or depolarize the 
plasma membrane. In stark contrast, opening of Na+ and Ca2+ channels will almost always 
depolarize the cell owing to the large inwardly-directed ion gradient and the inside-negative 
voltage. 
For a long time, the study of chloride channels had been neglected. The interest focused on 
voltage- or ligand-gated cation channels that underlie action potential conduction and synaptic 
transmission (343). In fact, Cl- channels were often considered a nuisance and their currents 
were often eliminated when studying cation channels. Notable exceptions are the large 
chloride conductance of skeletal muscle, that amounts to about 80% of the resting conductance 
4 
 
(83, 364, 477, 617), and inhibitory GABA and glycine receptor anion channels (300, 572, 752). In 
the 1980’s the application of the patch clamp technique revealed the presence of cation and 
anion channels in practically all cells (95, 343, 776). 
The first voltage-gated chloride channel to be molecularly identified was ClC-0, the founding 
member of the CLC gene family (393). Thomas Jentsch and colleagues cloned it from the 
electric organ of the marine ray Torpedo which is a rich source for ion channels that are needed 
to generate the large currents which these animals use to stun their prey. Besides the nicotinic 
acetylcholine receptor cation channel, which also was first cloned from this organ (596), the 
Torpedo electroplax contained a peculiar chloride channel which had been discovered by Chris 
Miller upon reconstituting electric organ membrane proteins into lipid bilayers (905), in this 
way establishing the first high resolution single channel recordings from lipid bilayers (548). 
Detailed biophysical analysis by Miller and colleagues strongly suggested that the channel 
contained two largely independent pores (324, 548, 549), a prescient conclusion amply 
confirmed after its molecular identification (211, 491, 492, 543, 897). Thomas Jentsch at first 
tried to identify the channel protein by its ability to covalently bind DIDS (388), which Chris 
Miller had shown to irreversibly inhibit the channel at micromolar concentrations (549). 
Following the failure of his approach (388), Jentsch and colleagues finally identified the channel 
using a painstaking combination of hybrid depletion and functional expression in Xenopus 
oocytes (393). After having identified the mammalian skeletal muscle chloride channel, which 
they named ClC-1 (for Cl- Channel 1), they proposed to name the prototype Torpedo channel 
ClC-0 (807). Personal accounts of Jentsch’s and Miller’s initial discoveries can be found in two 
recent reviews (385, 547). 
Using homology based methods, first in wet-lab experiments using hybridization of cDNA 
libraries with radioactive probes (807, 808, 832) and later in silico once large-scale DNA 
sequencing took off, CLC proteins (FOOTNOTE) were subsequently  identified in all phyla, with 
nine human CLC genes (384, 385) (Fig. 1). Apart from the skeletal muscle ClC-1 channel, whose 
function was known before its molecular identification (807), the function of the remaining 
CLCs was unknown. The study of their biochemical and biophysical properties and of their 
physiological role and their involvement in human genetic diseases led to the clarification and 
discovery of many biological and pathological processes (384, 802). A particularly important 
discovery was that several CLCs reside in the endo/lysosomal system (307, 429) and that these 
intracellular CLCs are actually not chloride channels but secondarily active, strictly coupled 2Cl- 
/1H+ antiporters (5, 651, 742). The precise physiological role of these intracellular transporters 
is still not fully understood. 
It should be mentioned that there are several structurally unrelated Cl- channel classes besides 
CLCs. These include the Cystic Fibrosis Transmembrane Conductance Regulator CFTR (480, 703), 
pentameric ligand-gated anion channels like GABA- and glycine-receptors (300, 752), Ca2+-
activated Cl- channels of the bestrophin (327, 818) and TMEM16 (or Anoctamin) (104, 605, 756, 
928) gene families, LRRC8 proteins that form volume-regulated anion channels (VRACs) (681, 
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865), and maxi-anion channels (723) that may be formed by the organic anion transporter 
SLCO2A1 that is known as prostaglandin transporter (724). This list is not complete and several 
biophysically characterized anion channels remain to be identified at the molecular level. 
However, several protein classes previously postulated to represent Cl- channels are now 
known not to function as ion channels, such as CLCAs (‘chloride channel, Ca2+-activated’) (75, 
288) and CLICs (‘chloride intracellular channel’) (30). The names given to these proteins are
misnomers and a source of confusion.
In the present review we will first provide a description of the general structural architecture of 
CLC proteins, general mechanisms of ion transport in CLC channels and transporters, and 
mechanisms of gating in the prototype ClC-0 channel, a well-studied channel that serves as a 
reference for other CLCs.  
We will then review the current knowledge on the properties of the nine mammalian CLCs and 
their associated β-subunits (Fig. 1). A particular focus will be laid on their physiological 
functions as highlighted by mouse models and human inherited disease. The associated 
pathologies impressively demonstrate the important, and often unexpected, role of chloride 
transport in many different tissues and cellular organelles.  
Finally we will summarize briefly the literature on CLC proteins in various model organisms and 
in plants. 
II. BIOPHYSICAL PROPERTIES OF CLC PROTEINS
CLC proteins exhibit several unique peculiar properties. These include the homodimeric 
architecture with independent ion transport in each subunit, the existence of passive channels 
as well as secondary active transporters, and the exquisite voltage-dependent regulation of CLC 
function by the transported substrates – anions and protons (126, 384, 385, 802, 964). 
A. The double barreled Torpedo ClC-0 channel
The first electrophysiological recordings of the Torpedo electroplax Cl- channel in planar lipid 
bilayers by Miller and colleagues revealed a peculiar “double barreled” single channel behavior 
(Fig. 2A). Single channels opened in bursts, separated by long closures. During each burst two 
equally spaced open conductance levels were visible that appeared to originate from the 
independent gating of two physically separated Cl- channels (324, 548, 828). Collectively, this 
behavior could be explained by a “double-barreled shotgun” model: Two identical protopores 
are present in the complex, each bearing a proper “fast gate” giving rise to the binomial gating 
behavior within a burst. A common “slow gate” is able to shut off both pores simultaneously 
(548, 550). The protopore gate was found to be voltage-dependent with an apparent gating 
valence around 1 elementary charge (324, 548). Direct evidence for the model was obtained by 
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applying low concentrations of DIDS which led to the sequential, irreversible inhibition of single 
protopores (549) (Fig. 2A). A further peculiarity of the Torpedo channel gating, namely a 
violation of microscopic reversibility, was revealed by single channel recordings in bilayers: 
Channels entered a burst predominantly into a state with both protopores being open, while 
bursts terminated predominantly from a state in which only one of the protopores was open 
(697). Such a time asymmetry is only possible in a system that is not in thermodynamic 
equilibrium and requires the dissipation of free energy to fuel the gating process. Initially, 
Richard and Miller concluded that the electrochemical Cl- gradient was the underlying source of 
free energy (697). More recently, Lísal & Maduke (478) discovered that not the Cl- gradient but 
instead the electrochemical H+ gradient quantitatively correlates with the degree of 
irreversibility of the gating process. This finding demonstrates unambiguously that protons are 
permeating through the ClC-0 channel in a manner that is coupled to the gating processes 
(970). In more general terms, such a behavior strongly favors the hypothesis that CLC anion 
channels evolutionary arose from stoichiometrically coupled anion / proton exchangers, losing 
most, but not all of their coupling efficiency (479, 546). It is nevertheless still a mystery how the 
common gate of the Torpedo channel that acts on both pores simultaneously is related to the 
better understood fast protopore gate or to the anion / proton exchange mechanism of CLC 
antiporters. The question is even more intriguing considering that the anion / proton exchange 
mechanism is independent of the dimeric structure (446, 705, 941). 
The cloning of the ClC-0 Torpedo channel (393), followed by the rapid identification of 
mammalian CLC genes (see (387)), allowed to investigate the architecture of CLC proteins using 
molecular methods. Importantly, the single cDNA encoding the 805 amino acid ClC-0 protein 
was able to fully reproduce the biophysical behavior of the Torpedo channel (50), 
demonstrating that the channel is homomeric. Early functional experiments using the ClC-2 
channel showed that the N-terminus and the large C-terminal domain (after amino acid E526) 
are entirely cytoplasmic (303). A multimeric structure of ClC-1 could be inferred from dominant 
negative functional effects of dominant myotonia causing mutations (806). Biochemical 
analysis, and concatamers and / or co-expression of WT and mutant ClC-0 or ClC-1 channels 
with different functional properties unambiguously showed that CLC channels are homodimers 
(492, 543, 544). Importantly, single channel analysis demonstrated that each subunit forms a 
proper protopore (492, 543) (see Fig. 2B), whose gating was completely independent from the 
neighboring pore (491). Such an architecture is quite different from that of classic ion channels 
like voltage-gated cation channels, in which a central ion conducting pore is formed at the 
interface of identical or homologous subunits (343), imposing thus a straight pore 
perpendicular to the membrane plane. 
The transmembrane topology of CLC proteins had been explored using a variety of techniques, 
correctly identifying the orientation of several membrane helices and intra/extracellular 
localization of loops (228, 303, 415, 437, 489, 544, 750). However, in retrospect, given the 
complex architecture revealed by CLC crystal structures, a full determination of the membrane 
topology was extremely challenging.  It is also interesting to note that functional CLC channels 
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can be formed from the separate expression of various pieces of the protein (223, 505, 512, 
560, 749) suggesting that CLC proteins are composed of modular domains that can fold 
independently and then associate. 
 
B. Structure of CLC proteins 
Eukaryotic, and in particular mammalian membrane proteins are generally more difficult to 
purify in large quantities needed for crystallization compared to prokaryotic proteins. As for K+ 
channels (200), bacterial homologues have been extremely useful to obtain direct structural 
information on CLC proteins. In pioneering studies, Maduke et al. (511) purified a CLC-
homologue from E. coli and biochemically confirmed a dimeric structure. A 2D-projection 
structure of EcClC-1 was in agreement with a homodimeric double-pore structure but the 
resolution of 6.5 Å was too low to allow further structural insight (553). A breakthrough was the 
determination of the crystal structures of EcClC-1 and of the highly homologous StClC from S. 
typhimurium (210, 211). In full agreement with the double pore architecture deduced from the 
functional studies, the crystal structures revealed a homodimeric structure with anion binding 
sites in the center of each subunit (Fig. 3A, B). Each subunit has a triangular shape (viewed from 
the outside or from the inside) and the subunits are interacting with a large, mostly 
hydrophobic and roughly planar interface of about 2300 Å2 suggesting a very strong binding of 
the two monomers. Indeed, using single molecule photobleaching of fluorescently labeled 
EcClC-1 subunits reconstituted into liposomes at very low density, Chadda et al. could estimate 
the free energy of dimerization finding that the CLC dimer is one of the strongest protein 
complexes measured so far (114). 
The subunits are composed of 18 alpha helices (denominated A-R), 17 of which are partially 
embedded in the membrane (Fig. 3C). Most helices are tilted and in addition several helices are 
not traversing the membrane completely, resulting in the presence of small loops within the 
membrane, which have important roles in anion coordination. A surprising feature emerging 
from the crystal structure was that each monomer presents an internal pseudo-symmetry: 
Helices A-I assume a structure similar to that of helices J-R but with an inverted membrane 
orientation (210) (Fig. 3C). Similar inverted repeat topology architectures have been found in 
many classes of membrane transporters (262), and in most cases the substrate binding sites are 
located at the interaction face of the two repeats. Two anion binding sites could be identified in 
the WT structure, called Scen and Sint (Fig. 4A). The ion bound at Scen is completely buried in the 
protein, whereas the ion in Sint appears to be in direct contact with the intracellular solution. 
Access of the anion bound at Scen to the extracellular solution is impeded by the presumably 
negatively charged side-chain of E148 (Fig. 4A) (E148 and the homologous residue in other CLCs 
is also called “gating glutamate”). In fact, in the crystal structure of the charge neutralizing 
mutant E148Q, a third anion was found to be bound at the position of the E148 side-chain of 
the WT structure, defining a third anion binding site, Sext (Fig. 4B) (211). The glutamine side 
chain of Q148 was instead found to be oriented towards the extracellular solution. 
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Interestingly, in E148Q crystals grown in fluoride, the Q148 side-chain was instead found to 
occupy Sext, as the gating glutamate in the WT structure, probably being stabilized by a fluoride 
ion bound in Scen (469).  
The CmClC crystal structure gave further insight into ion binding properties of CLC proteins. The 
transmembrane part of the CmClC is very similar to that of EcClC-1 (main-chain root mean 
square deviation (RMSD) of 1.7 Å) (242).  However, the amino acid side chain of the gating 
glutamate of CmClC occupies the Scen binding site, whereas Sext is occupied by an anion. The Sint 
site is occupied by an anion in CmClC as found in EcClC-1 (Fig. 4C). 
The crystallized prokaryotic CLCs lack the extended cytosolic C-terminal domain present in 
eukaryotic CLC proteins. Based on sequence analysis, Bateman (49) and Ponting (665) found 
that the C-termini of mammalian CLC proteins harbor two so-called CBS domains (from 
cystathionine-β-synthase). CBS domains are found in many different proteins and are usually 
not involved in the main protein function but are rather believed to exert a modulatory role. In 
general, as in CLCs, CBS domains are organized in pairs that dimerize to form a stable globular 
domain (365). Isolated C-terminal fragments containing the CBS domains have been crystallized 
from ClC-0, ClC-Ka and ClC-5 (526, 541, 542). As in other proteins, CBS1 and CBS2 form a 
sandwich structure via their beta strands, with an adenine nucleotide bound between the two 
domains in the fragment of ClC-5, but not in those of ClC-Ka or ClC-0. However, the relative 
orientation of the CBS-domain pairs with regard to the membrane embedded part remained 
unclear. This question was answered by the crystallization of a eukaryotic CBS domain-
containing CLC from the thermophilic red alga Cyanidioschyzon merolae, called CmClC (242) and 
recently in the cryo-EM structure of the bovine ClC-K homologue (628). As illustrated in Fig. 3, 
in CmClC, the CBS domains form a similar sandwich structure as in the isolated fragments. 
Interestingly, CBS1 is relatively far away from the membrane domain, whereas CBS2 is in close 
contact with the membrane part. Overall the cytosolic, C-terminal part of the proteins interacts 
with the membrane part involving an interacting area of about 2300 Å2 (242). The organization 
of the CBS domains is very similar in the ClC-K structure but their orientation relative to the 
transmembrane part is rotated by about 20 degrees compared to the CmClC structure (628).  
Several studies have addressed the role of the CBS domains in CLC proteins by deletion and 
transplantation assays and expression of “split” constructs (223, 259, 280, 332, 356, 505, 512, 
560, 749, 813). Depending on the channel / transporter and on the precise location of 
deletions, divergent results regarding the effect on channel function have been reported. There 
is ample evidence that the C-terminus, including the CBS domains, is involved in the common 
gate mechanisms of ClC-0 and ClC-1 (93, 223, 259, 512). However, the specific roles of CBS1 or 
CBS2 or the various linker regions are difficult to nail down because any alteration of the C-
terminus by mutagenesis, and in particular employing deletions or chimeric constructs, is 
expected to cause non-local structural changes. This problem is profound if the crystal structure 
of CmClC is applicable to other CLCs as well. In this structure, the C-terminus, including the CBS 
domains, interacts with the membrane embedded part of the proteins through an extensive 
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interface of 3600 Å2 with a large shape similarity “similar to an antibody-antigen interface” 
(242). In light of this, it is actually very surprising that in several cases in-frame deletions of 
single or even both CBS domains were functionally tolerated with sometimes only relatively 
mild consequences (223, 280, 332, 813).  Also the large physical separation (by ~20 Å) of the C-
termini of the ClC-0 dimer upon slow gate opening reported by Bykova et al. (93) is surprising if 
the C-terminus is so tightly bound to the membrane embedded part. CBS domains have also 
been proposed to be important for for correct trafficking of ClC-5 to endosomes and of the 
yeast CLC to the Golgi, respectively (107, 760). However, unspecific effects caused by structural 
alterations cannot be easily excluded. The C-terminus of ClC-1 contains a unique proline rich 
region downstream of CBS2, in which point mutations cause myotonia by altering the common 
gate and which might form a poly-proline helix (507). It will be interesting to obtain direct 
structural insight on how this putative helix interacts with the rest of the protein.  
The interaction of the C-terminal domains with the transmembrane part has been studied 
rather extensively by Strange and coworkers in the CeClC-3 homologue from C. elegans (816), 
as discussed in more detail below. Activity of this channel is regulated by the phosphorylation 
of serine residues in the linker connecting CBS1 and CBS2, and it has been proposed that the 
phosphorylation status is communicated via CBS2 to the transmembrane helices H and I, which 
are presumably close to CBS2 (816). 
An exciting finding was that CBS domain pairs from a variety of proteins including AMP-
activated protein kinase, IMP dehydrogenase-2, ClC-2, ClC-5, and CBS itself bind AMP, ATP and 
other adenine nucleotides, suggesting that CBS domains serve as sensors of the cellular energy 
status (763, 898). No nucleotides were found in X-ray structures of C-terminal fragments from 
ClC-0 and ClC-Ka and the full length structures of CmClC and ClC-K (242, 526, 541, 628), but ATP 
or ADP molecules were tightly bound between the two CBS domains in crystal structures of the 
isolated C-terminal fragment from ClC-5 (542). For ClC-1, mutant cycle analysis, in combination 
with a homology model based on the ClC-5 CBS domain structure, confirmed that the mode of 
nucleotide binding in ClC-1 is very similar to that in ClC-5 (842). Functional studies confirmed a 
regulatory role of nucleotide binding for ClC-1 and ClC-5 (55, 57, 58, 841, 968). The 
physiological role of nucleotide regulation, however, remains unclear, since all adenine 
nucleotides are almost equally effective, and their summated cellular concentration is generally 
in the millimolar range.  
In summary, CBS domains are clearly important for CLC function, highlighted also by the 
numerous mutations found in the C-termini of ClC-1, ClC-Kb, ClC-5 and ClC-7 causing diseases. 
In ClC-1, several myotonia causing mutations in the C-terminus lead to a shift of the common 
gate to more positive potentials (51, 89, 507, 535). Interestingly, in the lysosomal ClC-7 
transporter, some C-terminal mutations actually cause a gain-of-function effect in that the 
opening kinetics is significantly faster than in WT (453), probably acting via the common gate of 
the dimer. However, intracellular ATP had no effect on ClC-7 mediated currents (453). In 
general, the physiological relevance of nucleotide binding to the CBS domains of CLC proteins is 
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far from being understood. Knock in mice (or other organisms) carrying mutations that 
abrogate nucleotide binding might help to uncover potential physiological roles of nucleotide 
regulation. 
 
At the time of the publication of the EcClC-1 crystal structures (210, 211) only rudimentary 
knowledge of the functional properties of the protein was available (375, 511). It was however 
implicitly assumed that EcClC-1 is a Cl- channel because it showed anion transport activity in a 
reconstituted system with a Cl->I- preference (511), typical of CLC channels (389, 673). In 
addition, EcClC-1 was found to be dramatically activated by acidic pH (375). It was found only 
later, in the breakthrough study of Accardi & Miller (5), that EcClC-1 is actually a secondary 
active, strictly coupled and highly electrogenic 2Cl-/1H+ antiporter, as described in detail below. 
Furthermore, because of the low overall sequence identity of EcClC-1 with mammalian CLCs 
(less than 20%) it was unclear if the structure was representative for other CLCs. However, 
several lines of evidence supported the relevance of the EcClC-1 structure for mammalian CLCs. 
First of all, in the EcClC-1 and also in CmClC crystal structures the ion binding sites are formed 
by four separate protein regions which are highly conserved in CLC proteins (210, 242) and 
which are located at the N-terminus of various helices, including the GSGIP sequence of helix D, 
the G(K/R)EGP sequence of helix F, the GXFXP sequence of helix N, and a highly conserved 
tyrosine in helix R. Most of these regions had been identified in earlier work as being important 
for gating and permeation of ClC-0 and ClC-1 channels (227, 228, 231, 234, 470, 489, 492, 677, 
806, 912). The above mentioned helices are pointing their N-terminus towards Scen, potentially 
contributing to the stabilization of anion binding via the electrical helix dipole (210). However, 
several theoretical studies doubted a significant contribution of the helix dipole to the free 
energy of anion binding (142, 236). Interestingly, the bound anions are not directly coordinated 
by positively charged lysine or arginine residues but by side-chain hydroxyls (S107, Y445 in 
EcClC-1) and by main chain amides (I356, F357 in EcClC-1). However, significant long distance 
electrostatic interactions have been inferred to arise from the highly conserved K131 (helix E) 
that is pointing its positively charged side chain towards Scen, but is shielded from it by amino 
acids from the loop connecting helices C and D and by the glycine residue following the gating 
glutamate (236). In support of a conserved role of this residue, Chen and colleagues found that 
mutating the corresponding residue in ClC-0, had dramatic effects on ion conduction and gating 
(952). Several other studies, using the EcClC-1 structure as a guide for mutational analysis fully 
confirmed the overall conservation of the CLC structure from bacteria to vertebrates (121, 219, 
224, 471, 648, 691). A further, more extracellularly located Cl- binding site had been postulated 
by theoretical studies (236). However, this binding site could not be confirmed experimentally 
by site-directed mutagenesis (952). 
A puzzling feature of the available CLC crystal structures was that despite the presence of 
bound anions, no clear continuous aqueous permeation pathway for ions could be seen, at 
difference to crystal structures of classical voltage gated or ligand gated ion channels (948). In 
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retrospect, such an “occluded state” with bound substrate shielded from either aqueous face is 
not surprising for the structure of a stoichiometrically coupled antiporter. In order to avoid 
slipping, coupled transporters must make sure that the substrates are not simultaneously 
accessible to both aqueous compartments (277). The centrally bound anion in EcClC-1 is 
completely buried in the protein. In particular the passage towards the outside is impeded by 
the side chain of the gating glutamate (E148) that is occupying Sext. Access of the anion bound 
at Scen to the inside is impeded by the side chains of S107 and Y445 (Fig. 4), even though in 
several computational studies it has been suggested that local protein fluctuations could allow 
an efficient passage through this intracellular constriction (142, 929). However, this view was 
not shared by other authors (149, 552), and it is still disputed if Y445 constitutes a physical 
“gate” of the EcClC-1 transporter (1).    
The recent cryo-EM structure of the bovine ClC-K homologue provided the first view of the 
structure of a CLC channel pore at ~ 3.8 Å resolution, even though no bound anions were 
identified (628). The overall architecture of the pore is very similar to the Cl- ion translocation 
pathway of CLC exchangers. The side-chain of V166, the corresponding residue of the gating 
glutamate, does not appear to obstruct the pathway towards the extracellular solution, 
pointing somewhat parallel to the channel wall, and the conserved tyrosine Y520 
(corresponding to Y445 of EcClC-1) is similarly positioned, probably interacting with pore 
transiting Cl- ions (628). The major difference in the pore structure, compared to CLC 
exchangers, regards the conformation of the loop connecting helices C and D which results in a 
rotation of the side-chain orientation of the conserved S121 (corresponding to S107 of EcClC-1).  
The different conformation of the loop C-D reshapes the internal vestibule such that the side-
chain of S121 points away from the pore. This configuration frees the ion passage between the 
pore and the intracellular solution, with an estimated pore radius at the intracellular 
constriction of around 1.7 Å, significantly wider than in CLC exchangers (628). In addition, in 
ClC-K the cytosolic vestibule is positively charged which could lead to a local increase in the 
concentration of Cl- ions (628). It remains to be seen if this configuration is typical of all CLC 
channels and it will be interesting to find out why mutations of the tyrosine residue in ClC-0 
have little effect on ion conductance properties (7, 471), while mutations of the serine quite 
strongly affect ion conductance and selectivity (471, 492). 
 
C. Conductance and anion selectivity of CLC channels 
The reconstituted Torpedo channel as well as the heterologously expressed ClC-0 have a linear 
single channel current voltage relationship with a single pore conductance around 8-9 pS at 
“physiological” Cl- concentrations (50, 492, 543, 548). It saturates at ~ 16 pS at high Cl- 
concentrations with a half maximal concentration of ~ 60-80 mM in a manner that is consistent 
with single pore occupancy (121, 904). However, anomalous mole fraction effects in anion 
mixtures indicate multiple ion occupancy in ClC-0 (677) as well as in ClC-1 (722) and ClC-2 (730). 
Noise analysis indicated that the single channel conductance of ClC-1 is only 1-2 pS (at negative 
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voltages) (678, 912). Single channel recordings confirmed this result and demonstrated the 
double barreled architecture of this channel as well (739). ClC-2 has a slightly larger protopore 
conductance of ~ 3 pS (595, 815, 897) (see Fig. 2B). ClC-K channels exhibit the largest protopore 
conductance values among all studied CLC channels ranging from ~15 to 22 pS for various 
isoforms (249, 293, 296, 441, 754). The Fahlke group reported that association with barttin 
altered the single channel conductance of rat ClC-K1 (249, 754), an effect that was not seen in 
mouse ClC-K1 (441). 
Several residues at the intracellular pore entry or in the intracellular part of the narrow pore 
region have been identified that lead to reductions of the ClC-0 single channel conductance 
when mutated, including I515 and K519 of helix R (121, 127, 492, 543), S123 of helix D, the 
equivalent of which is coordinating the central chloride (Cl-cen) in the EcClC-1 structure (210, 
492), E127 of helix D (121). These residues appear to exert an electrostatic control on the local 
intracellular Cl- concentration (121, 127). Surprisingly, mutating the highly conserved Y512, 
equivalent to the Cl- coordinating Y445 of EcClC-1, has only relatively small effects on single-
channel conductance and ion selectivity (7, 121, 127, 224). 
ClC-1 shows a unique feature among CLC channels in that its “instantaneous current voltage 
relationship”, whose shape mirrors that of the single-channel current voltage-relationship, is 
extremely inwardly rectifying (678, 807): outward currents do hardly increase further for 
voltages above ~40 mV. The molecular basis for this rectification is still unknown. The mutation 
G230E, affecting the highly conserved glycine two residues upstream of the gating glutamate, 
appears to eliminate the rectification (227, 234), suggesting that structures in the external pore 
are involved. In agreement with this idea, a permeation model with a high affinity Cl- binding 
site very close to the outside was able to reproduce the rectifying phenotype (721). 
CLC channels are practically impermeable to cations (905)(Pusch, unpublished result), even 
though a relative sodium permeability as large as 0.1 has been reported for ClC-1 (234). Such a 
large Na+ permeability is, however, very unlikely because it would be disastrous for the 
excitability of skeletal muscle. Among halides, CLC channels generally exhibit a Cl- ≥ Br-> I- 
selectivity sequence with iodide actually leading to channel block (222, 489, 677, 722, 806, 832, 
869, 904). Large organic anions like cyclamate and glutamate are almost completely 
impermeable, SCN- and ClO4- block ClC-0 (490, 904),  whereas NO3- is relatively permeable 
(677). The conductance of ClC-0 exhibits an anomalous mole fraction effect in Cl- / NO3- 
mixtures, indicating that two anions can be simultaneously present in the pore (677). Similar 
results have been obtained for ClC-2, which shows anomalous mole-fraction effects in  SCN- / Cl- 
mixtures (730).  
Permeability has been extensively studied for ClC-1 resulting in the following permeability 
sequence based on reversal potential measurements: SCN- ~ ClO4- > Cl- > Br- > NO3- ~ ClO3- > I- 
>> BrO3- > HCO3- >> methanesulfonate ~ cyclamate ~ glutamate (722). The minimum pore 
diameter was estimated to be ~4.5 Å and anomalous mole fraction effects were found for 
mixtures of Cl- /SCN- and Cl- / ClO4-, suggesting a multi-ion pore (722). Surprisingly, small 
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organic acids showed a significant permeability (Cl- (1) > benzoate (0.15) > hexanoate (0.12) > 
butyrate (0.09) > propionate (0.047) ~ formate (0.046)) (721), showing that ClC-1 is more 
permeable to larger hydrophic anions than to smaller less hydrophobic one. A paradoxical block 
of inward currents by these organic acids applied from the outside could be accounted for by a 
rate constant model that explained both the strong rectification of ClC-1 and the block of 
inward currents induced by these acids by a high affinity superficial anion binding site (721). 
The pore diameter of the bovine ClC-K homologue at the narrowest point was found to be ~ 3.4 
Å based on a cryo-EM structure (628), substantially smaller than the size estimated from the 
permeability ratios. Possibly, organic anions interact with the pore in a dynamic manner, which 
is not easy to capture in a static structure.  
Interestingly, also intracellularly applied benzoate blocked ClC-1 in a voltage-dependent 
manner, in a complex interplay with ClC-1 gating, which will be described in a separate 
paragraph (721). 
 
D. Interaction of gating and permeation of the prototype Torpedo ClC-0 channel  
At the single channel level, the double barreled ClC-0 exhibits two qualitatively distinct 
mechanisms of gating (see Fig. 2). Within a burst the two protopores fluctuate between open 
and closed states with relatively fast kinetics (ms time range). This gating mechanism is called 
‘fast’ or ‘protopore’ gate. In contrast, burst lengths and interburst durations are much longer, 
and the mechanism underlying this gating is called slow gate or common gate. Miller and 
colleagues found that within bursts the protopore dwell time distributions are single 
exponential and thus the fast gate of a single protopore can be phenomenologically extremely 






with opening rate constant α, closing rate constant β, and open probability popen= α /( α + β) 
(324, 548, 549). At positive voltages, popen reaches practically unity, and the voltage 
dependence of the open probability can be roughly approximated by a Boltzmann distribution 
with an apparent gating valence of about 1 elementary charge and a voltage of half maximal 
activation depending strongly on pH (324). In contrast, the slow gate shows an inverted 
voltage-dependence, opening at negative voltages (550, 905)). Pusch et al. (677) discovered 
that the open probability of the fast gate of ClC-0 strongly depends on the extracellular Cl-
 concentration. Decreasing [Cl-]ext reduced popen by “shifting” the voltage-dependence to more 
positive voltages.  Pusch et al. postulated that voltage-dependent binding of extracellular Cl- 
ions opens the fast gate, resulting in a channel that is opened by the transported substrate 
(677). This simple model provides an explanation for the fact that the apparent gating charge of 
the fast gate is ~1 elementary charge. Furthermore, the voltage-dependence of the open 
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probability in mixtures of NO3- and Cl- showed an anomalous mole-fraction effect, in parallel to 
an anomalous mole fraction effect of conduction (677). Anomalous mole fraction effects are 
considered as good evidence for the presence and the interaction of more than one ion in the 
pore of an ion channel (343). Thus, these findings strongly support the conclusion of a tight 
coupling of permeation with gating. Chen & Miller (128) investigated the Cl- dependence of fast 
gating at the single channel level, dissecting effects on the opening and on the closing rate 
constants, α and β. Interestingly, they found that [Cl-]ext  only affects α, with almost no effect 
on β.  In addition, α showed a biphasic dependence on voltage, increasing exponentially at 
positive voltage with a slope corresponding to 0.6 elementary charges. Surprisingly, at negative 
voltages both α and β increase with more negative voltage, roughly in parallel, resulting in a 
non-zero open probability, Pmin, at negative voltages (128). Pmin depends mostly on [Cl-]int via 
the closing rate constant, in an apparent “foot-in-the-door” mechanism (124, 127, 128, 489). 
Pmin is also significantly influenced by mutation at the intracellular pore entrance. For example 
mutants of lysine 519 (now known to be located at the end of helix R) dramatically increase Pmin 
(489, 677), probably by influencing the ability of [Cl-]int to stabilize the open state. Chen & Miller 
also found that the effect of [Cl-]ext on the opening rate α saturated with an apparent KD of 
roughly 50 mM (128). From their studies, Chen & Miller (128) concluded that, in contrast to the 
original hypothesis that voltage-dependent binding to the pore confers the voltage-dependence 
of gating (677), Cl- binds in a voltage-independent manner to a superficial site. Opening is, 
however, coupled to Cl- permeation in subsequent voltage-dependent translocation step (128, 
669). A further detailed analysis of the [Cl-]ext dependence of fast gating was performed by Engh 
and Maduke (218), who found that their data but also the data of Chen & Miller (128) are 
actually more compatible with the idea that voltage-dependent binding of extracellular Cl- leads 
to fast gate opening (218) as in the original proposal (677). 
The dependence of the fast gate on intracellular Cl- and on amino acid residues at the 
intracellular pore entrance has been studied in great detail by Chen and colleagues (127). As a 
general rule, similar to [Cl-]int itself, also mutations at the intracellular end of the pore mostly 
affect gating by altering the closing rate constant with litte effect on the opening rate constant, 
via an electrostatic control of Cl- passage between the cytoplasmic solution and the deeper 
pore.  
The crystal structures of EcClC-1 provided important insight into possible molecular 
mechanisms underlying the Cl- dependence of fast gating (210, 211). Mutating E148 in EcClC-1 
to glutamine, “freed” the external anion binding site to be occupied by a third Cl- ion (Fig. 4). 
The analogous mutations in ClC-0 (E166Q, E166A) led to constitutively open, voltage-
independent channels (211, 838). This simple result pointed to E166 of ClC-0 as the essential 
structural part of the fast gate (hence the name “gating glutamate”). Furthermore, Dutzler et al. 
found, in agreement with Chen & Chen (120), that extracellular acidification led to large 
increase of the open probability of WT ClC-0. This was interpreted as being caused by a 
protonation of the gating glutamate from the outside, resulting in a structure mimicking the 
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E166Q mutant, with the side chain of the gating glutamate moving out of the permeation 
pathway (209, 211). Thus, a simple negatively charged side-chain obstructing the pore in the 
closed state, and being dislodged either by competition with permeating Cl- ions or by 
protonation mediated neutralization to open the channel is a very attractive simple model for 
the protopore gating process.  
However, the dependence of the fast gating process on voltage and intra- and extracellular pH 
and Cl- concentration is complex, and several details are still not fully understood. Furthermore, 
some experimental results are difficult to reconcile with this simple picture. For example, using 
the small molecule blocker, p-chloro-phenoxy acetic acid (CPA) as a tool, Accardi et al. (7) and 
Traverso et al. (838) concluded that fast gating is accompanied by conformational changes in 
addition to the simple side-chain movement of the gating glutamate. However, it cannot be 
excluded that the effects of the CPA blocker on gating were indirectly caused by effective 
alterations of local pH or Cl- concentration. In this respect, it is interesting to note that the 
affinity of CPA and other small molecules, which act exclusively when applied from the 
intracellular side, strongly depends on the chemical nature of the side present at the place of 
the gating glutamate (838, 954). Mutating E166 in amino acids with small side chains (Ala, Gly) 
results in high affinity block, whereas larger side chains result in low affinity block (954) even 
though practically all of these mutants have a completely open fast gate. Removing the side-
chain of the gating glutamate in mutant E166G allowed even the punch-through of small 
molecules like CPA through the pore of the channel (951). Thus, these small molecules clearly 
interact with the side chain in position 166, which is relatively difficult to reconcile with the idea 
that the side chain is oriented towards the outside in the open mutants. 
Among all studied mutants of the gating glutamate, E166D, in which the side-chain is shortened 
by just one CH2 group, has the most complicated effect (839). Using tandem-dimeric constructs 
with E166A, Traverso et al. could demonstrate that this mutant has an extremely low open-
probability (839). Low pHext induced an inward Cl- current with a small single channel 
conductance (deduced from noise analysis), and pHint dependence indicated that the aspartate 
residue might be directly protonated from the inside (839). 
The dependence of the protopore gate on pHint had been investigated in early studies by Hanke 
& Miller who found that acidification activated the fast gate (324). They could describe their 
data by an allosteric effect involving the protonation of an amino acid side chain that changes 
its pK from 6 to 9 upon protopore opening (324). In an extensive mutagenic screen Zifarelli et 
al. could not identify such an allosteric pH sensor (963). An attractive idea was that the proton 
glutamate could be directly protonated from the intracellular side leading to pHint dependent 
opening. The mechanism underlying such a direct protonation could be related to the Cl-/H+ 
antiport activity of EcClC-1, and has been dubbed the “broken antiporter hypothesis of gating” 
(546). However, this scenario would predict that the opening rate constant α, but less so the 
closing rate constant β depends on pHint. In contrast to this prediction, Zifarelli et al. found that 
only β is dependent on pHint, whereas α is practically independent of pHint (963). To explain this 
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discrepancy, Zifarelli et al. hypothesized that the protonation of the gating glutamate does not 
occur directly from a “free” proton, but stems from the dissociation of a water molecule into 
OH- and H+ ions (963). Fast water dissociation reactions have been described also in other 
enzymes like carbonic anhydrase with rates up to 106 s-1 (474). The dissociation could in fact be 
favored by the stabilization of the OH- in one of the anion binding sites. This model could 
explain an essentially pH-independent protonation rate and was in quantitative agreement with 
various other observations (963). It would be important to obtain more direct evidence for this 
mechanism and it is unclear if it has any relevance for proton transfer in CLC Cl- / H+ antiporters.  
In short summary, the fast gate of ClC-0 appears to involve mostly the displacement of the 
gating glutamate side chain from its blocking position. This somehow requires a synergistic 
action of Cl- ions and protons, the movement of which from the aqueous solutions depends on 
voltage. Open questions are, for example, whether the gating glutamate has to be protonated 
before it can be displaced from its binding site, how much its own movement contributes to the 
voltage dependence of opening, and if it can reach the central anion binding site, as in the 
crystal structure of CmClC (Fig. 4). One remarkable aspect of fast gating is that despite all these 
various influences on fast gating, the time course of fast gate relaxations can be extremely well 
described by a single exponential function. This supports the hypothesis that the same major 
rate limiting steps underlie fast gate opening and fast gate closing, respectively, under all 
conditions, which might be the movement of the side chain of the gating glutamate. 
 
 
E. The slow gate of ClC-0 
The common or slow gate of ClC-0 governs the appearance of the double barreled bursts (Fig. 
2). It acts on a much slower time scale than the fast gate, and is activated by hyperpolarization, 
i.e. has an inverted voltage-dependence compared to the fast gate (548, 550). Due to the very 
slow kinetics, in particular at positive voltages (676), the slow gate has been little studied in 
quantitative terms. Its voltage-dependence can be relatively well studied using macroscopic 
current recordings and exploiting the vast difference in time scales of the two gates (259, 489, 
492, 676). The gate does not close completely at positive voltages, resulting in a minimal open 
probability, Pmin> 0.  The voltage-dependent component that is activated by hyperpolarization 
can be phenomenologically described by a Boltzmann distribution with an apparent gating 
valence of ~2 elementary charges (259, 489, 676). At very negative voltages (<~ -140 mV), 
however, the open-probability tends to decrease again, a phenomenon called HICD 
(hyperpolarization induced current decrease) (259).  
By definition, the slow gate acts simultaneously on both pores of the double barreled channel. 
In agreement with complex structural rearrangements associated with slow gating, the kinetics 
of slow gate closure shows a very large temperature dependence with a Q10 ~ 40 (676). 
Furthermore, properties of slow gating can are altered by mutations in many protein regions, 
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including the inner selectivity filter (e.g. S123 (492) and Y512 (54)), helix R and the region 
between helix R and CBS1 (489), the C-terminus in general (223, 259, 507, 512), the 
intersubunit interface (933), the gating glutamate and the conserved lysine preceding the 
gating glutamate (470, 839), helix G (472), and others. These widespread mutational effects are 
in accord with large-scale conformational changes during slow gating. Chen (125) discovered 
that extracellularly applied Zn2+ reversibly inhibits ClC-0 at µM concentrations by stabilizing the 
closed state of the common gate. In search of the Zn2+ binding site, Lin & Chen (472) mutated 
all cysteine residues of ClC-0 and found that mutating C212 to serine or alanine completely 
abolished the slow gate, locking it in a permanently open state. Additionally, the C212S mutant 
was almost completely insensitive to Zn2+ (125). However, because of the abolition of the slow 
gate, it could not be concluded that C212 is directly involved in Zn2+ binding. In fact, the 
corresponding residue of EcClC-1, A188, located at the C-terminal end of helix G, is not directly 
accessible from the extracellular solution. Thus, the extracellular Zn2+ binding site of ClC-0 is still 
unknown. The fast gate of C212S is practically indistinguishable from that of WT ClC-0 (472), 
and the mutant serves as a simpler model system to study the fast gate in isolation (472).  
Similar to ClC-0, all mammalian CLC channels (ClC-1, ClC-2, ClC-Ka, ClC-Kb) are inhibited by 
extracellular Zn2+ and / or Cd2+ ions (139, 294, 438, 719). For ClC-1 it has been shown that Zn2+ / 
Cd2+ binding stabilizes the closed state of the common gate and possibly induces a deeply 
inactivated state that is normally not present (125, 206). A characteristic feature of ClC-2 is its 
rather high sensitivity to extracellularly applied Cd2+ and Zn2+ (139), which has helped to 
identify endogenous Cl- currents as being carried by ClC-2. The mechanism of Cd2+ and Zn2+ 
inhibition is probably similar to that of ClC-0 and ClC-1, i.e. binding of these divalent cations 
stabilizes the closed state of the common gate (971). Zn2+ binding sites in proteins involve 
histidine, cysteine, or acidic residues. Kürz et al. mutated several histidine and cysteine residues 
in ClC-1 and found that the triple mutant C242A/C254A/C546A had a drastically reduced Zn2+ 
sensitivity (439). However, these residues are not close to each other in 3D and C242 and C254 
are not exposed to the outside. Another interesting cysteine residue that is conserved among 
ClC-0, ClC-1 and ClC-2 has been indirectly implicated in Zn2+ / Cd2+ binding: Mutating C212 in 
ClC-0, C277S in ClC-1 or C256 in ClC-2 drastically reduces Zn2+ / Cd2+ sensibility (206, 472, 971). 
However, these mutations lead also to a dramatic stabilization of the open state of the 
common gate (472) (2, 971). Thus, the reduced Zn2+ / Cd2+ block seen with these mutations is 
probably caused indirectly. This is also supported by the finding that other mutations, e.g. in 
the C-terminus, that activate the common gate, are less sensitive to Zn2+ (223). Furthermore, 
the conserved cysteine residue (C212 in ClC-0), even though located at the extracellular end of 
helix G, does not appear to be directly accessible to the external solution (210), and it is not 
conserved in ClC-K channels, which are equally sensitive to Zn2+ (294). Recently, also 
intracellular Cd2+ binding in ClC-0 was found to modulate the common gate via a binding site 
close to the subunit interface (933).  
The presence of large conformational changes associated with slow gating has been 
experimentally tested using FRET of C-terminally fused fluorescent proteins (93). Maneuvers 
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predicted to perturb slow gate opening were associated with FRET changes corresponding to a 
separation of the C-terminally fused GFP tags on the order of 20 Å (93). This finding is in 
agreement with the fact that mutations in many part of the C-terminus affect slow gating (223, 
259, 507, 512). However, it is unclear if these inferred conformational changes of the C-termini 
are causally involved in the slow gate, i.e. if the “gate” is constituted by a C-terminal structure, 
or if these conformational changes are secondary to gate-opening conformational changes of 
the transmembrane part of the protein. Furthermore, large conformational changes of the C-
termini are surprising in light of the CmClC crystal structure, in which the C-terminus forms an 
extended interface with the transmembrane part (242).  
The slow gate is also markedly dependent on the extracellular and intracellular Cl- 
concentrations, with low concentrations favoring the closure of the slow gate (128, 674). This 
hints to a strong coupling of slow gating to the pore occupancy by anions. Complex interactions 
of the slow gate with ion pore occupancy has been described for mutant T484S, located at the 
extracellular end of helix P: the mutant is characterized by an inwardly rectifying phenotype in 
normal extracellular Cl- solutions, but extracellular ClO4-, which blocks WT ClC-0, partially 
recovers the fast gate deactivating currents, probably by stabilizing the slow gate in an open 
confirmation (490). Furthermore, charge neutralizing mutations of the gating glutamate (e.g. 
E166A) lock the slow gate in an open state (839). Also the charge preserving mutation E166D 
eliminates slow gating transitions (839). Interestingly, heteromeric WT/E166A or WT/E166D 
ClC-0 channels partially recover slow gating transitions (839). On the contrary, charge 
neutralization of the conserved lysine K165, a residue that points its side chain in the 
extracellular pore just above the gating glutamate (210), lock the slow gate completely shut 
(470). Modifying K165C channels with positively charged cysteine reactive probes recovers 
channel activity, and heteromeric WT/K165C showed only one pore in single channel recordings 
(470). In light of these findings, the reported hyperpolarization activation exhibited by the 
charge conserving mutation K165R (490), is most likely caused by a dramatic destabilization of 
the slow gate open state. In agreement with this, combining the slow gate activating mutation 
C212S with K165R (double mutant K165R/C212S) leads to a channel with almost WT like 
behavior (Pusch, unpublished observation).  
A further pore residue that has been implicated in slow gating only recently is Y512, one of the 
two residues in the inner selectivity filter of EcClC-1 (210). Mutating Y512 to Ala, Phe, or His 
locked the slow gate open similar to mutations of C212 or E166 (54). These results were 
interpreted in the framework of a possible direct hydrogen bond interaction between Y512 and 
the gating glutamate with its side chain in the Scen position as in the CmClC structure (54). 
However, it has not been noted that the analogous mutation in ClC-Ka, Y520A, caused a similar 
dramatic increase of the open probability (296). Since ClC-K channels lack the gating glutamate, 
carrying instead a valine residue (415, 869) at the equivalent position, the interaction proposed 
by Bennetts et al. (54) is not possible in this case. Thus, a different mechanism underlying the 




In summary, there is an obvious link of pore ion occupancy with slow gating. In addition, as 
shown by Lisal and Maduke, the irreversible gating transitions manifested by time-asymmetric 
bursting kinetics is coupled to the transmembrane pH gradient (478). These findings suggest 
that CLC channels are degraded anion / proton exchangers, in which certain mechanisms 
important for exchange are “used” as modifiers of gating. Nevertheless, we are still lacking a 
clue on the essential conformational changes associated with the slow gating process. A 
conformational change associated with a relative re-arrangement of the two monomers of a 
CLC channel was suggested by the presence of two structural classes present in the single 
particle images used to obtain the cryo-EM structure of the bovine ClC-K channel (628). The two 
classes differed by a movement of the two transmembrane domains with a ~ 6 degrees tilt 
relative to each other, involving a quite substantial  difference in the subunit interface (628). It 
will be interesting to explore if this conformational difference is related to the common gate of 
CLC proteins.  
 
F. The transport mechanisms of CLC Cl-/H+ exchangers 
It was a breakthrough discovery of Accardi & Miller that the bacterial homologue EcClC-1 is not 
a passive Cl- channel, but a secondary active, strictly coupled 2:1 Cl- / H+ antiporter (5). This 
finding has dramatically changed our view of CLC proteins in general. In particular, it was 
subsequently found that all intracellular mammalian CLCs, i.e. ClC-3 through ClC-7, and several 
plant CLCs are actually anion proton antiporters (164, 316, 453, 576, 651, 742), whose 
physiological functions we are only beginning to fully understand. The biophysical mechanisms 
of the Cl- / H+ exchange are best understood for the E. coli homologue, which serves as an 
important model for the eukaryotic CLCs as well. 
Accardi et al. succeeded in producing extremely pure EcClC-1 at high yield, allowing the 
reconstitution of large amounts of the protein into planar lipid bilayers without significant 
contamination (3). Careful analysis of electrophysiological experiments in various Cl- and pH 
gradients clearly excluded a passive anion permeability and demonstrated that EcClC-1 is a 
strictly coupled 2:1 Cl- / H+ antiporter (5). Flux measurements demonstrated that EcClC-1 is able 
to transport Cl- or protons against their respective electrochemical gradient exploiting the 
gradient of the other substrate, a hallmark of secondary active transport (5). The tight 2:1 
coupling was confirmed directly using H+ flux measurements at different imposed voltages 
(583), and the same 2:1 stoichiometry was found for the human ClC-5 (966), human ClC-7 (453), 
plant CLCs (164), other prokaryotic CLCs  (379, 645), and the red algal CmClC (242), 
demonstrating that the basic mechanism of coupling and transport is conserved in these 
evolutionary divergent antiporters. Quite surprisingly, a clade of distantly related CLC proteins 
from several bacteria, called CLCF proteins are fluoride/proton antiporters with a 1:1 
stoichiometry (78, 811). However, the sequence of these CLCF proteins is quite distinct from 
that of mammalian CLCs and of EcClC-1 in the core anion binding regions.  
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In retrospect, the fact that EcClC-1 is a transporter and not a channel is not surprising 
considering the crystal structure of the protein (210, 211): Contrasting with K+ channel 
structures, no open aqueous diffusion pathway for Cl- ions can be seen in EcClC-1. The centrally 
bound Cl- ion is completely buried in the protein. Its access to the outside is impeded by the 
side chain of the gating glutamate, E148, whereas it is shielded from the inside by the side 
chains of S107 and Y445. In fact, these three amino acids appear to play the most important 
roles in determining anion selectivity and gating of both CLC channels and CLC transporters.  
Since coupled transport requires concerted conformational rearrangements in response to 
substrate binding and unbinding, the turnover rate of transporters is generally much smaller 
than that of ion channels (545, 546). Using the “Cl- dump assay”, reconstituting EcClC-1 at low 
density in proteo-liposomes, a turnover of ~ 2000 s-1 at 0 mV (with valinomycin in symmetrical 
K+) in a 300 mM : 1 mM Cl- concentration gradient at pH 4.5 was determined  (378, 870). This is 
a small number compared even to the low conductance ClC-1 Cl- channel, whose single channel 
conductance of ~ 1.5 pS (739) corresponds to a movement of  106 ions per second at -100 mV, 
but is large in the transporter world (546). No direct turnover measurements have been 
reported for animal or plant CLC exchangers but indirect noise analysis indicated an extremely 
fast turnover of ~ 105 s-1 at 100 mV for ClC-5 (941, 966, 967) and ClC-4 (334). However, the 
latter estimate has been obtained with iodide in the intracellular solution, limiting its relevance 
for coupled Cl- / H+ exchange, because the coupling efficiency is critically dependent on the 
anion species (583, 941).  In any case, it is highly desirable to achieve direct estimates of the 
turnover rate of these mammalian CLC transporters. High turnover is, however, not a defining 
characteristic of CLC transporters. For example homologues from cyanobacteria or from 
Citrobacter koseri exhibit a turnover of only ~ 20 s-1 (379, 645). 
Without doubt, the most fundamental role in coupled CLC anion / proton exchange is played by 
the gating glutamate, E148 in EcClC-1, which blocks the communication of the central Cl- ion 
with the extracellular bulk solution (210, 211). Neutralizing the gating glutamate by mutation to 
alanine, glutamine or serine completely abolishes H+ transport, resulting in a passive Cl- 
transport activity (5). The same uncoupling is seen in eukaryotic CLC transporters (60, 453, 576, 
651, 742). As discussed above, in several CLC channels, the equivalent neutralization of the 
gating glutamate results in an almost constitutive activation (211, 224, 588, 838). Interestingly, 
neutralization of the gating glutamate does not increase the throughput of Cl- ions, but rather 
slightly decreases it in EcClC-1 (378) and it reduces currents also in ClC-5 (941). In fact, a 
structure distinct from the available crystal structures corresponding to an outward facing open 
state has been inferred from NMR studies, in which the narrow constriction between Sext and 
the extracellular solution is widened transiently, suggesting that a small conformational change 
above Sext is involved in the transport cycle (412). In CLC channels, the pore conductance is not 
significantly altered by mutations of the gating glutamate (211, 838, 954). Quite surprisingly, 
the recent cryo-EM structure of the bovine ClC-K homologue revealed that the ion pore is very 
similar to that of the transporter homologues in the vicinity of the position of the gating 
glutamate (which is a valine in the bovine ClC-K) (628).  
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Also mutations of the inner tyrosine residue, Y445, that is part of the constriction towards the 
inside do not dramatically alter Cl- transport rates in EcClC-1 (378). At difference to the gating 
glutamate, mutations of Y445 drastically reduce but do not abolish H+ transport (4). The 
simultaneous mutation of E148 and Y445 to alanine dramatically increases Cl- throughput to ~ 
20 000 s-1 (378). This result strongly favors the idea that two “gates” are involved in CLC 
transport: The extracellular gate is constituted by E148, whereas the intracellular gate is formed 
in part by Y445. Only removal of both gates allows fast diffusion of Cl- ions through the 
permeation pathway. However, even these “opened” mutants do not present a large hydrated 
pore, but only a very narrow passage, even of smaller dimensions than a Cl- ion, predicting that 
protein structure fluctuations must help in allowing Cl- movement. In fact, so far, the crystal 
structures reported for practically all mutants of EcClC-1 are almost superimposable on the WT 
structure, except at the site of mutations (4, 9, 47, 211, 467-469, 482, 582, 583, 705). 
Interestingly however, in the crystal structure of the uncoupled mutant Y445A no Cl- ions were 
found bound to the Scen site, and the partially uncoupled mutation Y445L showed intermediate 
Cl- occupancy (4). This suggested a correlation of Cl-/ H+ flux coupling and the ion occupancy of 
Scen. Such a correlation of anion binding with flux coupling was strengthened by the finding that 
H+ transport coupling is practically absent if Cl- is substituted by the polyatomic anions SCN- and 
SeCN- and that the occupancy of Scen in crystals grown in the presence of these anions 
correlated with the degree of uncoupling (583). NO3- ions had a similar but smaller effect on 
uncoupling. Similar uncoupling of H+ transport in SCN- and NO3- was seen in ClC-5 (941) and ClC-
4 (22). The phenomenon of uncoupling in the Y445 mutants and in SCN- probably reflects a 
“slippage” of the transport. The mechanism underlying this uncoupling, however, remains 
largely unknown. One possibility is that anion occupancy of Scen electrostatically favors the H+ 
passage from the proton glutamate to the gating glutamate, probably via transient water wires 
(321, 396, 434, 957). 
Further detailed information of Cl- ion binding to the EcClC-1 protein was provided by 
crystallography and isothermal titration calorimetry (ITC) (482, 650). Crystallographic analysis 
indicated that all three anion binding sites (Sint, Scen, Sext) can be occupied simultaneously with 
millimolar affinity (482). A major advancement was achieved by Picollo et al., who measured 
thermodynamically well-defined equilibrium Cl- binding affinities using ITC on detergent 
solubilized purified WT and mutant EcClC-1 proteins (650). The WT protein was found to bind 
Cl- ions with an affinity of ~ 1 mM, probably reflecting the affinity of the central site, with the 
external site occupied by the negatively charged side chain of the gating glutamate (650). In 
order to correlate this equilibrium binding binding affinity with chloride binding during the 
transport cycle, Picollo et al. determined the half-maximal “trans” chloride concentration that 
was necessary to reduce the transport rate in a large Cl-  gradient and found a value of the same 
order of magnitude of 1 mM (650). This result  supported the relevance of the equilibrium 
binding affinities for the transport mechanism (650). Eliminating the putative inner gate in the 
mutant Y445A, in which Cl- binding to Scen was absent in crystal structures (4), almost 
completely abolished Cl- binding also in ITC experiments (650). Very surprisingly, the E148A 
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mutant, which lacks the gating glutamate, exhibited high affinity Cl- binding to two sites with an 
affinity of 12 µM, despite their spatial proximity (650). While a definite explanation for the high 
affinity is still lacking, tight binding of Cl- in the E148A mutant may underlie its rather slow Cl- 
transport rate (378).  
Two residues form the constriction of the Cl- pathway between Scen and the intracellular 
solution: Y445 and S107. However, these two residues play clearly different roles. While 
mutations of the tyrosine affect Cl- binding and transport coupling in EcClC-1 and slow gating in 
CLC channels (4, 54, 296), surprisingly the ion selectivity and turnover / single channel 
conductance of tyrosine mutations is not much different from that of the respective WT 
proteins (7, 224, 870). In contrast, S107 and the respective residues in other CLCs, are 
important for ion selectivity and conductance. This was first shown for ClC-0 in which the quite 
conservative mutation S123T changes ion selectivity among halides and reduces the single 
channel conductance to 1.5 pS (492). Interestingly, several plant homologues, which perform 
2:1 NO3- / H+ exchange and only poorly transport Cl-, carry a proline residue at the 
corresponding position (164). The human ClC-5 exchanger could be converted to a NO3- / H+ 
exchanger by simply substituting the serine by a proline residue, demonstrating the role of the 
serine/proline for ion selectivity in CLC exchangers (60, 966). Importantly, the NO3- / H+ 
exchange was tightly coupled with 2:1 stoichiometry and Cl- was very poorly transported (966). 
The analogous mutation in EcClC-1 led to a loss of Cl- binding and a significant increase in NO3- 
binding affinity assessed with ITC (650). Analogously, the reverse mutation in the plant AtClC-a 
homologue, P160S, leads to a loss of its NO3- / Cl- selectivity (60, 893) and the mutant is not 
able to complement the defect in NO3- accumulation of AtClC-a knockout plants (893). Even in 
the ClC-0 channel, the S123P mutation increases NO3- permeability in the context of the gating 
glutamate neutralization mutant E166A (650). Surprisingly, the side chain of the corresponding 
serine was found to point away from the pore in the recent cryo-EM structure of the bovine 
ClC-K channel (628). 
The potential involvement of the external binding site, Sext, in ion selectivity in CLC exchangers 
or channels has been studied less extensively. Functional effects of mutations of the gating 
glutamate in CLC exchangers suggested that Sext has no prominent role in anion selectivity (3, 
269, 651, 941). In ClC-5, charge neutralizing mutations of the lysine residue that precedes the 
gating glutamate (K210) reversed the NO3- over Cl- preference, but did not modify the H+ / 
anion coupling stoichiometry (179). Effects were however smaller at saturating anion 
concentrations, suggesting that K210 is critical for the association rate of extracellular anions to 
Sext (179). Mutation of the equivalent lysine in ClC-1 has been reported to alter ion selectivity 
(234). However, these measurements are questionable because the mutant K210A is strongly 
inwardly rectifying and reversal potentials, which were measured in current clamp, are 
unreliable in such a condition. 
While the Cl- permeation pathway is clearly visible in the CLC crystal structures, protons are 
invisible in X-ray crystallography and their transport pathway has been inferred indirectly from 
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mutagenesis and theoretical studies. Related to this technical difficulty is the lack of a definite 
picture of the coupling mechanism, which will be discussed below. It is practically universally 
accepted that the gating glutamate is directly involved in proton transport from / to the 
extracellular solution in a protonation / deprotonation cycle, since its neutralization abolishes 
H+ transport (5, 6, 211, 651, 742). In this picture, the coupling between Cl- and H+ transport 
involves the alternative occupation of Sext and Scen by Cl- ions or by the negatively charged side 
chain of the gating glutamate. Even stronger evidence for this notion of competition of Cl- and 
the glutamate side chain was obtained by Feng et al. who could reconstitute H+ transport in the 
E148A mutant by adding high concentrations of free glutamate or gluconate (243). This H+ 
transport was blocked by submillimolar Cl- (243) in agreement with the high Cl- affinity of this 
mutant (650).  
A more difficult question regards the pathway of H+ between the gating glutamate and the 
intracellular solution. In a pioneering study, Accardi et al. identified E203 as the most likely 
intracellular proton acceptor of EcClC-1 (6, 9). For convenience, this residue is also called the 
“proton glutamate” (941). It is located in a highly conserved sequence stretch at the subunit 
interface at the end of helix H, close to the intracellular solution. It is preceded by another 
glutamate residue that is one of the most conserved residues in all CLC proteins. However, 
mutating E202 preserved coupled transport (9). Neutralizing the proton glutamate in the E203Q 
mutant resulted in a complete loss of proton transport, preserving however Cl- transport at a 
rate about 3-fold slower than WT (9, 467), and showing Cl- binding affinities similar to WT in ITC 
experiments (467). Also the crystal structure of the E203Q mutant was almost identical to that 
of WT EcClC-1, except at the site of mutation (9). These results suggested divergent pathways 
for Cl- and H+ to or from the intracellular solution: Cl- ions enter via Sint, whereas protons enter 
through a lateral pathway via the proton glutamate (9). The preservation of Cl- transport in a 
mutation that presumably blocks the binding of one of the substrates is counter-intuitive for a 
classical “ping-pong” antiporter mechanism, and is one of many signs that the coupling 
mechanism in CLC transporters is rather unique. More in line with a classical coupling 
mechanism, equivalent mutations of the proton glutamate in ClC-5 (E268Q, E268A) completely 
inhibit steady state transport of Cl- and protons (941). Interestingly, the E268A mutant in ClC-5 
gives rise to transient, “pre-steady state” currents upon voltage-steps (788), which will be 
discussed in more detail below. For ClC-5 it was also found that mutating the proton glutamate 
to some other titratable residues including Asp and His allowed coupled Cl-/H+ exchange (941), 
a finding extended later to EcClC-1 (467). 
All known CLC channels carry a non-titratable residue at the position of the proton glutamate 
(9), even though introducing a glutamate residue in the CLC channels is not sufficient to confer 
H+ transport activity but rather alters gating characteristics (941). It was thus believed that a 
defining characteristic of CLC exchangers was the presence of a titratable residue at the 
position of the proton glutamate. However, this is not strictly necessary:  Coupled Cl-/H+ 
antiport was found in a homologue from Citrobacter koseri (645), which carries an isoleucine, 
and in the crystallized CmClC (242), which carries a threonine at the equivalent position. 
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The access of the proton glutamate from the intracellular solution has been investigated in 
detail by Lim et al.  (468), underlining that the proton glutamate is not freely accessible to the 
intracellular solution and suggesting that the glutamate E202 serves as a “water organizer” 
(468). The protein region between the proton glutamate and the gating glutamate is rather 
hydrophobic, raising the important question of how protons can move between these two 
residues. The crystal structure of CmClC shows the side chain of the gating glutamate in the Scen 
position (242), which is closer to the proton glutamate than the Sext position. Thus, it is possible 
that protons are delivered from the inside to the deprotonated gating glutamate side chain in 
the Scen site in CLC exchangers in general. Recently, flux measurements favor the possibility that 
the gating glutamate can reach the central binding site also in EcClC-1 (860). Transport activity 
decreased when Cl- was elevated on both sides of the membrane suggesting that the gating 
glutamate becomes trapped between two Cl- ions and the trapped state was eliminated by 
mutations supposed to disrupt hydrogen bonds that stabilize the gating glutamate in the 
central binding site (860). Several theoretical studies highlighted the possibility of transient 
water wires between the two glutamates (434, 872, 957). Recently, a combination of 
theoretical and experimental studies provided strong evidence for water wires, involving 
residues A404 and I109 in the passage of protons (321). However, even though intriguing and 
theoretically possible, the involvement of water wires in the H+ passage is extremely difficult to 
nail down with certainty.  
 
G. The mechanism of transport coupling 
The homodimeric architecture with an extensive subunit interface of all CLC proteins studied so 
far might suggest an important role of this peculiar arrangement for transport. However, the 
functional properties of dimeric constructs of WT and uncoupled mutants of ClC-5 
demonstrated that each monomer unit of the dimeric protein is able to carry out Cl-/H+ 
exchange independently from the neighboring subunit (941). For EcClC-1, “straight-jacketed” 
constructs in which the two subunits were covalently linked with cysteine bridges behaved 
almost like WT showing that no large rigid body movement of the two subunits is involved in 
coupled transport (582). Furthermore, by introducing tryptophan residues at the dimer 
interface at two positions Robertson et al. (705) succeeded in obtaining monomeric EcClC-1 
proteins that were fully functional, showing unambiguously that the fundamental unit of 
transport is the CLC monomer. 
Many features of CLC Cl-/H+ exchange are conceptually different from a classical alternate 
access antiporter system. In such antiporters, like e.g. Cl-/HCO3- exchangers (24), the exchanged 
substrates never bind simultaneously. The binding site is alternatively exposed to the inside or 
to the outside, and coupling is assured by the condition that only the “loaded” transporter can 
undergo the conformational change between outwardly to inwardly exposed binding sites. 
“Slippage”, or uniport activity occurs to the extent that the unloaded transporter is able to 
undergo this transition. 
25 
 
In contrast, in CLC anion / H+ antiporters, both substrates bind simultaneously and 
synergistically.  This has been demonstrated elegantly by Picollo et al., who showed, using ITC, 
that Cl- binding triggers protonation of the transporter with a 0.5 H+ to Cl- binding stoichiometry 
(652). Proton binding most likely reflects the protonation of the gating glutamate. However, 
since the measurements of Picollo et al. were performed under equilibrium conditions, they do 
not reveal the temporal order of the binding events, i.e. if Cl- ion binding is followed by 
protonation or vice versa. Interestingly, mutating the tyrosine Y445 to leucine reduced  the 
binding stoichiometry to about 0.12 H+ per Cl- bound (652) similar to its effect on transport 
stoichiometry (4). In contrast, neutralizing the proton glutamate (E203Q) had almost no effect 
on the synergistic Cl- / H+ binding (652), suggesting that protonation of E203 is not directly 
involved in transport coupling. Synergistic binding of Cl- and protons has also been supported 
by theoretical calculations (130, 449). 
Triggered by the CmClC crystal structure, in which the gating glutamate side chain occupies Scen, 
Feng et al. proposed a coupling mechanism without involvement of a steric intracellular gate, 
and rather suggested a “kinetic” gate (242) (Fig. 5A). The model involves conformations of the 
transporter that are “open” for Cl- ions to both sides of the membrane, and in which the 
protonated or deprotonated gating glutamate points to the extracellular side (see states 5 and 
6 in Fig. 5A). These states allow passive diffusion of Cl- ions. In a strictly coupled transporter 
such states are theoretically “forbidden” because they introduce slippage, i.e. a loss of tight 
coupling. In the model of Feng et al. these conductive states are visited only transiently such 
that they introduce only a marginal degree of slippage. However, the model predicts that these 
uncoupled states are stabilized at acidic pH, predicting uncoupled Cl- transport at acidic pH. This 
has, however, not been observed experimentally even at pH 3 (5). In addition, the model does 
not involve conformational changes associated with transport that have been inferred in other 
studies (47, 53, 216). In an alternative picture, a true intracellular gate, involving Tyrin, strictly 
controls access of intracellular Cl- ions (1), and opening of the gate involves conformational 
changes of helix O (1, 47) (Fig. 5B).  
Additional Insight into the sequence of events in transport was obtained by the analysis of 
transient currents measured in the proton glutamate mutant of ClC-5, E268A (788). From a 
detailed analysis of such transient currents it was concluded that the first events in the 
transport cycle are the movement of the gating glutamate from Sext to Scen, accompanied by a 
movement of a Cl- ion from Scen to the inside, which is then followed by the binding of an 
extracellular Cl- ion to Sext (961). A transport model that incorporates these initial events and a 
hypothetical swap of a Cl- ion and the protonated gating glutamate is shown in Fig. 5C. A major 
difference to the model proposed by Feng et al. (242) (Fig. 5A) is that after the initial downward 
movement of the gating glutamate and external Cl- binding (transition from state 1 to state 2 in 
Fig. 5C), and protonation of the gating glutamate by an internal proton (transition from state 2 
to state 3 in Fig. 5C), the previously bound Cl- ion is not released back to the outside (as in the 
model of Feng et al., Fig. 5A) but moves further inside, swapping its position with the 
protonated gating glutamate (transition from state 3 to state 4 in Fig. 5C). Similar to the model 
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of Feng et al. (242) (Fig. 5A), a “kinetic” gate has to be present to make the freely Cl- ion 
conductive states 5 and 6 short-lived to avoid too much slipping. Preliminary simulations 
indicate that the model shown in Fig. 5C largely prevents uncoupling of the transporter at acidic 
pH, which instead occurs in the model of Feng et al. (Fig. 5A), using comparable model 
parameters (Pusch, unpublished results). Such an uncoupling at acidic pH has in fact not been 
observed experimentally for pH values as low as 3 (1, 3, 5). However, the proposed “swapping” 
of the protonated glutamate side-chain with a pore-bound Cl- ion is purely hypothetical and 
requires experimental verification. 
 
H. The current-voltage relationship of CLC transporters 
The bacterial EcClC-1, reconstituted in planar lipid bilayers, shows a relatively linear current-
voltage relationship, suggesting that none of the voltage-dependent translocation steps 
becomes significantly rate-limiting in the studied voltage-ranges (3, 5). The mammalian CLC 
exchangers, ClC-3 to -7 are all expressed predominantly in endosomes and lysosomes, which 
are not simply accessible to directly electrophysiological recordings. Among these, ClC-4 and 
ClC-5 exhibit, however, significant plasma membrane localization in heterologous expression 
systems, allowing their analysis using the two-electrode voltage clamp technique in Xenopus 
oocytes or the patch clamp technique in transfected cells (269, 808, 855). Both transporters 
show an extremely pronounced outward rectification with no detectable inward currents, even 
using tail current protocols (269, 808, 855). The ion selectivity of the conductance at positive 
voltages is similar to that of CLC channels: NO3->Cl->Br->I- (269, 334, 808, 855). ClC-5 is inhibited 
by extracellular pH (269), in a manner that is compatible with a voltage-dependent binding 
from the extracellular solution (649). ClC-3 behaves similarly to ClC-4 and ClC-5, even though its 
expression level is much smaller (456, 457, 651). Several other publications reporting different 
current phenotypes, including e.g. a phenotype similar to that of swelling activated anion 
currents, must be considered wrong as discussed by Stauber et al (802) and below. More 
recently, several splice variants of ClC-3 have been studied, with some of them showing more 
pronounced plasma membrane expression than others (317). Neutralizing the gating glutamate, 
which abolishes H+ transport in CLC transporters (964), completely eliminates the outwardly 
rectifying phenotype and any current relaxations in ClC-3, ClC-4 and ClC-5 (269, 457). These 
mutants yield currents with an almost linear IV relationship and an anion selectivity that is 
similar to that of the WT (941). This suggests that anion permeation through the uncoupled 
transporters per se is not rectifying. An alternative explanation for the observed rectification is 
that one of the proton translocation steps is voltage-dependent (941). However, even in the 
presence of SCN-, which leads to almost complete uncoupling and loss of H+ transport, currents 
are strongly rectifying (941), and also the H+ block is similar in these conditions (649), arguing 
against a fundamental role of H+ translocation as the basis of the rectification. A possible 
“gating phenomenon” underlying the strong rectification will be discussed below. 
ClC-6 could be partially targeted to the plasma membrane by N-terminal fusion of GFP (576). 
The electrophysiological activity was compatible with a Cl- / H+ exchange and currents were 
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strongly outwardly rectifying and small, such that reversal potentials could not be determined 
reliably (576). Neutralizing the gating glutamate eliminated the rectification, but currents 
remained very small. Simultaneous mutation of the internal tyrosine to serine augmented 
currents (576), similar to the enhanced turnover in EcClC-1 of the E148A/Y445S mutant (378). 
From a biophysical perspective, ClC-6 remains one of the least studied mammalian CLC 
proteins. 
For a long time, ClC-7/Ostm1 transporters could not be studied electrophysiologically because 
of their very tight targeting to lysosomes (391). Using flux assays on native lysosomes, Graves et 
al. found that the dominant Cl- transport was characterized by 2Cl-/1H+ antiport activity (298). A 
more direct investigation of the biophysical properties of ClC-7/Ostm1 became possible after 
the discovery that the proteins could be partially redistributed to the plasma membrane by the 
mutation of N-terminal leucine targeting motifs (801), allowing for the first time their 
electrophysiological characterization (453). ClC-7/Ostm1 currents are strongly outwardly 
rectifying and reflect coupled 2:1 Cl- / H+ antiport, but unlike ClC-5, they exhibit very slow 
activation kinetics and inwardly directed tail currents (453). Similar to ClC-3, -4, and -5, 
neutralizing the gating glutamate results in voltage-independent, practically linear, uncoupled 
Cl- transport (453).  
Thus, all mammalian CLC transporters exhibit strong outward rectification, in contrast to the 
linear IV characteristics of EcClC-1. In the case of ClC-7, the rectification appears to almost 
exclusively reflect a gating phenomenon, since the instantaneous current-voltage relationship 
obtained by tail current protocols is almost linear (453). For ClC-3 to ClC-6 the mechanisms 
underlying the rectification are not yet fully understood. 
 
I. Pharmacology of the bacterial EcClC-1 transporter 
While not of immediate medical relevance, small molecule ligands of the bacterial EcClC-1 
transporter have a great potential as mechanistic tools. In addition, the co-crystallization of 
potential ligands may provide important structural insights in ligand / protein interaction 
applicable to human CLCs. Initially, Matulef & Maduke reported that DIDS inhibits EcClC-1 
specifically from the intracellular side, allowing a “functional orientation” of the reconstituted 
protein (534). However, later the same group discovered that DIDS is chemically highly unstable 
in aqueous solution and that the active fractions inhibiting EcClC-1 are polythiourea derivatives 
of DIDS (533). Building on these insights, Howery et al. designed an inhibitor of EcClC-1 
combining 4,40-diaminostilbene-2,20-disulfonate (533) with the two aliphatic side chains 
present in octanoic acid, which blocks ClC-0 and ClC-1  (721, 954). The resulting compound, 
called OADS, inhibits EcClC-1 mediated transport with µM affinity and probably binds to the 
protein in a superficial position (353). Unfortunately, so far no high resolution structure of any 




III. CELL BIOLOGY, PHYSIOLOGY AND PATHOLOGY OF MAMMALIAN CLC 
PROTEINS 
When ClC-0, the founding member of the CLC family, was cloned in 1990 (393), most of the 
diverse and often crucial roles of Cl- channels were not appreciated and largely unknown. Only 
two human pathologies were attributed to an inheritable impairment of Cl- channels: myotonia 
congenita, a disorder of skeletal muscle excitability, and cystic fibrosis, a multi-system disorder 
associated with defects in transepithelial transport. The identification and characterization of 
nine mammalian CLCs (Fig. 1) not only showed that myotonia congenita is indeed due to 
mutations in a muscle Cl- channel (423, 805), but revealed many hitherto unexpected roles of 
Cl- transport. These roles were most often gleaned from human genetic diseases or mouse 
models in which CLC genes were disrupted or specifically altered by point mutations. Mutations 
in seven of the nine human CLCN genes are now known to cause human disease (187, 246, 359, 
423, 429, 481, 747, 748, 780). Likewise, mutations in the three genes encoding ancillary CLC ‘β-
subunits’ (barttin (65, 222), Ostm1 (116, 445), and GlialCAM (395, 483)) cause human 
pathologies which substantially overlap, or are sometimes identical, to those caused by a loss of 
the associated CLC ‘α-subunit’. Genetic mouse models sometimes led the way to the 
corresponding human disease (68, 429) and always helped to unravel the underlying 
pathological mechanisms as well as the function of Cl-transport for the cell and the organism.   
In the following, we will review the current knowledge of each mammalian CLC, beginning with 
the plasma membrane Cl- channels ClC-1, ClC-2, ClC-Ka and –Kb and proceeding to the 
overwhelmingly intracellular chloride/proton exchangers ClC-3 to ClC-7. As general features of 
CLC structure-function relationships have been discussed in detail in the preceding chapters, we 
will mention these aspects only shortly and when they are relevant and specific for the 
particular CLC isoform.  We will discuss their regulation, pharmacology, their roles for cells, 
tissues, and the organism. Particular emphasis will be laid on diseases and mouse phenotypes 





IV. CLC PLASMA MEMBRANE CHLORIDE CHANNELS 
Among mammalian CLCs, only ClC-1, ClC-2 and the two highly homologous ClC-K channel 
isoforms, both of which require the β-subunit barttin, are Cl- channels. They reside in the 
plasma membrane and display different tissue distributions. ClC-1 is highly specific for skeletal 
muscle, whereas the ClC-K isoforms are differentially expressed in epithelial cells of the 
nephron, the inner ear and salivary glands. By contrast, ClC-2 is widely and almost ubiquitously 
expressed in epithelial and non-epothelial cells. By providing the major resting conductance of 
skeletal muscle, ClC-1 is crucial for ensuring appropriate excitability of that tissue, and ClC-
K/barttin channels have well-defined roles in transepithelial transport. Functions of ClC-2 are 
more diverse and less defined. They may range from extra- and intracellular ion homeostasis 
over regulation of cellular excitability to transepithelial transport. Human genetic diseases and 
genetic mouse models demonstrate the physiological importance of all these plasma 
membrane channels. 
 
V. CLC-1 – THE SKELETAL MUSCLE CL- CHANNEL MUTATED IN MYOTONIA  
ClC-1 was the first mammalian voltage-gated Cl- channel that was identified at the molecular 
level (807). Skeletal muscle was an obvious choice for a tissue to look for a homologue of ClC-0 
because the electric organ is derived from muscle during development (263, 264). Indeed, ClC-1 
is the closest mammalian homologue of the Torpedo channel. With a mass of around 120 kDa 
(998 amino-acids), ClC-1 is the largest mammalian CLC protein. This is owed to a relatively long 
cytosolic amino-terminus (larger only in ClC-7), a relatively large segment between the cytosolic 
CBS1 and CBS2 domains (also found in ClC-2 and ClC-6), and a particularly large cytosolic tail 
after CBS2 (the largest of mammalian CLCs). These relatively large cytosolic regions may be 
important for the trafficking and regulation of ClC-1 (358, 507, 710). In skeletal muscle, ClC-1 is 
strongly regulated both on the transcriptional and post-transcriptional levels. Its regulation, 
biophysical properties, structure-function relationship, pharmacology, and role in muscle 
physiology have been extensively investigated for more than twenty years (for excellent 
reviews see (34, 367, 640, 827)).  
ClC-1 is almost exclusively found in skeletal muscle (807) where it mediates the bulk of plasma 
membrane Cl- conductance (gCl) as evident from the close match of the properties of 
heterologously expressed ClC-1 with those of native gCl (reviewed in (34)) and, above all, from 
the loss of skeletal muscle chloride conductance upon Clcn1 disruption (537, 805). Skeletal 
muscle is unusual in that gCl provides about 80% of the resting conductance (83). This high level 
of gCl is crucial for the control of muscle excitability. Indeed, CLCN1 mutations abolishing or 
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otherwise reducing ClC-1 plasma membrane currents lead to myotonia, a disorder associated 
with muscle hyperexcitability, in humans (423) and other mammals (51, 72, 568, 694, 805, 906) 
(for reviews on ClC-1 and myotonia, see (485, 670, 827), and for more general reviews on 
myotonia: (97, 402, 817)). The reduction of gCl due to aberrant splicing of the CLCN1 mRNA 
contributes to myotonic symptoms in two neurodegenerative diseases, myotonic dystrophy 
(119, 518) and Huntington disease (890). Hence, ClC-1 plays a crucial role in muscle physiology 
and pathology.  
 
A. Transcriptional regulation of ClC-1 expression 
ClC-1 is almost exclusively expressed in skeletal muscle as demonstrated by Northern blots that 
compared skeletal muscle with with cardiac muscle (654) and several additional tissues (807). 
Whereas more sensitive RT-PCR/Northern analysis could detect ClC-1 transcripts also in liver, 
ClC-1 levels were reported to be only ≈0.01% of those found in mature skeletal muscle (43). The 
recently reported expression of ClC-1 in brain and other organs (123) has to be viewed with 
considerable skepticism (see below).  
In rodents, skeletal muscle Cl- conductance (145) and the expression of ClC-1 (807, 909) strongly 
increase in parallel within a few weeks after birth and decrease again with ageing (654). 
Northern blots were unable to detect the small amount of ClC-1 transcripts in myotubes which 
represent the embryonic stage of muscle (909), but sensitive RT-PCR showed that ClC-1 levels 
increased during the differentiation of myogenic cells to myotubes in cell culture (909). ClC-1 
transcription may be controlled by MyoD and myogenin transcription factors (419). In addition, 
developmental regulation of Clcn1 splicing may contribute to the postnatal increase in gCl and 
ClC-1 levels in rodents (495). Shortly after birth, a considerable fraction (~30%) of Clcn1 mRNA 
contains an additional exon (exon7a+) that introduces a frameshift and reduces mRNA levels by 
nonsense-mediated mRNA decay. Over the next few weeks, skipping of this extra exon 
increases, resulting in a rise in Clcn1 mRNA levels and functional channels (495).  
ClC-1 is more highly expressed in fast twitch than in slow twitch muscles and is modulated by 
electrical activity as revealed by myotonic mouse models in which ClC-1 levels were increased, 
and denervation experiments which decreased ClC-1 transcript levels (419). These changes in 
ClC-1 expression correlate well with the previously described decrease of muscle Cl- 
conductance upon denervation (145). Immobilization of muscles in a hindlimb unloading model 
appeared to moderately increase ClC-1 mRNA levels specifically in low-twitch soleus muscle of 
rats (655), an effect that may, however, be less important than the activation of ClC-1 that 
results from decreased protein kinase C (PKC) activity under these conditions (656). Hence 
transcriptional regulation of ClC-1 not only plays a role during development, but also during the 




B. Basic properties and posttranslational regulation of the ClC-1 channel 
ClC-1 is the closest mammalian orthologue of the electric organ chloride channel ClC-0. The 
general properties of heterologously expressed ClC-1 channels are in agreement with those of 
the skeletal muscle Cl- conductance (83, 617, 807). However, before the cloning of ClC-1, the 
skeletal muscle Cl- conductance had been studied mostly using current-clamp recordings of 
skeletal muscle fibers, which does not allow a precise determination of biophysical parameters 
(83). Recently, whole cell patch clamp recordings and two electrode voltage-clamp recordings 
have shown that the properties of the endogenous conductance are practically identical to that 
of heterologously expressed ClC-1 channels (196, 496, 497). Like this prototype channel, it 
shows a typical ‘double-barreled’ electrophysiological fingerprint with two equally spaced, 
independent conduction levels (739). However, since its single-channel conductance is  ~1.5 pS, 
as first determined by noise analysis (678) and later confirmed by single channel recordings 
(739, 814, 894, 897), much lower than that of ClC-0 (~10pS) (50, 548), it is technically more 
challenging to measure single channel currents of ClC-1. Moreover, compared to ClC-0, it is 
more difficult to distinguish between common gating (that affects both pores of the dimeric 
channel) and protopore gating (that affects only one pore). Whereas the common gate 
activates ClC-0 very slowly (within seconds) upon hyperpolarization, the protopore gate is fast 
(in the 10 ms range) and opens upon depolarization. By contrast, both the common and 
protopore gates open upon depolarization and do not show drastic differences in gating 
kinetics at physiological voltages with slow and fast time constants that differ by less than 
roughly a factor of 5 and are smaller than 100 ms  (8, 720, 721, 739). Hence more sophisticated 
analysis is needed to distinguish both gates in ClC-1 (8, 739), which can be affected 
differentially by myotonic mutations. The voltage-dependence of both gates contributes to the 
outward-rectification of macroscopic currents. ClC-1 is about 40 % open at resting voltages of 
skeletal muscle (894) and can be opened further by depolarization. It displays a Cl->Br->NO3->I- 
selectivity sequence (722) that is typical for CLC channels.   
Biophysical properties and structure-function aspects of ClC-1 have been studied extensively (2, 
8, 35, 54-56, 113, 205, 206, 224, 356, 503-505, 719-722, 739, 749, 920). ClC-1 is voltage-
dependent, deactivating at negative voltages, with a steady state open probability curve that 
can be approximated by a Boltzmann distribution with an apparent gating valence of ~1 
elementary charge (233, 678, 679, 720). This gating behavior is reminiscent of the fast gate of 
ClC-0, and, at physiological pH, the channel shows no sign of a slow, hyperpolarization activated 
gate (see Fig. 6). Only at acidic extracellular pH (5.5), and keeping a positive holding potential, 
the channel exhibits activation by hyperpolarization, with some features similar to the slow 
gating of ClC-0 (720). Furthermore, single point mutations in various protein regions induce a 
gating phenotype that is fully or partially characterized by activation by hyperpolarization, some 
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of which are causally involved in myotonia (230, 233, 319, 674, 718, 918, 947). In all cases 
studied, the hyperpolarization activation was sensitive to the intracellular Cl- concentration 
(674, 718, 918), as is the gating of ClC-2 (588, 674). This suggests that the basic gating 
phenotypes seen in CLC channels share common mechanisms, possibly being ultimately 
attributable to a facilitation of opening by pore occupancy and competition with the gating 
glutamate. 
In contrast to the fast gate of ClC-0, the deactivating current relaxations of ClC-1 cannot be 
described by a single-exponential function, but bear at least two exponential components 
(720). While Fahlke and colleagues concluded that intrinsic sensors of the protein are 
underlying its voltage-dependence (232, 233), there is ample evidence that the basic 
mechanisms of voltage dependent gating of ClC-1 are similar to those of ClC-0, and that gating 
is strongly coupled to anion / proton movements within the pore (8, 479, 719-721). In 
particular, reduction of the extracellular Cl- concentration leads to a shift of the voltage-
dependence of the open probability to more positive voltages (720), similar to its effect on ClC-
0 fast gating. Compared to ClC-0, gating of ClC-1 is relatively insensitive to the intracellular Cl- 
concentration (720). Interestingly, the myotonia causing mutation A331T, located in the 
extracellular loop connecting helices I and J, induce a [Cl-]int sensitivity of gating (886). Similar to 
the fast gate of ClC-0, gating of ClC-1 is dependent on intracellular pH, with faster deactivation 
at more alkaline pH (479, 720). 
A major difference to ClC-0 is that certain impermeant anions, like methanesulfonate or 
cyclamate, can partially substitute for Cl- in promoting gate opening (722). This somewhat 
paradoxical behavior could be related to a complex interrelationship between fast and slow 
gate, analogous to the effect of ClO4- in certain ClC-0 mutations (490). In fact, a major 
complication of the earlier studies on ClC-1 was that contributions of the single protopore gate 
and the common gate could not be distinguished. Single channel analysis showed that both 
gates are present but that they show considerable kinetic overlap, with the single protopore 
gate being only ~ 3-5-fold faster than the common gate at negative voltages (739). Accardi & 
Pusch discovered that the time constant of the protopore gate exhibits an exponential voltage 
dependence at positive voltages, becoming very fast and reaching values in the order of 10-20 
µs at 200 mV (8). This finding by itself is interesting regarding the mechanism of fast gate 
opening, i.e. the rate limiting step underlying fast gating has to be able to operate on a time-
scale faster than this. By comparison, the fast gate time constant of ClC-0 showed a similar 
exponential voltage dependence, being, however, almost 10-fold slower (8). The exponential 
voltage dependence of the opening rate constant for voltages up to 200 mV additionally implies 
that the rate limiting opening step of the fast gate is associated with the movement of an 
electric charge with an apparent valence of ~0.79 for ClC-1 and ~0.55 for ClC-0 (8). 
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Importantly, the slow gate time constant of ClC-1 is much less voltage dependent such that the 
two gating processes become kinetically distinct by a factor of more than 100 at large positive 
voltages, allowing an efficient separation of the two gating processes using adequate pulse 
protocols (8). In this way, assuming independence of the protopore and common gates, the 
voltage-dependence of the two processes can be determined separately. It has to be 
underscored, however, that this procedure is approximate because of the relatively strong 
interdependence of the two gates. 
Using this procedure, Accardi & Pusch found that both gates are activated at positive voltages 
and that the common gate shows a significant minimal open probability even at negative 
voltage (8). The procedure allowed to dissect also the [Cl-]ext and pHint dependence of the two 
gates, finding that both gates are in fact dependent on these parameters (8). The detailed  
analysis of Lisal & Maduke of the pHint dependence of fast and slow gating of ClC-1 (479) 
revealed that ClC-1 behaves very similar in that respect compared to ClC-0. Bennetts et al. (56) 
reported that the common gate of ClC-1 has a much larger temperature dependence than the 
fast gate, however less so than the common gate of ClC-0 (676). 
An important piece of evidence that the slow gate, defined through the prepulse protocols of 
Accardi & Pusch, corresponds to the common gate of ClC-0, was that the C277S mutation, 
which corresponds to C212S of ClC-0, almost completely abolished the slow gate, as does  
C212S in ClC-0 (2, 472). The same mutation almost abolished Zn2+ block of ClC-1 (206), similar to 
its effect in ClC-0 (472). From their studies of Zn2+ block of ClC-1, Duffield et al. concluded that 
Zn2+ stabilizes a closed state of the channel, recovery from which is much slower and more 
temperature dependent than the regular gating kinetics (206). Such a deeply inactivated state is 
an interesting hypothesis, which might apply to other CLC proteins as well. The Zn2+ binding 
site, however, remains unknown for ClC-1 and for ClC-0. 
More recently, Bennetts et al. discovered that mutating the tyrosine of the selectivity filter 
(Y578 in ClC-1, Y512 in ClC-0) dramatically activated the common gate in both channels (54). 
Like in ClC-0, neutralizing the gating glutamate in ClC-1 completely eliminates slow and fast 
gating components (224, 234). 
Thus, there is highly convincing evidence that the common gate of ClC-1 shares many features 
with the slow gate of ClC-0, despite an inverted voltage-dependence.  Using FRET analysis of C-
terminally fused fluorescent proteins Ma et al. reported a movement of the C-terminal regions 
upon maneuvers that are expected to manipulate the common gate open probability  (504). 
The extent of the movement was, however, smaller than that reported for ClC-0 in analogous 
experiments (93). 
Of likely physiological importance, the intracellular pH dependence of ClC-1 is highly dependent 
on intracellular nucleotide concentration. Whereas currents of heterologously expressed ClC-1 
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where rather increased by acidic pHint when studied in whole-cell patch-clamp or in inside-out 
patches without intracellular ATP (8, 720, 739), ClC-1 is inhibited by intracellular acidification 
when studied in the presence of physiological ATP concentrations (55, 841). As discussed later, 
the inhibition of native ClC-1 channels by acidic intracellular pH may play an important role in 
the adaptation of muscle to intense exercise (639). 
Two other means of modulating ClC-1 activity, namely intracellular binding of ATP and 
modulation by protein kinase C (PKC), are important for muscle physiology. ClC-1 conductance 
at resting voltages can be inhibited by intracellular ATP and other nucleotides which shift its 
current-voltage relationship to more positive potential, probably by acting on the common gate 
(55, 57, 841, 842). The inhibitory effect of ATP is stronger at acidic pHint (841) and is controlled 
by oxidation and reduction (953), a finding that may explain why another study (968) failed to 
reproduce an influence of ATP on ClC-1. Site-directed mutagenesis provided convincing 
evidence that ATP acts by binding to the cytosolic CBS domains of ClC-1 (57, 842). Also 
intracellular β-nicotinamide dinucleotides (NAD) inhibit ClC-1 and endow an exquisite pHint-
sensitivity on the channel (58). Like ATP, NAD probably exerts their effects by binding to the 
CBS domains and changing the common gating of ClC-1. Both modulation by pHint and 
[ATP]int are posed to link ClC-1 activity to muscle metabolism, but are predicted to have 
qualitatively opposing effects on gCl: a drop of pHint and [ATP]int upon muscle exercise should 
decrease and increase, respectively, muscle chloride conductance. 
Currents of heterologously expressed ClC-1 could be inhibited by activating PKC with phorbol 
esters (711). However, the effect of phorbol esters is slow and PKC has pleiotropic effects which 
may include a reduction of surface expression. Thus, a change in biophysical channel properties 
more convincingly demonstrates a direct effect of PKC than a change in current amplitudes 
(711). More recent studies reported that phorbol esters shifted the voltage-dependence of ClC-
1 by nearly 20 mV to more positive potentials (358, 701), predominantly by changing the 
common gate and without affecting maximal current amplitudes (701). Channels carrying 
double mutations of PKC consensus sites suggested that phosphorylation of carboxy-terminal 
serines/threonines (891-893 in human ClC-1) may mediate the shift in voltage-dependence 
(358). It remains an open question whether such a change in ClC-1 properties or other factors 
like the reported PKC-dependent change of its localization in myofibers (625) accounts majorly 
for the well-established inhibition of muscle gCl by PKC (84, 840). A role of protein kinase C in 
regulating muscle gCl has recently been confirmed genetically by studying mice devoid of 






C. Role of ClC-1 in muscle physiology 
Skeletal muscle is unusual in that about 80% of the resting conductance is mediated by Cl- 
rather than K+ ions as in most other tissues (12, 14, 83, 364, 477, 617). ClC-1 mediates the bulk 
of this conductance as is evident from myotonic animal models that carry inactivating CLCN1 
mutations. Although skeletal muscle expresses the Na+K+2Cl--cotransporter NKCC1 (851, 913) 
which uses the inwardly-directed Na+-gradient to accumulate Cl- in cells, the high Cl- 
conductance of skeletal muscle ensures that [Cl-]i is nearly at its electrochemical equilibrium. 
ClC-1 therefore stabilizes the resting membrane potential of skeletal muscle (which is 
eventually determined by the interplay of the Na+/K+-ATPase and K+ channels) and significantly 
contributes to the repolarization of action potentials in a role that resembles that of K+ 
channels in most other cells. Muscle action potentials may further lead to incremental voltage-
dependent activation of ClC-1 during repetitive firing (679, 843). As discussed below, however, 
regulation of ClC-1 by kinases, pH and ATP may be physiologically more important than its 
voltage-dependent activation.  
If skeletal muscle plasma membrane conductance would be carried predominantly by K+, as is 
the case with loss-of-function mutations of Clcn1 in myotonia, there would be a significant 
increase of extracellular K+ concentration during the repolarization of action potentials, in 
particular in the narrow t-tubules that penetrate and criss-cross the muscle to ensure efficient 
excitation-contraction coupling by voltage-gated L-type Ca2+ channels. Since extracellular [K+] is 
in the 5 mM range, a rather small repolarizing outward flow of K+ into these tubules would lead 
to a relatively large increase in t-tubular [K+] (265). This may lead to a depolarization of t-
tubular membranes with the danger of eliciting unwanted action potentials and muscle 
contraction (as actually observed as ‘myotonic runs’ in myotonia). Since extracellular [Cl-] is 
much higher (~120 mM), the same amount of charge transfer during repolarization would lead 
to ~25-fold lower relative extracellular concentration change of Cl- compared to K+. The influx of 
Cl- into the muscle fiber will not significantly change [Cl-]i either because of the large 
intracellular volume of muscle fibers. Hence, for the repolarization of muscle action potentials, 
Cl- is better suited than K+. 
These considerations rest largely on the assumption that ClC-1 is expressed in t-tubules, which 
was indeed suggested by a substantial decrease of K+-, but not of Cl—conductance, upon tubular 
disruption with glycerol (617), and by experiments on mechanically skinned muscle fibers (146, 
177, 208, 639). However, immunohistochemistry did not detect ClC-1 on t-tubules, but rather 
on the sarcolemma (313, 625). Two recent studies, both of which were commented (226, 969), 
come to opposite conclusions concerning the presence of ClC-1 on t-tubules (196, 497). Hence, 
although a careful discussion tends to rather support a t-tubular expression of ClC-1 (640), this 
issue remains unresolved.  
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A recent series of elegant studies revealed that regulation of ClC-1 activity plays an important 
role in the control of excitability of working muscle (176, 637, 638, 701). Repetitive action 
potential firing in muscle leads at first to an increase in the electrical resistance of the muscle 
membrane. The increased resistance, which increases the electrical excitability by reducing 
shunt currents, could be attributed to an inhibition of ClC-1 by protein kinase C (176, 638) and 
also, to some degree, to an inhibition of ClC-1 by intracellular acidification (636). In fast-twitch, 
but not in slow-twitch muscle fibers, prolonged action potential firing later leads to a marked 
increase in membrane K+ and Cl- conductance that is mediated by an activation of KATP and ClC-
1 channels, respectively (637). Since both channels are inhibited by intracellular ATP their 
activation is probably caused by a decrease in [ATP]i during exercise. The resulting increased 
shunt conductance decreases action potential amplitudes and muscle excitability and is a 
correlate of muscle fatigue.  
 
D. ClC-1 in myotonia 
Myotonia is a symptom of several neurological diseases and is associated with an impaired 
relaxation of skeletal muscles after voluntary contraction (97, 402, 712, 817). Electromyograms 
typically reveal ‘myotonic runs’, trains of action potentials which are elicited by single stimuli 
that would trigger only one action potential in normal muscle. This suggests that myotonia is 
caused by a muscle-intrinsic electrical hyperexcitability. Myotonia can be caused by mutations 
in ion channels like ClC-1, the Nav1.4 Na+-channel, the Cav1.1 Ca2+ channel, or several inwardly-
rectifying Kir K+-channels (for review, see e.g. (97)) and also by a more indirect decrease of 
channel activity (like aberrant splicing of ClC-1 in myotonic dystrophy (119, 518)). The term 
myotonia congenita is reserved for myotonia caused by mutations in the CLCN1 gene. 
The first clinical description of myotonia was given by Julius Thomsen in 1876 (835). He himself 
suffered from the disease which segregated in his family in an autosomal dominant manner. 
The dominant form of myotonia congenita is therefore known as ‘Thomsen disease’. We now 
know that Dr. Thomsen carried the P480L mutation in the CLCN1 gene (806).  
The first animal model for myotonia was the ‘fainting goat’ which spontaneously arose as a 
probably dominantly inherited trait in North America. Early work indicated that the 
hyperexcitability of their muscles was not due to altered innervation (86). Bryant and 
colleagues discovered that their muscles displayed reduced Cl- permeability (13, 476) and found 
similar changes in myotonic patients (477). A well-established animal model for recessive 
myotonia are adr mice (891) which also display severely reduced muscle Cl- conductance (537). 
Almost immediately after the molecular identification of ClC-1 as the major skeletal muscle Cl- 
channel (807) the Clcn1 gene of adr mice was shown to be inactivated by the insertion of a 
transposon (805). Following this seminal finding, CLCN1 mutations were identified in human 
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myotonia (423), in the myotonic goat (51), and in several other mammals with myotonia, 
including dog (248, 694), sheep (568), horse (906) and water buffalo (72). To date, more than 
200 CLCN1 mutations (485, 667, 670) have been identified in patients with myotonia congenita 
and many of these have been studied functionally after heterologous expression. 
In humans, myotonia congenita can be inherited as an autosomal dominant or recessive trait 
(known as Thomsen disease and Becker disease, respectively). However, following the 
identification of the underlying gene, it became clear that low-penetrance dominant CLCN1 
mutations can be associated with dominant myotonia in some families, and recessive myotonia 
in others (435). Since only one CLCN1 allele is mutated in dominant myotonia, Thomsen disease 
is in general clinically less severe, with particularly mild forms sometimes being called myotonia 
levior (452). In both recessive and dominant forms of the disease, muscle stiffness is particular 
severe after rest and gets better with exercise (the ‘warm-up’ effect) (97, 712). A sudden, 
severe muscle stiffness after rest also explains the startle response of myotonic goats (86), adr 
mice (891) and myotonic buffalos (72), in which these animals fall down when trying to run 
away after being scared. This startle response has led to the misnomer ‘fainting goats’ for 
myotonic goats. There is no muscle dystrophy in myotonia congenita and patients rather have 
an athletic appearance. Their muscles are hypertrophic owed to the increased muscle exercise 
caused by myotonia. Muscle hypertrophy is also seen in animal models of myotonia as 
impressively demonstrated for buffaloes (72).  
Reduction of skeletal muscle Cl- conductance contributes in at least two ways to the 
pathogenesis of myotonia congenita. As discussed above, a decrease of muscle resting 
conductance (down to ~20% with a complete loss of ClC-1) causes electrical hyperexcitability 
because depolarizing currents are now less opposed by electrical shunting. Hence action 
potentials can be elicited by smaller depolarizing currents. Second, and probably more 
important, a much larger proportion of the repolarizing currents terminating action potentials is 
now carried by K+ which accumulates in the small extracellular space of the t-tubular system. 
The resulting depolarization may exceed the threshold for the activation of Na+ channels and 
thereby elicits aberrant action potentials that result in the typical ‘myotonic runs’ of patients.  
Myotonia-causing mutations in CLCN1 are scattered over the entire coding region and may also 
affect non-coding regions if they affect transcription or RNA processing. There is also a sizeable 
~5% fraction of patients with recessive myotonia who display exon deletions or duplications in 
CLCN1 (687). Protein-truncating and missense mutations are scattered all over the 
transmembrane part of the protein, but can also be found in the cytosolic amino- and carboxy-
terminal parts of the protein. Nonsense or frameshift mutations are almost always associated 
with recessive myotonia with the exception of a few mutations that truncate only a short part 
of the long cytosolic tail of ClC-1 (540, 698). Premature stop codons can decrease mRNA levels 
by nonsense-mediated mRNA decay and in most cases the truncated protein will not form 
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functional channels. Moreover, most truncated proteins (with the above-noted exceptions) will 
be unable to form a dimer with WT ClC-1 proteins and are therefore expected to lack dominant-
negative effects in heterozygous patients. Conversely, almost all dominant CLCN1 mutations 
result in single amino-acid exchanges that still allow the mutated protein to interact with its WT 
partner and thereby change its function in a mutant/WT dimer. Random point mutations are 
less likely to produce such mutants than causing a complete loss of channel function, explaining 
why more recessive than dominant mutations have been found in myotonia (485, 670). It is 
presently impossible to predict whether a particular novel CLCN1 missense mutation is 
associated with recessive or dominant myotonia.   
Graded pharmacological inhibition suggested that muscle Cl- conductance has to be decreased 
by roughly 75% in order to cause myotonia (274, 440). This result is consistent with the 
observation that complete loss-of-function CLCN1 mutations on only one allele, which might be 
expected to reduce muscle Cl- conductance by 50%, does not result in myotonia. However, 
despite having halved functional gene dosage, heterozygous Clcn1adr/WT mice displayed normal 
muscle gCl owing to some type of post-transcriptional regulation (122). In dominant myotonia, 
gCl is reduced close to the critical 25% of WT level, thereby explaining that Thomsen disease is 
generally less severe than Becker-type myotonia in which there may be a total loss of ClC-1 
function. If the efficiency of dimer formation is not changed in the dominant channel mutant, 
heterozygous patients will express 25% fully functional WT/WT ClC-1 channels. Even if 
mutant/mutant and WT/mutant channels would be non-functional, gCl would remain at 25% of 
WT levels. 
Many, and probably most, dominant CLCN1 mutations shift the voltage-dependence of ClC-1 to 
positive voltages where the channel no longer contributes significantly to resting gCl and to the 
repolarization of action potentials (679) (Fig. 6). This shift is not only seen with mutant/mutant 
homodimers, but to a lesser degree (that depends on the particular mutation (435)) also in 
WT/mutant heterodimers (679) (Fig. 6). This dominant effect on gating is mediated by the 
common gate that affects both protopores and thereby allows for a cross-talk between the 
subunits (739). These mutations include I290M (679), which is located at the dimer interface 
(210). The residues of the two subunits corresponding to I290 in EcClC-1 (I201 in helix H) are 
directly contacting each other in the crystal structure of EcClC-1, underscoring the importance 
of the dimer interface for the common gate. Interestingly, the mutation I201W, together with 
the I422W mutation was sufficient to yield monomeric EcClC-1 proteins (705). Another 
dominant mutation is P480L that was found to cause myotonia in Thomsen’s own family (806). 
Homomeric mutant channels are non-functional, and the mutant exerts a strong dominant 
negative effect on the WT (806), by dramatically shifting the voltage-dependence to more 
positive voltages (679). P480 is not located at the dimer interface but in the loop preceding 
helix N, close to the selectivity filter, suggesting that the strong effect of the mutant on the 
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gating might be caused by alterations in ion binding properties. Mutant I556N, that has a mixed 
dominant/recessive inheritance, was found to shift the overall voltage-dependence of gating 
but to have virtually no dominant negative effect in co-expression with WT (435). Dissection of 
fast and slow gating components revealed that indeed the I290M mutation has a large effect on 
the slow gate, whereas the I556N mutation has a stronger effect on the fast gate (8, 739). Over 
the past two decades, many more dominant mutations were found to shift the voltage-
dependence of ClC-1 (89, 305, 319, 369, 435, 485, 535, 670, 784, 912, 918, 946). 
 
However, not all mutations shifting the ClC-1 voltage-dependence exert dominant effects and 
are rather associated with recessive myotonia (like V236L or G190S) (189, 667, 770). Mutations 
that only confer a moderate shift in voltage-dependence on mutant/WT heterodimers have 
sometimes been found in recessive and dominant pedigrees (435). In addition to an effect on 
the common gate, missense mutations may also affect the processing or trafficking of 
WT/mutant heteromers. Several missense mutations in the ClC-1 amino-terminus affected the 
surface expression of ClC-1, with Q43R also strongly affecting the surface expression of 
WT/mutant concatemeric channels (710). However, this mutation was associated with 
recessive myotonia, suggesting that the observed dominant effect on surface expression may 
just occur with covalently linked concatemers. 
The mechanisms by which recessive CLCN1 mutations can cause myotonia are manifold as the 
required final outcome is just a significant reduction of ClC-1 currents under physiological 
conditions. Recessive CLCN1 mutations may affect ClC-1 by abolishing protein expression 
altogether, by enhanced degradation of probably misfolded proteins (450) (626, 861), impaired 
surface expression (710), or changes in biophysical properties like single channel conductance 
(894, 912) and gating (189, 233, 667, 894, 912, 918, 947).  
Myotonia is also a symptom of myotonic dystrophy, a multi-system disorder which is caused by 
(CTG)n expansion in the 3’-untranslated region of the DM1 protein kinase (DMPK) gene or 
(CCTG)n repeats in an intron of the zinc finger protein-9 gene (ZFN9). Both DMPK and ZFN9 
mutant transcripts accumulate in nuclei of skeletal muscle and sequester CUG-repeat binding 
proteins such as muscleblind-like which have a role in regulated splicing (119, 405, 551). This 
entails aberrant splicing with an inclusion of the frameshift-inducing exon7+, which is also 
observed in early postnatal muscle (495), and reduces ClC-1 mRNA and gCl to levels that cause 
myotonia (119, 496, 518). Several preclinical studies aim at restoring normal Clcn1 splicing in 
mouse models for myotonic dystrophy using oligonucleotides (424, 903) or small molecules 





E. A role for ClC-1/ClC-2 heteromers in skeletal muscle? 
Skeletal muscle not only expresses ClC-1, but also the widely expressed ClC-2 Cl- channel (832) 
with which it shares roughly 55% identity. ClC-1 and ClC-2 can form heteromeric channels with 
altered properties when co-expressed (484). Whereas ClC-1 is opened by depolarization and 
ClC-2 opens slowly with hyperpolarization, ClC-1/ClC-2 heteromers showed almost time-
independent, ohmic currents (484). Prominent and roughly similar changes in gating were also 
observed with ClC-1—ClC-2 concatemers in which both subunits were covalently linked (814). 
However, the covalent linkage affected the phenotype which was evident from different gating 
properties when subunits were arranged in the opposite order and which may relate to the role 
of the ClC-2 amino-terminus in slow gating (303). Very surprisingly, single channel conductances 
of ClC-1—ClC-2 concatemers were reported to differ from those of ClC-1 or ClC-2 homodimeric 
channels (814). This contrasts with the unchanged single channel amplitudes of ClC-1, ClC-2 and 
ClC-0 protopores with ClC-1—ClC-0 and ClC-2—ClC-0 concatemers (897). Unchanged single 
channel properties would be expected from the observation that the permeation pathway is 
entirely contained in each CLC protein subunit (210).   
Regardless of these discrepancies, the question arises whether ClC-1/ClC-2 heteromers, which 
do not yield significantly more currents than a superposition of currents from the respective 
homooligomers, play a significant physiological role. In view of the probably much higher 
skeletal muscle expression of ClC-1 compared to ClC-2, which is supported by the near-total loss 
of gCl and the appearance of myotonia upon genetic loss of ClC-1, but not of ClC-2, the answer 
is most likely negative.  
 
F. Roles of ClC-1 beyond skeletal muscle? 
Northern blot analysis using a full-length ClC-1 cDNA as probe detected robust ClC-1 mRNA 
expression in skeletal muscle (807). ClC-1 transcripts were almost undetectable in tissues like 
brain, liver, kidney and lung, with heart possibly showing a very faint hybridization signal (807). 
Likewise, Northern analysis by Conte Camerino and colleagues detected ClC-1 in skeletal 
muscle, but not in heart (654). Surprisingly, Noebels and coworkers recently suggested that ClC-
1 shows widespread tissue expression which prominently includes brain and heart (123). 
However, the antibodies used to detect ClC-1 in Western blots of brain and muscle were not 
knock out controlled and the RT-PCR employed to detect Clcn1 transcripts used a large number 
of amplification cycles (35 to 40). Indeed, the similar abundance of amplification products in 
brain, heart, and muscle, suggests that PCR amplification had reached saturation (123). In 
particular, there was no difference in signal intensities when PCR was performed on RNA 
derived from 10 days-old or adult mouse skeletal muscle (123), which conflicts with the well-
known increase of ClC-1 expression (807, 909) during that time.   
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Noebels and coworkers also suggested a role of brain-expressed ClC-1 in human epilepsy (123). 
They reported a three-fold increase of non-synonymous single nucleotide polymorphisms in the 
CLCN1 gene of patients with idiopathic epilepsy versus controls and identified a heterozygous 
nonsense mutation in CLCN1 (R976X; which deletes the last 12 amino-acids of the ClC-1 
protein) in one of the patients. The functional effect of this truncation, which deletes a 
significantly shorter part of the C-terminus than the well-characterized myotonia-associated 
R894X mutation (287, 333, 507, 540, 626), was not assessed functionally and the patient 
carrying this mutation did not display myotonia (123). A recent report (466) found one patient 
with epilepsy and limbic encephalitis in a family affected by dominant (Thomsen) myotonia due 
to the well-characterized I290M mutation (670, 679), but epilepsy in that patient was likely due 
to the presence of anti-GAD antibodies. Hence, there is currently no convincing evidence for a 
role of ClC-1 in epilepsy. Moreover, such a role appears unlikely because patients with CLCN1-
associated myotonia generally don’t display epilepsy and because brain expresses only low 
amounts of the highly muscle-specific ClC-1 channel. 
 
G. Pharmacology of ClC-1 
Small organic acids have long been known to reduce the skeletal muscle Cl- conductance, gCl. In 
particular, gCl is reduced by 9-anthracene-carboxylic acid (9-AC) (87, 618) and clofibric acid 
derivatives (144, 174). Both types of compounds have been confirmed to act directly on ClC-1 
(33, 38, 807) with apparently different mechanism of function: 9-AC reduces the currents in a 
voltage-independent manner, whereas 2-(p-chlorophenoxy)propionic acid (CPP) leads to an 
apparent shift of the voltage-dependence to more positive voltages (33). In qualitative 
agreement with its effect on skeletal muscle GCl (144), only the S(-) enantiomer was effective 
(33). The reported small activating effect on GCl of the R(+) enantiomer (144, 174) is not seen in 
heterologously expressed ClC-1 (33, 675).  
Using inside-out and outside-out patch clamp recordings, both CPP and 9-AC were found to act 
directly on ClC-1 only when applied to the intracellular side of the membrane (672, 675), and 9-
AC block was found to be voltage-dependent similar to CPP induced inhibition, however with a 
slow unlocking kinetics at positive voltages (672).  
The relative specificity of channel block by 9-AC for ClC-1 versus ClC-0 and ClC-2 was 
experimentally exploited e.g. to characterize heterodimers of ClC-0 with ClC-1 (897) and in a 
study of heteromeric channels between ClC-1 and ClC-2 (484), respectively. Furthermore, using 
a chimeric strategy and mutagenesis guided by the Ec-ClC-1 crystal structure, the putative 
binding sites of 9-AC and the CPP analogue CPA, were found to be overlapping and close to the 
permeation pathway in a hydrophobic pocket (224). Lacking a ClC-1 crystal structure, however, 
the precise binding site is not clear at atomic detail. A modelling study of CPA binding to ClC-0 
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(569) identified superficial access binding modes by docking, and a deeper site in the pore by 
forced molecular dynamics (569). In the deep configuration the negatively charged carboxylate 
moiety pointed to the gating glutamate (569) in agreement with strong effects of mutations of 
the gating glutamate on the apparent CPA affinity (224, 838). Several analogues of CPP, as well 
as niflumic acid, were found to inhibit ClC-1 in a similar manner, with adding a second phenoxy 
group resulting in a much more potent block (458-460). 
The voltage-dependent inhibition of ClC-1 by CPP and CPP analogs is phenomenologically very 
similar to the action of intracellularly applied benzoate, hexanoate and propionate (721). The 
mechanism by which these CPP analogs inhibit muscle type CLC channels has been extensively 
studied in ClC-0, mostly using the simpler, non chiral CPA. Using single channel recordings, 
Pusch et al  (671) found that CPB (p-chloro-phenoxy-butyric acid) inhibits individual protopores 
of the double barreled channel, inducing long closures consistent with a model in which CPB 
binds preferentially to closed channels in competition with Cl- ions. Similarly, Accardi  & Pusch 
interpreted the voltage-dependence of CPA / CPP block using a model in which CPA binds with 
high affinity to the closed state (of the fast gate) to act essentially as a gating modifier (7). 
Traverso & Pusch (838) found, in agreement with the mutagenesis study of Estévez (224), that 
the neutralization of the gating glutamate in the E166A mutant dramatically increased CPA 
affinity. They suggested that the E166A mutant can assume a conformation which resembles 
the closed state even though it is essentially locked open. CPA was proposed to bind to the 
closed conformation with rather high affinity, even though a simpler sequential binding model 
to a single open state could not be excluded (838). 
These results show that the side chain of residues at position 166 have a significant steric 
influence on the affinity and permeability for CPA, even though the conduction of Cl- ions is 
almost not affected. This “state dependent” binding model was questioned by Chen and co-
worker who found that other mutations of the gating glutamate, like E166Q or E166K, exhibited 
a very small affinity to CPA (954). They interpreted the effects of CPA on WT and mutated 
channel in a model with sequential binding of CPA to two binding sites, one close to the 
intracellular solution, and another one deep in the pore (954). In addition, Zhang et al. 
proposed that CPA is aligned in the pore with its hydrophobic end oriented towards the gating 
glutamate, i.e. in the opposite orientation proposed by Moran et al. (569). In addition, Zhang & 
Chen found that in the E166G mutant CPA can actually “punch” through the pore, when driven 
by large negative inside voltage (951). These results show that the side chain of residues at 
position 166 have a significant steric influence on the affinity and permeability for CPA, even 
though the conduction of Cl- ions is hardly affected. In light of the crystal structure of the 
bovine ClC-K channel (628), which exhibits a very narrow pathway, it is rather surprising that 
molecules as large as CPA can permeate the ClC-0 pore. The result is however in agreement 
with the ability of intracellularly applied cysteine modifying reagents to modify the E166C 
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mutant, in which the gating glutamate is replaced by a cysteine (955). In contrast, 
extracellularly applied cysteine modifying reagents are unable to affect this mutant (Pusch, 
unpublished result). It will be interesting to determine the precise binding of CPA and other 
small molecules in ClC-0 and ClC-1 at atomic resolution. Such studies could help to clarify if fast 
gating of these channels is associated with conformational changes beyond the movement of 
the side chain of E166. 
In some cells including myotubes, the effect of drugs on ClC-1 currents is confounded by an 
(often Ca2+-dependent) activation of PKC that may inhibit ClC-1 by phosphorylation (460, 653). 
For instance, all investigated statins inhibited ClC-1 by activating PKC, with only fenofibrate 
additionally blocking ClC-1 directly (653). Also niflumic acid, often used to inhibit Ca2+-activated 
Cl- channels (326) and which indeed acts on TMEM16A (104, 756) and TMEM16B (657), inhibits 
ClC-1 directly (42 µM) and indirectly through  [Ca2+]i –dependent activation of PKC  (460).  
Unfortunately, we are still lacking ClC-1 inhibitors that display high affinity and specificity. While 
such drugs would be valuable for experimental studies in cells or animals, specific activators of 
ClC-1 might be useful to treat myotonia in those patients in which ClC-1 currents are not 
abolished, but reduced or shifted in their voltage-dependence. Sadly, no useful drug has 
emerged so far. The R(+) enantiomer of CPP increased muscle Cl- conductance (144), but had no 
effect on heterologously expressed ClC-1 (33, 675). So far, only modulation of muscle Cl- 
conductances by taurine (170, 171), insulin-like growth factor IGF1 (172) or PKC (173) appear to 
be feasible. However, no direct effect of taurine on ClC-1 expressed in Xenopus oocytes could 
be detected (Pusch, unpublished observation). 
 
 
VI.  CLC-2 – A WIDELY EXPRESSED CL- CHANNEL INVOLVED IN VARIOUS 
PROCESSES  
ClC-2 is a plasma membrane chloride channel that is found in cells of many, if not all, 
mammalian tissues (832). Macroscopic hyperpolarization-activated ClC-2-like currents have 
been described in many native cells including neurons in various brain regions (140, 256, 508, 
702, 790, 797), sympathetic neurons (139), rod bipolar cells (221), astrocytes (239, 247, 346, 
515, 516, 595) and oligodendrocytes (346), carotid chemoreceptors (643), trabecular meshwork 
cells (143), adrenal glomerulosa cells (246), hepatocytes (443), colon epithelial cells (109, 371),  
pancreatic acinar cells (105), salivary gland acinar (577, 629) and duct (197, 426, 709) cells, 
testicular Leydig and Sertoli cells (74), and erythrocytes (76, 361). Several studies used Clcn2-/- 
mice as controls to firmly establish that these currents are owed to ClC-2 (74, 246, 346, 361, 
516, 577, 702, 709). Clcn2-/- mice also revealed that a prominent, cAMP-stimulated inwardly-
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rectifying Cl- current of choroid plexus cells (403), although reported to be reduced by anti-ClC-
2 siRNA (404), is not mediated by ClC-2 (795). Less critical reviews focusing exclusively on ClC-2 
and related diseases have been published recently (62, 875). 
 
A. Properties of ClC-2 
ClC-2 is a dimeric, ‘double-barreled’ Cl-. channel with two pores and a single channel 
conductance of about 3 pS (815, 834, 897) which remained unchanged when, in concatemeric 
channels, the neighboring subunit is from ClC-0 rather than from ClC-2 (897) (Fig. 2). It mediates 
macroscopic Cl- currents that are slowly activated by hyperpolarization (832) (Fig. 7A) that 
display the typical Cl>I selectivity of CLC channels. Hyperpolarization-activation of ClC-2 
depends on an amino-terminal cytoplasmic stretch which remained functional when 
transplanted to a cytoplasmic site between the two CBS domains (303), and an intracellular 
loop between helices J and K that was hypothesized to interact with the amino-teminal 
‘inactivation domain’ (399). Many mutations in either region lead to ‘constitutively open’ ClC-2 
channels (Fig. 7B) that almost totally lacked gating relaxation and displayed much larger 
currents (303, 399). Much later, these regions turned out to be hotspots for human CLCN2 
mutations that cause primary aldosteronism by depolarizing aldosterone-producing adrenal 
glomerulosa cells through markedly increased efflux of Cl-  (246, 747). The effect of N-terminal 
ClC-2 deletions or point mutations on gating is probably affected by a still unknown cytoplasmic 
factor because it is observed in two-electrode voltage-clamp measurements of Xenopus oocytes 
(303) or perforated patch measurements on transfected cells (856), but not in whole-cell patch-
clamp (856) or excised oocyte patches (674). The activation kinetics of ClC-2 also depends on 
the cell used for expression (629) and on the cholesterol content (344) and is slightly changed 
by intracellular ATP levels that most likely act by binding to its intracellular CBS domains (589, 
815). Surprisingly, these CBS domains seem to be dispensable for ClC-2 channel function (280).  
Akin to other CLC channels and transporters, the gating of ClC-2 depends on the concentrations 
of Cl- and H+. Raising the intracellular Cl- concentration shifts the voltage-dependence of ClC-2 
to more positive potentials and thereby opens the channel (166, 588, 674, 730, 731), an effect 
that is likely to be physiologically important. At low [Cl-]i, ClC-2 gating is also influenced by 
extracellular Cl- (730).  
ClC-2 is strongly dependent on the extracellular pH in a biphasic manner: Slightly acidic pH 
activates the channel, whereas stronger acidification blocks ClC-2 (36, 399). Activation occurs 
with an apparent Hill-coefficient of 1 whereas block is more steeply dependent on the proton 
concentration with a Hill coefficient around 2 (36). Niemeyer et al. identified histidine 532 at 
the extracellular, N-terminal end of helix Q as the underlying proton sensor for acidification 
induced inhibition (587). Interestingly, mutants H532N and H532A were non-functional, 
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whereas H532F lost acid induced inhibition (587). The analogous histidine (H497) mediates part 
of the inhibition of ClC-K channels by acidic pH (296). The mechanism underlying this inhibition 
is still unknown. In particular it is unclear if protonation of this histidine residue results in the 
closure of the common gate. The respective histidine residue is conserved in ClC-0 and ClC-1, 
but its role in these channels is unknown. 
The neutralization of the gating glutamate leads to an almost completely open phenotype as in 
ClC-0 and ClC-1 (588), with only some residual gating relaxations  (178), suggesting that the 
gating glutamate is the key element of gating in ClC-2 and that basic gating mechanisms are 
conserved among these channels. The additional mutation H811A in the CBS-2 domain, the 
equivalent of which eliminated common gating in ClC-0 (223), resulted in a completely open 
phenotype (935). Further evidence for the presence of the two gating mechanisms in ClC-2, 
protopore gate and common gate, comes from the observation that mutating cysteine 256 
(equivalent to C212 in ClC-0) to alanine led to a quite large fraction of constitutively open 
channels and to reduced block by extracellular Cd2+ (178, 971). Furthermore, in WT ClC-2, 
activation time constants of both processes were highly temperature sensitive, suggesting that 
in ClC-2 the two gates appear to be strongly coupled as in ClC-1 (971). 
In contrast to ClC-0 and ClC-1, extracellular Cl- and intracellular protons (731) have little effect 
on ClC-2 gating , which is instead mostly controlled by voltage, extracellular pH and intracellular 
Cl- (36, 399, 588, 674). The activation by mild acidic pH is most likely mediated by the 
protonation of the gating glutamate of ClC-2 (587).  However, a major question is if the primary, 
voltage-dependent event, driving the displacement of the gating glutamate from its blocking 
position is a movement of a Cl- ion from the inside, pushing the glutamate side towards the 
outside, or a H+ ion, protonating the gating glutamate from the outside. Niemeyer et al. found 
that the apparent pK of acidification activation was voltage-dependent with an apparent 
electrical distance from the outside of 0.62, favoring the idea that voltage-dependent 
protonation followed by allosteric stabilization by a Cl- ion underlies gating of ClC-2 (587). In 
contrast, detailed studies from the Arreola group favor the idea that a Cl- ion, coming from the 
inside, displaces the negatively charged gating glutamate, which is then stabilized by voltage-
independent protonation from the outside in the open configurations (166, 730, 731). A strong 
argument of Arreola and colleagues was that they could open ClC-2 channels even at 
extracellular pH 10, which appears impossible if protonation is a prerequisite for channel 
opening (730, 731). Interestingly, also several intracellularly applied, impermeant anions are 
able to favor channel opening (166). Overall, these experiments indeed strongly favor the idea 
that ClC-2 is opened by intracellular Cl-. Nevertheless, it might be insightful to perform detailed 
kinetic analysis in a simplified system, for example with channels harboring mutations that 
eliminate slow gating in addition to the H532F mutant, allowing to extract opening and closing 
rate constants over large voltage-ranges, similar to what has been done for ClC-0 (128, 963). 
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ClC-2 can also be activated by osmotic cell swelling (303, 399). This process involves the same 
intracellular structures that are important for the activation by hyperpolarization (303, 399). 
Native bona fide ClC-2 currents were increased by osmotic cell swelling in parotid acinar cells 
(577), but the volume regulation of these cells did not differ in Clcn2-/- mice. Although 
Bergmann glia appears to be slightly swollen in Clcn2-/- mice (346) and though insect cells 
heterologously overexpressing ClC-2 appear to display accelerated regulatory volume decrease 
(923), there is currently no convincing evidence that native ClC-2 plays a significant role in cell 
volume regulation. This contrasts with the volume-regulated anion channel VRAC which is 
clearly involved in regulatory volume decrease (386). It should again be made clear that the 
inwardly rectifying ClC-2 is distinct (303) from the slightly outwardly rectifying VRAC which is 
now known to be composed of LRRC8 heteromers (821, 865).  
Besides modulation by Cl-, H+ and ATP, other pathways may influence or regulate ClC-2 activity. 
Several reports suggest that ClC-2 may be the direct or indirect target of quite a few different 
kinases (271, 276, 352, 417, 619, 630, 887), but most of these studies need to be replicated and 
their biological relevance remains unclear. The same holds true for the reported interactions of 
ClC-2 with cereblon (347), Hsp90 (345) and the dynein motor complex (192). By contrast, the 
interaction of ClC-2 with the adhesion molecule GlialCAM (also known as HepaCAM) appears 
firmly established. As discussed below, it changes the subcellular localization of ClC-2 and its 
biophysical properties (98, 346, 394, 395).  
 
B. Loss of ClC-2 leads to male infertility, blindness, and leukodystrophy 
Disruption of Clcn2 in mice leads to male infertility and blindness (74) as well as to slowly 
developing leukodystrophy, a degeneration of brain white matter (68). These phenotypes were 
reproduced in independently generated ClC-2 KO mice (150, 577) and in a chemically induced 
mouse mutant in which a stop codon truncates the ClC-2 protein within the transmembrane 
part (212). Moreover, Clcn2 disruption decreased intestinal Cl- absorption (111, 939).  
Initial screening of 150 leukodystrophy patients (68) and of 18 patients with megalencephalic 
leukoencephalopathy with subcortical cysts (746) gave negative results, but CLCN2 mutations 
(often resulting in stop codons on both alleles) were later identified in leukoencephalopathy 
patients who variably presented also with ataxia and visual disturbances (187, 289, 886) or 
paroxysmal dyskinesia (323, 944). A CLCN2 mutation associated with leukodystrophy, 
electroretinogram abnormalities and male infertility due to azoospermia has also been 




Clcn2-/- mice display severe testicular degeneration and azoospermia (74). Testes histology is 
normal during the first postnatal week, but seminiferous tubules of ClC-2 deficient mice fail to 
develop their normal lumen during their postnatal development. Germ cells are lost during the 
first four postnatal weeks after which tubules are filled with abnormal Sertoli cells. In the 
absence of changes in sex hormones, the testicular degeneration was suggested to result from 
defective transepithelial transport by Sertoli cells (74). These cells form the blood-testis barrier 
and ‘nurse’ the developing germ cells by, for instance, regulating the ionic environment of 
spermatids and spermatocytes, providing nutrients, and phagocytosing residual cytoplasm from 
spermatids. Intriguingly, ClC-2 is concentrated in patches at contacts between Sertoli cells (74). 
Whereas a superficially similar patchy localization of ClC-2 at astrocytic contacts is mediated by 
the cell adhesion protein GlialCAM (346), the mechanism underlying ClC-2 clustering at Sertoli 
cell contacts remains unknown.  
The blindness of Clcn2-/- mice ensues from an early postnatal degeneration of the 
photoreceptors, which eventually entails a complete degeneration of the retina (74). Again, this 
phenotype was tentatively attributed to impaired ion transport by ‘nursing cells’, in this case 
the retinal pigment epithelium (RPE) (74). These cells form the blood-retinal barrier, regulate 
the ionic environment of photoreceptors, remove metabolites and supply nutrients, and 
phagocytose photoreceptor outer segments. Impaired ion transport by the RPE of Clcn2-/- mice 
was supported by reduced transepithelial currents in Ussing chamber experiments, with the 
caveat that the degeneration might already have changed the structural integrity of the RPE 
(74). Clcn2-/- RPE cells showed extended microvilli even before the loss of photoreceptors, and 
electroretinograms from heterozygous Clcn2+/- mice (which lack retinal degeneration) revealed 
moderately changed RPE responses (193).  Hence both the testicular and retinal degeneration 
were suggested to result from impaired control of the extracellular environment by ‘nursing’ 
epithelial cells (74). The transport of lactate by both the RPE and Sertoli cells requires an 
efficient regulation of extracellular pH in the narrow clefts between these ‘nursing’ cells and 
photoreceptors and germ cells, respectively. It was therefore hypothesized that this regulation 
involves an interplay between Cl-/HCO3- exchangers and the (pHo-sensitive) ClC-2 Cl- channel 
(74). 
 
C. Gain-of-function CLCN2 mutations lead to aldosteronism 
Gain-of-function mutations in the CLCN2 gene were recently found to result in primary 
aldosteronism (246, 747), a condition in which dysregulated, constitutive production of 
aldosterone by adrenal glomerulosa cells entails severe hypertension and hypokalemia (245, 
794). Gratifyingly, several of the identified human mutations (246, 747) change amino-acids in 
the amino-terminal ‘inactivation domain’ of ClC-2 that had been identified previously by 
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structure-function analysis (303). One mutation affects a residue in the linker between helices J 
and K (747), a region previously postulated to interact with the amino-terminal ‘inactivation 
domain’ (399). These mutations, like those previously engineered in the above-mentioned 
structure-function studies (303, 399), largely abolish the voltage-dependent gating of ClC-2 and 
significantly increase Cl- currents (Fig. 7B) (246, 747). This gain of function agrees with the 
dominant effect of the mutations that in patients are present in a heterozygous state. Because 
cytoplasmic chloride concentration in glomerulosa cells is higher than predicted by the Cl- 
equilibrium potential, expression of these ClC-2 mutants depolarized adrenocortical H295R-S2 
cells (246) and led to an induction aldosterone synthase and increased aldosterone production 
(246, 747). Experiments with Ca2+ channel inhibitors strongly suggested that the increase in 
aldosterone synthesis is mediated by an increase of cytosolic Ca2+ due to an opening voltage-
gated Ca2+ channels (246) (Fig. 7C). It is currently unclear whether the ‘opening’ of ClC-2 by 
these mutations entails pathological changes in other tissues or cells and whether WT ClC-2 
influences aldosterone production under physiological conditions. Since the resting membrane 
potential of glomerulosa cells is very close to the K+ equilibrium potential (794), however, a loss 
of ClC-2 is unlikely to significantly hyperpolarize these cells. No changes in blood pressure were 
reported for Clcn2-/- mice (74, 577) nor for patients with loss-of-function mutations in CLCN2 
(187, 289, 886), but this issue has not been investigated in detail. 
 
 
D.  ClC-2 in epithelia 
ClC-2 was suggested to play a role in Cl- secretion in lung surface epithelia (66, 67, 574, 762) and 
in the intestine (158, 318, 565) and was also proposed to be able to compensate for the loss of 
CFTR Cl- channels in cystic fibrosis. This hypothesis, however, requires that ClC-2 is present in 
apical membranes, an assumption that is most likely wrong. 
The localization of ClC-2 to either the apical or basolateral membranes of epithelial cells was a 
matter of considerable controversy because of the lack of specific, knock out controlled 
antibodies. Initially ClC-2 was reported to reside in the apical membranes of lung surface 
epithelia (66, 475, 574) and at tight junction complexes of ileal surface epithelia (318). The 
latter labeling superficially resembles the KO-controlled dot-like ClC-2 staining of testicular 
Sertoli cells (74). However, it is now firmly established that ClC-2 is expressed at the basolateral 
membrane of intestinal epithelia (jejunum and colon) (109, 110, 475, 641) (Zdebik and Jentsch, 
unpublished) and salivary gland ducts (709). Several of these results were controlled by the 
absence of staining in Clcn2-/- tissue (641, 709)(Zdebik and Jentsch, unpublished). Moreover, 
when transfected into polarized epithelial cell lines like MDCK, ClC-2 was sorted to basolateral 
membranes (167, 641). Initially a dileucine motif in the second intracellular CBS domain was 
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suggested to mediate basolateral sorting (641), but a more recent study (167) demonstrates 
that rather a dileucine motif in the first CBS domain interacts with AP-1 adaptors and is crucial 
for the basolateral sorting of ClC-2. These data suggest that ClC-2 may universally localize to 
basolateral membranes, with the likely exception of choroid plexus and retinal pigment 
epithelium in which normally basolateral proteins like the Na+/K+-ATPase are targeted to apical 
membranes. 
Functional data also support a basolateral localization of ClC-2. Whereas there was no effect of 
Clcn2-disruption on the secretion of saliva (709), currents across colonic epithelia investigated 
in Ussing chambers showed that cAMP-stimulated Cl- secretion was increased in Clcn2-/- mice 
(939), indicating that, in contrast to apical cAMP-activated CFTR, basolateral ClC-2 mediates Cl- 
reabsorption. Moreover, the early lethality of CftrΔF508/ΔF508 mice, that likely results from 
intestinal obstruction as a consequence of decreased fluid secretion, was ameliorated rather 
than exacerbated by the additional disruption of Clcn2  (939). The role of ClC-2 in colonic Cl- 
reabsorption rather than secretion was confirmed in another study that used a different Clcn2-/- 
strain (111). A basolateral localization of ClC-2 is bolstered by functional studies in which apical 
membranes of colon surface epithelia were permeabilized (110). Finally, immunohistochemistry 
and electrophysiology localized ClC-2 to the surface epithelium that is involved in salt 
reabsorption, rather than to crypts that co-express CFTR and NKCC1 and are the sites of 
intestinal Cl- secretion (109-111, 318, 371). 
In spite of the well-established basolateral localization of ClC-2 and its role in intestinal Cl- 
reabsorption, a drug lubiprostone has been widely claimed to ameliorate obstipation by 
specifically opening apical ClC-2 channels in the intestine (25, 117, 158). However, the assertion 
that lubiprostone is a specific activator of ClC-2 is based on a publication by Cuppoletti and co-
workers that reported effects on linear, time-independent currents that differ markedly from 
ClC-2 currents (158). When tested at the same concentration (1 µM) on typical, slowly 
activating inwardly rectifying  currents obtained from heterologously expressed ClC-2, however, 
lubiprostone had no effect (599). Lubiprostone was also reported to activate a small-
conductance, ‘ClC-2-like’ channel in Xenopus A6 cells, but the gating kinetics of those channels 
(41) appeared slower than those reported for mammalian ClC-2 in other studies (815, 834, 
897). Lubiprostone activated CFTR, but not ClC-2, when co-expressed with the prostanoid 
E4 receptor (599). Several studies showed that lubiprostone, a bicyclic fatty acid derived from 
prostaglandin E1, acts by stimulating prostanoid receptors (15, 48, 117, 159, 376). The effect on 
intestinal Cl- secretion may occur by stimulating cAMP-dependent CFTR (29, 64, 599), although 
CFTR-independent actions were also reported (169, 376). Since ClC-2 has a role in intestinal Cl- 
reabsorption rather than Cl- secretion, the beneficial effect of lubiprostone on obstipation 
cannot be explained by an opening of ClC-2 (255, 384). If lubiprostone activates intestinal ClC-2 
channels, it would cause obstipation rather than alleviating it.  
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The effect of lubiprostone on the recovery of the intestinal mucosal barrier after ischemia led 
Blikslager and coworkers to postulate a role of ClC-2 in this process (561). They further 
supported this notion by experiments with Clcn2-/- mice (398, 591). These results await 
replication by other laboratories.  
ClC-2 was also speculated to be the Cl- channel expressed in apical and tubulovesicular 
membranes of gastric parietal cells, where it is thought to be involved in gastric HCl  secretion 
(517). However, the Cl->I- selectivity of ClC-2 (275, 399, 832) and its 3 pS single channel 
conductance (815, 834, 897) differs from the I->Cl- selectivity and 7 pS conductance of Cl- 
channels reconstituted from bona fide acid-transporting membranes from gastric mucosa (157). 
ClC-2 is weakly expressed in stomach as indicated by Northern (351, 832) and Western blots 
(590) (but see (351)). Immunohistochemistry seemed to suggest prominent ClC-2 expression in 
parietal cells (771). However, the labeling lacked essential KO controls and was much stronger 
and broader compared to the sparse dot-like fluorescence later reported by the same group 
(590). Although KO-controlled ClC-2 immunostaining prominently labeled ClC-2 in the colon and 
duodenum, it failed to detect ClC-2 in the stomach (641). Most importantly, Clcn2 deletion did 
not affect histamine-induced gastric acid secretion (74). In contrast, Blikslager, Cuppoletti and 
colleagues more recently reported impaired gastric acid secretion in different Clcn2-/- mice 
(590). These mice, however, showed changes in gastric morphology, including a loss of parietal 
cells and H+/K+-ATPase (590), observations not made by others (641). Hence there is no 
convincing evidence that ClC-2 is the apical parietal cell Cl- channel that, together with the 
H+/K+-ATPase, is responsible for gastric HCl secretion.  
 
E. ClC-2 in the nervous system and interaction with GlialCAM 
Being almost ubiquitously expressed, ClC-2 has been detected in neurons, astrocytes and 
oligodendrocytes using electrophysiology (139, 221, 239, 247, 256, 346, 508, 515, 516, 595, 
702, 797) and immunohistochemistry (68, 187, 346, 777). ClC-2 has been localized to cell bodies 
and neurites of hippocampal neurons (777), prominently on Bergmann glia (68, 346), and was 
found in clusters at astrocytic endfeet contacting brain capillaries and at contacts between 
astrocytes and oligodendrocytes (68, 187, 346, 777). These results have been controlled by 
absence of staining in Clcn2-/- mice (68, 346). Disruption of Clcn2 in mice led to slowly 
developing widespread vacuolization in the white matter of the brain and the spinal cord (68). 
Vacuolization was particularly evident in cerebellum and was associated with an upregulation 
of inflammation markers and with a disruption of the blood-brain barrier (68).  Fluid-filled 
spaces appeared between myelin sheaths of central, but not peripheral neurons. Neurons 
appeared normal and, except for a decrease in nerve conduction velocity in the central auditory 
pathway, no neurological abnormalities were noticed (68). More recently, mild neuronal 
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degeneration has been observed in old Clcn2-/- mice which also displayed mild abnormalities in 
electro-corticographic recordings (150). However, no spontaneous epilepsy nor a reduction of 
seizure thresholds were observed (68, 150). By contrast, various and variable neurological 
abnormalities, including ataxia, spasticity and visual disturbances have been found in patients 
with homozygous inactivating CLCN2 mutations (187, 193, 323). Human CLCN2-related 
leukoencephalopathy is characterized by characteristic signs of white matter edema in MRT 
imaging (187). 
Akin to the hypothesis brought forward to explain the testicular and retinal degeneration, the 
leukodystrophy caused by loss of ClC-2 might result from impaired regulation of the 
extracellular space (68), in this case by the astrocytic-oligodendrocytic syncytium. Extracellular 
potassium, which is released from neurons during electrical activity, is taken up by astrocytes 
and equilibrated with the blood through astrocytic endfeet in a process dubbed ‘potassium 
siphoning’. This is important as in the narrow clefts surrounding neurons extracellular K+ could 
otherwise easily reach concentrations sufficiently high to depolarize and excite neurons. 
Similarly, ClC-2 may serve to buffer extracellular chloride at GABAergic synapses (777) and 
guarantee net electroneutral uptake of K+ and Cl- through independent, parallel K+ and Cl- 
channels (68). Indeed, ClC-2 is co-expressed with key components involved in K+ siphoning such 
as the K+ channel Kir4.1 (KCNJ10), aquaporin 4, and the gap junction proteins Cx47 and Cx32 at 
astrocytic endfeet and astrocyte-oligodendrocyte contacts (90, 418, 579). Disruption of Kir4.1 
and double-KO of Cx32 and Cx47 led to myelin vacuolization (538, 539, 579) resembling that of 
Clcn2-/- mice. In optic nerves, this vacuolization could be prevented by inhibiting its electrical 
activity with tetrodotoxin (539). The fact that optic nerves lacked vacuolization in Clcn2-/- mice 
(which are blind (74)) indirectly bolsters the hypothesis that glial ClC-2 functions in buffering 
extracellular K+ and Cl- concentrations (68). 
In glia, the abundance of ClC-2 and its subcellular localization depend on the cell adhesion 
molecule GlialCAM (346) which physically binds ClC-2 (395). Although also called HepaCAM 
because of its downregulation in hepatocellular carcinoma (137, 562, 563), GlialCAM is mainly 
found in brain where its expression is restricted to astrocytes and oligodendrocytes (240). 
Mutations in GlialCAM (483) and of its protein interaction partner MLC1 (451) lead to 
megalencephalic leukoencephalopathy with subcortical cysts (MLC), another form of 
leukodystrophy. Heterologous expression showed that GlialCAM localizes both MLC1 and ClC-2 
to cell-cell contacts (395, 483) (Fig. 8). Indicative of homophilic GlialCAM interactions in trans, 
this localization requires the presence of GlialCAM in both cells (346). In Glialcam-/- mice, the 
loss of Glialcam mislocalizes and destabilizes Mlc1 and ClC-2, and rather surprisingly also the 
loss of Mlc1 (in Mlc1-/- mice) destabilizes and mislocalizes GlialCAM and ClC-2 (88, 204, 346), 
suggesting a complex formed by all three proteins.  
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GlialCAM not only affects the subcellular localization of ClC-2, but also changes its biophysical 
properties. Heterologous co-expression increases ClC-2 current amplitudes and converts its 
slowly activating, inwardly rectifying currents to almost linear, time-independent currents (395) 
(Fig. 8E) by an effect on the slow ClC-2 gate (394). When comparing WT with Glialcam-/- mice, a 
similar effect on ClC-2 currents was observed in oligodendrocytes, but surprisingly not in 
Bergmann glia (346). The similarities in the leukodystrophies of Clcn2-/-, Glialcam-/- and Mlc1-/- 
mice (346) suggest that this pathology may be in part due to the loss of ClC-2 currents and 
resulting consequences for ion homeostasis. However, the additional disruption of Glialcam 
worsened the white matter vacuolization of Clcn2-/- mice (346). Hence the loss of Glialcam likely 
has additional detrimental effects, possibly because of the loss and mislocalization of Mlc1 
(100, 346) or other binding partners (919).  
Disease-causing mutations in GLIALCAM interfere with its binding to ClC-2 and Mlc1 (31, 32, 
395, 483) and GlialCAM regions required for the interaction with ClC-2 and MLC1 have been 
mapped (98). It was found that the extracellular domain of GlialCAM is necessary for cell 
junction targeting and for mediating interactions with itself or with MLC1 and ClC-2 (99). The C-
terminus is also necessary for proper targeting to cell-cell junctions, but is not needed for the 
biochemical interaction. Interestingly, the first three amino acids of the transmembrane 
segment of GlialCAM are essential for the activation of ClC-2 currents but are not involved in 
the clustering (99). It has been proposed that in astrocytes a ternary complex between ClC-2, 
GlialCAM and MLC1 forms only upon exposure to high extracellular potassium concentrations 
(785). However, the physiological importance and the underlying mechanism remain obscure. 
The stoichiometry of the ClC-2/GlialCAM complex and the regions of the channel involved in 
the interaction are still unknown.   
GlialCAM has been suggested as a ClC-2 auxiliary ‘β-subunit’ (395). However, in contrast to 
barttin, the β-subunit of ClC-K channels (222), and Ostm1, the β-subunit of ClC-7 (445), it is not 
specific for this CLC isoform. In heterologous expression, GlialCAM also modifies currents of 
ClC-0, ClC-1, and ClC-K and clusters them at cell-cell contacts (394). The fact that GlialCAM 
interacts with ClC-Ka/barttin suggests that GlialCAM and barttin subunits have non-overlapping 
interaction regions. Since GlialCAM also clusters and stabilizes MLC1 (483) and connexin43 
(919) its interaction with transmembrane proteins seems quite promiscuous and hence its loss 
of function might cause leukodystrophy via several pathways.  
In most adult neurons, [Cl-]int is below electrochemical equilibrium to enable hyperpolarizing 
influx of Cl- through inhibitory GABAA- or glycine-receptor Cl- channels. Likewise, the presence 
of a partially constitutively open Cl- channel like ClC-2 may dampen neuronal excitability by 
providing hyperpolarizing and shunting currents. It is therefore conceivable that disruption of 
ClC-2 might lead to epilepsy. Intriguingly, linkage analysis identified a locus for idiopathic 
generalized epilepsy to 3q26, the chromosomal region that harbors the CLCN2 gene (732). 
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However, Clcn2-/- mice display neither spontaneous epilepsy nor reduced seizure threshold (68, 
74). A widely cited paper asserting that CLCN2 mutations underlie different forms of epilepsy in 
humans appears to be fraudulent and has been retracted (328). Even though there are some 
reports of CLCN2 variants in epileptic patients (160, 225, 726), there is no convincing evidence 
that CLCN2 mutations cause human epilepsy (68, 586, 589, 812).  
ClC-2 may also influence neuronal [Cl-]int. In turn, ClC-2 activity is strongly dependent on [Cl-]i 
(588, 674, 730). In contrast to the neuronal K+Cl- cotransporter KCC2, the main player in 
establishing the low [Cl-]int of adult neurons (362, 704), a Cl- channel such as ClC-2 can lower [Cl-
]i only down to its electrochemical equilibrium, as experimentally demonstrated by transfection 
of ClC-2 into dorsal root ganglia neurons whose [Cl-]int is normally above equilibrium (798). 
Owing to lower [Cl-]int, transfected neurons displayed hyperpolarizing rather than depolarizing 
GABA-responses. ClC-2 might also lower neuronal [Cl-]int when it is elevated by intense GABA-
ergic activity (256, 702), although mathematical modeling suggests that this does not occur 
under physiological conditions (692). However, the model by Ratté and Prescott appears of 
limited value in that it did neither take into account the fundamental activity of the Na+ / K+ 
pump, nor the  [Cl-]int-dependence of ClC-2 (692). 
Two groups studied the role of ClC-2 in neurons using hippocampal slices from WT and Clcn2-/- 
mice (256, 702). Stein and coworkers recorded substantial, typical ClC-2 currents from CA1 
pyramidal cells and found rather surprisingly that ClC-2 contributes about 40% to their resting 
conductance (702). When lacking ClC-2, CA1 cells were intrinsically hyperexcitable, but this did 
not result in increased basal synaptic transmission in field recordings and unexpectedly led to 
decreased input/output relations. These may be explained by increased feed-forward inhibition 
by hyperexcitable interneurons (702). Földy et al. (256) reported differential effects of 
postsynaptic ClC-2 at inhibitory basket cell – pyramidal cell synapses, with ClC-2 proposed to 
lower cytoplasmic Cl- specifically at fast-spiking synapses where intense activation of GABAA-
receptors may lead to an increase in [Cl-]i.  
 
F. Pharmacology of ClC-2 
ClC-2 is only weakly sensitive to classical Cl- channel blockers like DIDS or 9-AC (139, 675, 832) 
as well as by Zn2+ and Cd2+ (139, 971). Using the differential sensitivity of ClC-1 and ClC-2 to 9-AC 
and clofibrates, and employing a chimeric strategy, Estévez et al. found that by the single amino 
acid change T518S, ClC-2 became 8-fold more sensitive to 9-AC, while the opposite mutation in 
ClC-1 (S537T) decreased 9-AC sensitivity about 40-fold (224). The residue is located between 
helices O and P in the above described putative hydrophobic binding pocket. The same 
mutation also dramatically increased affinity for CPA in ClC-2 (224). As for ClC-1, these 
compounds act from the intracellular side (224). 
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Thompson et al. reported that a component of the Leiurus quinquestriatus scorpion venom 
moderately inhibited ClC-2 from the extracellular side in a voltage-dependent manner (833). 
Later, a peptide from the venom, called GaTx2, was isolated that inhibited ClC-2 with a 
surprisingly high apparent affinity of 20 pM with no effect on other CLCs or GABA receptor Cl- 
channels, but the same moderate effect (~60% inhibition) (834). Unfortunately, the toxin has 
not been used or independently verified in follow-up studies. 
As discussed above, the evidence for activation of ClC-2 by lubiprostone, a drug used to treat 
chronic constipation (25), is highly controversial. In summary, no specific or high affinity small 
molecule ligands exist for ClC-2 and the GatTx2 toxin has still to prove its usefulness. 
 
 
VII. CLC-KA/KB-BARTTIN CHANNELS – HIGHLY CELL-SPECIFIC CL- CHANNELS 
MUTATED IN CERTAIN FORMS OF KIDNEY DISEASE AND DEAFNESS 
Human ClC-Ka and –Kb, or rodent ClC-K1 and –K2 (10, 415, 845), are two highly homologous 
epithelial Cl- channels  which need the ancillary β-subunit barttin (encoded by the BSND gene), 
a small protein with two transmembrane domains (65), for functional expression at the plasma 
membrane (222). Both ClC-K isoforms and barttin are expressed in a highly tissue-specific 
pattern in nephron segments and epithelial cells of the cochlea and the vestibular organ. The 
nearly ohmic voltage-dependence of ClC-K/barttin channels is well suited for the transepithelial 
Cl- transport in the nephron and for recycling Cl- to support K+ secretion and voltage generation 
in the inner ear.  
Disruption of mouse ClC-K1 (532) entails a severe renal concentration defect (nephrogenic 
diabetes insipidus), whereas loss of mouse ClC-K2 (302, 336) or human ClC-Kb (780) cause 
severe renal salt loss, which in humans is called Bartter syndrome type III. Since barttin 
disruption abolishes the plasma membrane ion transport of both CLC isoforms it entails an even 
more severe renal phenotype and additionally leads to deafness in both mice (699) and humans 
(in Bartter syndrome type IV) (65). The same severe phenotype is observed in the rare patients 
with disruption of both CLCNKA and CLCNKB channel genes (601, 748).  
 
A. Basic properties of ClC-K/barttin proteins and transcriptional regulation 
ClC-K proteins have 687 amino acids and display the transmembrane topology and cytoplasmic 
CBS domains typical for eukaryotic CLC proteins. They are N-glycosylated in the extracellular 
loop between helices L and M (415). The crystal structure of the cytoplasmic CBS domains from 
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human ClC-Ka was obtained at 1.6 Å resolution (526). Contrasting with ClC-5 (542) and ClC-1 
(57), no evidence for these domains to bind ATP was found (526). A recent cryo electron 
microscopical study reveals the structure of a bovine ClC-K channel at ~3.9 Å resolution (628). It 
highlights the rather small differences in the pore structures between CLC 2Cl-/H+-exchangers 
and Cl- channels and will allow detailed structure-function analysis of CLC channel pores. A 
unique structural feature of ClC-K proteins is the lack of a ‘gating glutamate’ (211) which is 
replaced by valine (in ClC-K1, -Ka and -Kb) or leucine (in ClC-K2) (415). 
The human CLCNKA and CLCNKB genes, which encode ClC-Ka and ClC-Kb, respectively, are 
located in close proximity (separated by about 10 kb intervening sequence) on human 
chromosome 1p36.13. This close proximity and the ~90% identity at the amino-acid level 
suggest that they have arisen by a recent gene duplication. The two rodent isoforms are also 
~90% identical to each other, but only 80% identical to the human proteins. Based on 
homology, it was therefore impossible to decide on the correspondence of human and rodent 
isoforms and the nomenclature –Ka, -Kb and –K1, -K2 was adopted for the human and rodent 
isoforms, respectively (415) (the K was introduced by Uchida and colleagues (845) to highlight 
their prominent expression in kidney).  Expression patterns and functional data later indicated 
that ClC-K1 and –K2 correspond to ClC-Ka and -Kb, respectively. Promoters of Clcnk genes and 
relevant transcription factors have been analyzed in detail (686, 844, 846, 848) and mice driving 
the EGFP reporter gene under the control of the human CLCNKB promoter have been 
generated and analyzed (422, 513).  
Renal transcription of ClC-K channels appears to be regulated by osmolarity and/or NaCl 
concentration. ClC-K1 is upregulated by water deprivation and hyperosmolarity (59, 845, 853). 
Experiments with renal cell lines suggested that such an upregulation of ClC-K1 and barttin 
might be cell-autonomous (59). Conversely, ClC-K1 and barttin are downregulated by diuretics- 
(furosemide)-induced salt loss (911). The ClC-K2 mRNA was moderately decreased under high 
salt diet (862), which is reminiscent of the transcriptional regulation of OmClC-K from tiliapia 
fish by changes from fresh to salt water (556).  
 
B. Localization of ClC-K/barttin channels 
Mammalian ClC-K proteins appear to be exclusively expressed in the kidney and the inner ear, a 
pattern exactly mirrored by that of their β-subunit barttin (222). The renal expression pattern 
differs substantially between the –K1 and –K2 isoforms. Early studies aimed at determining 
their segment-specific expression by RT-PCR of manually dissected nephron segments were in 
part plagued by mRNA contamination and lack of linearity (415, 845, 853, 868), and 
immunohistochemistry in many cases cannot distinguish between the two isoforms because of 
the difficulty in  obtaining isoform-specific antibodies against these highly homologous proteins 
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(222, 336, 421, 853, 908). However, one ClC-K1 antibody seems specific for this isoform (420, 
847) and the ClC-K1/K2 antibody described by Kieferle et al. (415) might label predominantly 
ClC-K2 in the mouse kidney (336). Renal ClC-K2 expression has also been investigated by in situ 
hybridization (931). Knock out controlled immunohistochemistry (336, 421) and CLCNKB 
promoter-driven reporter gene expression (422) now gives a clear picture of the expression of 
either isoform along the nephron that fits to (patho-)physiological data.  
In the kidney, immunohistochemistry initially detected ClC-K1 exclusively in the thin ascending 
limb (tAL) of Henle’s loop, the nephron segment with the highest Cl- permeability. In this 
segment, the channel is expressed in both basolateral and apical membranes (847). The 
specificity of labeling was confirmed using Clcnk1-/- mice (532). In vitro perfusion of the tAL 
revealed a loss of transepithelial Cl- permeability in the KO (532). However, also the medullary 
thick ascending limb (mTAL) appears to express significant amounts of ClC-K1 in their 
basolateral membranes, as suggested by labeling of Clcnk2-/- kidney sections with a ClC-K1/K2 
antibody (336). One might hypothesize that the additional mTAL expression of –K1 occurs in 
compensation for the disruption of Clcnk2. However, the finding that furosemide (which, like 
Clcnk2 disruption, inhibits salt absorption in the TAL) rather decreased ClC-K1 expression (911) 
weakens this hypothesis. The detection of basolateral ~40 pS Cl- channels in the cortical thick 
ascending limb (cTAL) (633) might suggest some presence of ClC-K1 (which display 40 pS 
conductances (441)) in that segment where it has not been detected by immunohistochemistry.  
Unlike ClC-K1, ClC-K2 is prominently expressed in basolateral membranes of the cTAL, the distal 
convoluted tubule (DCT), and α- and β-intercalated cells of the connecting tubule (CNT) and 
collecting duct (222, 336, 421). These results, which were obtained by immunohistochemistry 
with different ClC-K1/K2-reactive antibodies, hav been ascertained using both Clcnk1-/- (421) 
and Clcnk2-/- (336) mice. This localization of ClC-K2 is further supported by RT-PCR of 
microdissected tubules (862) and the disappearance in Clcnk2-/- mice of a ~10pS Cl- channel 
from basolateral membranes of TAL, DCT, and CNT/CCD intercalated cells (336). Human ClC-Kb 
displays an identical expression pattern as revealed by transgenic mice expressing EGFP under 
the control of the human CLCNKB promoter (422).  
Until recently, the only confirmed extra-renal site of ClC-K expression (and that of its β-subunit 
barttin) was the inner ear (Fig. 9). Recent work detected barttin in basolateral membranes of 
salivary gland duct cells (774), strongly suggesting the presence of ClC-K/barttin channels also in 
this epithelium. In the inner ear, both ClC-K isoforms are expressed in basolateral membranes 
of K+ secreting epithelial cells, i.e. of the marginal cells in the cochlear stria vascularis  (Fig. 9) 
and of dark cells in the vestibular organ (222, 422, 699, 725). The widespread expression of ClC-
K in the cochlea reported by Qu et al. (682) is questionable because it has not been observed by 
others and relies on an antibody which has not been tested in knock out animals. Whereas 
immunohistochemistry could not prove the strial presence of both isoforms because it used 
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ClC-K1/K2 antibodies (222, 725), both ClC-K1 and –K2 mRNAs were detected in the cochlea 
(222). Patch-clamp analysis revealed the presence of a Cl- channel in strial marginal cells which 
displayed the Ca2+- and pH-sensitivity of ClC-K (26). Reporter mice suggest the presence of ClC-
Kb (-K2) (422) and RT-PCR the expression of ClC-K1 in the stria (26). Perhaps the most 
convincing evidence for the presence of both ClC-K isoforms in stria vascularis comes from 
genetics: only disruption of both isoforms, or of the common β-subunit barttin, leads to 
deafness in Bartter syndrome IV (65, 601, 699, 748). 
The renal and inner ear localization of the β-subunit barttin has been studied by in situ 
hybridization (65) and immunohistochemistry (222, 699). In both organs, its localization 
matches perfectly those of the α-subunits ClC-K1 and ClC-K2 (Fig. 9). In kidney, Clcnk1 and Bsnd 
mRNAs are upregulated in parallel upon dehydration (59), suggesting similar transcriptional 
control. Barttin may be useful as histochemical marker for certain types of renal (773) and 
salivary gland (774) tumors.  
 
C. Interactions of ClC-K α-subunits with their β-subunit barttin 
Upon heterologous expression, only rodent ClC-K1, but not ClC-K2 or human ClC-Ka and –Kb 
give plasma membrane currents by themselves (845, 847, 869). Site-directed mutagenesis 
proved that the observed currents are indeed mediated by ClC-K1 (869). For instance, the 
V166E mutant which, as we now know, inserted a ‘gating glutamate’ (211), drastically changed 
the voltage-dependence of currents and thereby led to an activation by hyperpolarization 
(869). The currents initially ascribed to ClC-K2 and to a variant with a deletion of 
transmembrane domains (10) are most likely endogenous to the expression system. The failure 
to functionally express these channels was surprising since immunohistochemistry (847, 853) 
and the role of ClC-Kb in Bartter syndrome (780) strongly indicated that they mediate plasma 
membrane ion transport. Analysis of chimeras between ClC-K1 and ClC-Kb narrowed down a 
ClC-K1 region that was sufficient to allow plasma membrane currents without a β-subunit 
(roughly helices N-R) (869).  
The mystery surrounding the lack of plasma membrane currents upon overexpression of most 
ClC-K isoforms was lifted shortly after Hildebrandt and colleagues (65) used positional cloning 
to identify BSND, the gene encoding barttin, as underlying Bartter syndrome type IV (444). 
Consistent with the renal and hearing phenotypes of Bartter IV, mouse barttin was localized to 
relevant nephron segments and the cochlear stria vascularis by in situ hybridization (65). 
Barttin, which lacks homology to other proteins, is a 320 amino acid protein (in humans) which 
displays two transmembrane domains. Both the short N-terminus and the longer C-terminus 
are cytosolic (222). The renal phenotype of Bartter IV, though somewhat more severe than in 
CLCNKB-related Bartter III, suggested barttin as a candidate subunit of ClC-K channels. Indeed, 
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co-expressing ClC-K1 with barttin enhanced currents >10-fold and co-expression with ClC-Ka or 
ClC-Kb elicited plasma membrane currents that could not be detected without this ancillary 
subunit (222, 868). Other CLC channels or transporters such as ClC-1 or ClC-5 did not interact 
with barttin upon co-expression (222, 868). Co-immunoprecipitation experiments using over-
expressing cells indicated that barttin directly binds ClC-K proteins (329, 868). Binding may 
occur through ClC-K helices B and J which, as expected, are located at the periphery of the 
channel (822). The cytoplasmic carboxy-terminus of barttin could be deleted substantially 
without losing the effect on ClC-K currents, but the extent of tolerated deletions appears to 
depend on the expression system (222, 754). The main mechanism by which barttin facilitates 
plasma membrane currents is an increased surface expression of ClC-K proteins which are 
otherwise stuck in the endoplasmic reticulum or Golgi (222, 329, 441, 754, 868). Akin to other 
membrane proteins (e.g. ClC-7 (445)), the correct localization of ClC-K proteins appears to 
enhance their stability. Mice lacking barttin in the inner ear (699) or expressing instead the 
Bartter IV-associated R8L mutant (598) had dramatically reduced ClC-K levels. Also in vitro ClC-K 
was stabilized by barttin (329). In addition to boosting ClC-K plasma membrane currents by 
increasing surface expression, barttin can change current properties, e.g. the sensitivity of ClC-
K1 to extracellular calcium ([Ca2+]o) (868). The transmembrane part of barttin may act as a 
chaperone for the transport to the plasma membrane, whereas a short cytoplasmic stretch, 
which needs to be tethered to the membrane, might influence properties of ClC-K currents 
(754). Detailed analysis of more mutants indicates, however, that also transmembrane residues 
influence current properties (910). Moreover, barttin is palmitoylated at two cysteine residues 
shortly after the second transmembrane domain (804). Barttin mutants in which both cysteines 
were replaced by serine were fully competent in bringing ClC-K proteins to the plasma 
membrane, but failed to stimulate currents. It is, however, premature to conclude that this 
failure is owed to a loss of palmitoylation because an effect of the mutation per se could not be 
excluded. It should be stressed again that barttin is not required for intrinsic ClC-K channel 
activity. This is not only evident from currents elicited by rodent ClC-K1 without barttin, but also 
from recent experiments with purified ClC-K proteins. While bovine ClC-K needs barttin for 
plasma membrane insertion and hence plasma membrane currents, it mediates Cl- transport 
also without barttin when reconstituted into lipid bilayers (628).  
The cytoplasmic tail of barttin displays a sequence (PQPPYVRL) which contains a tyrosine- based 
consensus site for endocytosis (YxxL) (71) and bears weak resemblance to WW domain-
interacting ‘PY’ motifs (214, 614). Binding of WW domain-containing ubiquitin ligases leads to 
ubiquitination and internalization of e.g. the ENaC Na+ channel (799) or the 2Cl-/H+-exchanger 
ClC-5 (355, 759). Compatible with either mechanism, disruption of this site by the Y98A 
mutation increased ClC-Ka/barttin and ClC-Kb/barttin currents about twofold (222) and 
augmented their presence in the plasma membrane (329), creating a tool which is now widely 
used to boost ClC-K/barttin currents (368, 441, 465, 528, 934). The Nedd4-2 ubiquitin ligase was 
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reported to mediate ClC-K/barttin downregulation (217), but since dominant negative forms of 
WW-domain containing ubiquitin ligases failed to have an effect (Jentsch lab, unpublished 
results), the PPYVRL motif in barttin may rather function as a tyrosine-based, AP-adaptor 
interacting internalization signal.   
 
D. Biophysical properties of ClC-K/barttin channels 
Currents from both ClC-Ka/barttin and ClC-Kb/barttin, although differing in detail, show little 
gating relaxations and do not display strong rectification (222).  The small gating relaxations of 
ClC-Ka and ClC-Kb expressed in Xenopus oocytes show an inverse voltage-dependence: ClC-Ka 
activates at negative voltages, whereas ClC-Kb activates at positive voltages (222, 463, 648). 
One structural difference underlying this behavior has been spotted to an aspartic acid at the 
end of helix B (D68). The side chain of the corresponding D54 of EcClC-1 projects into the 
extracellular vestibule in EcClC-1 (210), and mutating the corresponding aspartate in ClC-0 and 
ClC-1 dramatically alters common gating (233, 490). ClC-Ka and rat ClC-K1 carry an asparagine 
at position 68 and the ClC-Kb D68N mutant shows a gating phenotype, which is very similar to 
that of ClC-Ka, activating at negative voltages (648). The same residue is also important for the 
binding of several extracellularly acting small molecule ClC-K blockers (648).  
The absence of a ‘gating glutamate’ largely eliminates the protopore gate (249, 441) which in 
part confers voltage-dependence to other CLC channels (211). Evolution may have selected for 
the absence of a ‘gating glutamate’ to enable constitutive channel activity over a broad voltage 
range as required for transepithelial transport. They display a typical Cl>Br>I permeability 
sequence (222, 868, 869), but the conductance of Br- is higher than that of Cl- in ClC-K1 without 
barttin (845, 869).  Similar to ClC-2, ClC-K channels behave quite differently when expressed in 
mammalian cell lines, compared to Xenopus oocytes (222, 229, 295, 368, 441, 648, 754). In 
oocytes, the open probability of ClC-K/barttin channels is very small, as estimated by noise 
analysis and single channel recordings (293, 295, 296, 441). In contrast, when expressed in HEK 
cells, the open probability is very high (249, 441). The reason underlying this difference is 
unknown, but most likely independent of the cholesterol content of the cell membrane (368). 
L’Hoste et al. found that mouse ClC-K1/barttin showed time dependent gating in cell-attached 
patches but not in whole cell recordings or inside-out patches and suggested that some 
intracellular factor is necessary to maintain the voltage-dependence (441). 
ClC-K1 (847, 869) as well as ClC-Ka/barttin and ClC-Kb/barttin (222, 868) are activated by 
extracellular Ca2+ in the mM range, a feature of unknown physiological significance. The 
sensitivity of ClC-K1 to [Ca2+]o is modulated by barttin. In its presence currents reach maximal 
activation around physiological values of [Ca2+]o, whereas currents of ClC-K1 alone continue to 
increase when  [Ca2+]o is further raised from 7 to 12 mM (868). In a mutagenic screen, 
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Gradogna et al. identified two acidic residues, E261 and D278, that reduced Ca2+ mediated 
activation when mutated singly, and completely abolished Ca2+ sensitivity when both were 
mutated in the double mutant E261Q/D278N (293). Interestingly, these residues are localized in 
the loop connecting helices I and J, a relatively long loop that traverses the whole extracellular 
surface, relatively close to the dimer interface in EcClC-1 (210). The corresponding loop is not 
resolved in the CmClC crystal structure (242) and neither in the bovine ClC-K structure (628). 
Even more interesting is that, based on the Ec-ClC-1 structure, E261 from one subunit is 
physically close to D278 from the neighboring subunit, suggesting that these residues form two 
symmetrical, intersubunit low affinity Ca2+ binding sites (293). Further investigation of the 
binding site, using also a homology model of ClC-Ka, revealed the contribution of two other 
residues (E258 and E281) that are probably involved in the binding site, both also being located 
within the I-J loop (294). Zn2+ block of ClC-K channels was unaffected by these I-J lop mutations, 
showing that the inhibitory Zn2+ binding site, which is probably conserved among ClC-0, ClC-1, 
ClC-2 and ClC-K channels, is unrelated to the activating Ca2+ binding site of ClC-Ks. Furthermore, 
Ca2+ sensitivity could be conferred to ClC-0 by transplanting the I-J loop. However, the ClC-0 
construct with the transplanted loop exhibited a profoundly inwardly rectifying phenotype, 
suggesting that the loop has a large effect on the common gate (294). Surprisingly, a Bartter III-
associated mutant of ClC-Kb (R538P) in the linker between the transmembrane part and the 
CBS domain abolished the Ca2+ sensitivity of ClC-Kb/barttin, but not of ClC-Ka/barttin, by an 
unknown mechanism (528). Other disease-causing CLCNKB mutations that change the Ca2+-
sensitivity affect still other residues (R351W (934) and V170M (28), suggesting indirect effects 
by conformational changes. 
ClC-K1, ClC-Ka/barttin and ClC-Kb/barttin currents are also inhibited by extracellular 
acidification in the range between pH 8 to 6 (222, 847, 868, 869). The responsible residue has 
been mapped to extracellular histidine H497 (293) which is homologous to the histidine (H532) 
involved in the block of ClC-2 by extracellular protons (587). ClC-K channels are also blocked by 
strongly alkaline pH (pH 8 - 11), an effect mapped to lysine 165 in the extracellular vestibule of 
the channel (296). The sensitivity of ClC-K2/barttin to both intra-and extracellular pH may play a 
role in the regulation of Cl-/HCO3- exchange and NaCl reabsorption in β-intercalated cells of the 
distal nephron (658, 907).  
In spite of being ~90% identical, ClC-K1/barttin and ClC-K2/barttin channels surprisingly appear 
to have rather different single channel conductances.  The directly measured single channel 
conductance of heterologously expressed (rodent) ClC-K1 is ~40 pS (441) or ~34 pS (249), 
similar to native Cl- channels previously reported for the cortical thick ascending limb (633). 
Human ClC-Ka/barttin conductance amounts to 18-20 pS by noise analysis (804, 962) or 26 pS 
by single channel recordings (696). By contrast, ClC-K2/barttin displays a single channel 
conductance of ~10 pS as indicated by the lack of ~8 and ~11 pS channels in the basolateral 
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membranes of the cortical thick ascending limb (cTAL) and of intercalated cells of the 
connecting tubule (CNT) and cortical collecting duct (CCD) in Clcnk2-/- mice (336). Such 10pS 
channels have already been observed previously in these segments (593, 594, 658, 936). Patch-
clamp studies suggest that the channel activity of bona fide ClC-K2 channels native to the CCD is 
acutely enhanced or decreased by insulin-like growth factor 1 (IGF-1) and insulin, respectively 
(936).  
However, these ‘single channel’ conductances in part reflect the combined conductance of both 
protopores of double-barelled channels. Rare ‘half-conductance’ states were observed with 
mouse ClC-K1/barttin (441) and apparently more often in rClC-1 without barttin (249), 
suggesting that these states represent the ‘true’ single channel (protopore) conductance of ClC-
K1. Presumably these ‘half-conductance states’ are rarely observed because ClC-K proteins lack 
the ‘gating glutamate’ which is crucial, albeit not absolutely required, for protopore gating of 
ClC-0 (211). The ~40 pS ‘single channel’ conductance of ClC-K1 likely represents the combined 
conductance of two pores that are gated together by the common gate. Indeed, introduction of 
a ‘gating’ glutamate with the V166E mutation not only changes the voltage-dependence of rClC-
K1 (869), but results in ~20 pS mClC-K1/barttin channels apparently gated by an introduced 
protopore gate (441). It is not entirely clear whether single-channel conductances reported for 
other ClC-K channels represent single or combined protopore conductances. While the absence 
of the ‘gating glutamate’ favors the second possibility, the ~20pS conductance of hClC-
Ka/barttin (804, 962) was suggested to represent the protopore conductance (249). Individual 
residues responsible for the differences in the single channel conductances between the ClC-K 
isoforms have not yet been identified. However, we speculate that it might be due to the 
residue at the position of the ‘gating glutamate’ found in all other mammalian CLCs. ClC-K1 
displays a valine, and ClC-K2 a leucine at this position (415). The bulkier leucine side chain may 
lead to the observed smaller conductance of the ClC-K2 pore. Although ClC-K1 and –K2 are 
likely to heteromerize upon co-expression, double-barreled channels displaying two different 
single channel conductances (as observed with co-expression of ClC-0 and ClC-1 or -2 (897)) 
have not yet been reported. 
Barttin has no significant effect on the single channel conductance of ClC-K1 (249, 441), but 
Fahlke and coworkers reported that barttin drastically changed the voltage-dependence of the 
ClC-K1 V166E mutant and increased its single channel conductance from ~9 to ~20 pS (754). 
However, these latter findings could not be reproduced by Teulon and colleagues (441).  
 
E. Roles of ClC-K/barttin channels in physiology and pathology 
The physiological roles of ClC-K/barttin channels are evident from the pathologies observed 
upon their disruption in mice or mutations in human genetic disease. Loss of ClC-K/barttin 
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function leads to diverse, severe renal phenotypes that are sometimes associated with 
sensorineuronal deafness. Renal roles of ClC-K channels were the subject of several recent 
reviews (27, 229, 432, 937).  
In addition to the well-established roles of CLCNK and BSND mutations in monogenic disorders 
of the kidney and the inner ear, less convincing genetic association studies suggest 
contributions of CLCNKA and CLCNKB polymorphisms to other pathologies. A common CLCNKB 
polymorphism  (381) has been associated with high blood pressure in human populations (382, 
778), but could not be replicated in other studies (118, 238, 425, 796). Moreover, this 
polymorphism (T481S) increased ClC-Kb/barttin currents upon expression in Xenopus oocytes   
(381), but not in HEK cells (778). Non-coding SNPs in CLCNKA were associated with salt-sensitive 
hypertension (45), and CLCNKB variants were suggested to underlie differences in hearing 
thresholds (268). Moreover, a nonsynonymous coding CLCNKA polymorphism has been linked 
with heart failure (101). The corresponding R38G exchange, which reduced ClC-Ka/barttin 
currents by ~50%, was speculated to operate via the renin-angiotensin axis, whereas a 
subsequent study of another cohort rather found an association of the polymorphism with 
glomerular filtration rate without providing a mechanistic explanation (829).  
 
ClC-K1/barttin: a crucial role in concentrating urine 
By ensuring the hyperosmolarity of the kidney medulla (16), ClC-K1/barttin is crucial for the 
concentration of urine (532). The high osmolarity of kidney medulla is needed to generate an 
osmotic gradient in the medullary collecting duct to allow passive reabsorption of water 
through vasopressin-regulated aquaporin2 (AQP2) water channels (244). This high osmolarity is 
generated by the countercurrent system embodied by the loop of Henle. To perform its 
function, it needs, as we now know from Clcnk1-/- mice (16, 532), the high ClC-K1/barttin-
mediated Cl- permeability of both apical and basolateral membranes of the thin ascending limb 
(tAL)  (532, 847).  
 
ClC-K2/barttin channels are crucial for renal salt reabsorption 
By contrast, ClC-K2/barttin is essential for NaCl reabsorption in the thick ascending limb of 
Henle’s loop (TAL) and the distal convoluted tubule (DCT). Its expression in intercalated cells of 
the connecting tubule (CNT) and cortical and medullary collecting duct (CCD and MCD) may also 
play a role in transepithelial transport of NaCl (658) or in acid-base regulation. Indeed, CLCNKB 
is mutated in Bartter syndrome type III (780), a severe genetic form of renal salt wasting 
associated with hypokalemic metabolic alkalosis, hyper- or normocalciuria, and 
hyperprostaglandinemia (27, 431, 767). The majority of symptoms probably arise from impaired 
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transepithelial transport in the TAL, although a role of ClC-Kb in the DCT is also important (336) 
and the impairment of transepithelial transport in that segment may lead to symptoms 
resembling Gitelman’s syndrome (17, 134, 151, 220, 380, 607, 942) which is distinguished from 
Bartter’s syndrome by hypocalciuria and hypomagnesemia (766, 767). Gitelman’s syndrome is 
caused by mutations in the thiazide-sensitive NaCl-cotransporter NCC (SLC12A3) (783) which is 
expressed in apical membranes of DCT epithelial cells and reabsorbs NaCl from the tubular 
lumen. This reabsorption needs ClC-Kb/barttin for the basolateral exit of Cl-. In the collecting 
duct, ClC-Kb/barttin is thought to facilitate apical H+-secretion through the proton pump by 
recycling Cl- for the basolateral AE1 Cl-/HCO3- exchanger in parallel to the KCl cotransporter 
KCC4 (69), and to facilitate Cl- reabsorption in both α- and β-intercalated cells (937). 
Transepithelial transport in the TAL, a major site of renal salt absorption, is well understood and 
supported by human mutations that underlie various forms of renal salt loss. Powered by the 
sodium gradient that is generated by the basolateral Na+,K+-ATPase, the apical Na+K+2Cl 
cotransporter NKCC2 (SLC12A1), which is mutated in Bartter syndrome type I (781), takes up 
Na+ and Cl- from the primary urine. Na+ is pumped across the basolateral membrane by the  
Na+,K+-ATPase and Cl- exits passively across the same membrane through ClC-Kb/barttin Cl- 
channels (with CLCNKB and BSND mutated in Bartter III (780) and IV (65), respectively). 
Potassium ions co-transported by the apical NKCC transporter must be recycled across the 
apical membrane, a process mediated by ROMK (Kir1.1, KCNJ1) channels. This process is 
essential for NaCl reabsorption as revealed by mutations in KCNJ1 that cause Bartter syndrome 
II (782). 
Pathogenic mutations include large deletions, nonsense and missense mutations (780). Several 
deletions of CLCNKB sequence resulted from unequal crossing over of the neighboring genes. 
Interestingly, one such event predicts a fusion protein between ClC-Ka and ClC-Kb which is 
under the control of the CLCNKA promoter, highlighting the importance of a correct expression 
pattern along the nephron (780). Following the original report (780), many more CLCNKB 
mutations were found in Bartter syndrome (17, 28, 85, 134, 272, 273, 322, 411, 427, 607, 708, 
768, 823, 934, 942). 
Obviously, deletions or nonsense mutations in CLCNKB lead to a loss of channel function. Many 
of the CLCNKB missense mutations affect surface expression (411), leading to a reduction of 
plasma membrane currents. Although located at different positions (P124L, V170M, R351W, 
R538P), several mutants affect the response of ClC-Kb/Barttin to external pH and Ca2+ (28, 528, 
934), but it has not been established that this change explains the pathogenicity of these 
mutations. Some mutations were identified in patients with mild forms of the disease (17, 28), 
but symptoms can markedly vary even with patients carrying the same mutations (707, 708). 
The phenotype of CLCNKB-related Bartter syndrome is highly variable (427). However,  recent 
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studies found that the reduction of ClC-Kb/barttin currents of CLCNKB mutants expressed in 
HEK cells correlates with the clinical severity of renal disease (131, 768).  
Whereas Clcnk1-/- (532)  and Bsnd1-/- mice (699) were reported in 1999 and 2008, respectively, 
it took another eight years for two independent Clcnk2-/- mouse lines to be published (302, 
336). Both mouse models display the symptoms typical for Bartter III such as renal salt loss, 
hypokalemia, metabolic alkalosis, and increase of prostaglandin E2. They also displayed 
hypertrophy of the juxtaglomerular apparatus and proliferation of renin-producing cells (302, 
336). The mouse strains seem to differ in the sensitivity to drugs inhibiting the apical cation-
chloride cotransporters of the TAL (furosemide, acting on NKCC2) and the DCT (thiazides, 
inhibiting NCC). Whereas Hennings et al. (336) report that the sensitivity to furosemide is 
abolished and that to thiazides reduced, Grill et al. (302) state a reduction of furosemide 
sensitivity and abolishment of thiazide sensitivity. This apparent discrepancy might be owed to 
the use of different drug concentrations or other differences in experimental design. In any 
case, these experiments clearly indicate crucial roles of ClC-K2/barttin in both the TAL and the 
DCT. By using ClC-K1/K2 antibodies in Clcnk2-/- mice, Hennings et al. (336) further show that 
ClC-K1 expression extends from the tAL to include the mTAL. Their patch-clamp experiments on 
cTAL cells and CNT/CCD intercalated cells revealed the disappearance in Clcnk2-/- mice of a ~10 
pS channel (336), confirming that this previously described channel (593, 594, 658, 936) is 
encoded by Clcnk2.  
 
Loss of barttin, or of both ClC-K1 and ClC-K2, entail deafness and severe renal salt loss 
Since the surface expression of ClC-K ion-conducting α-subunits depends on the β-subunit 
barttin (222, 868), disruption of the BSND gene leads to an almost complete loss of both ClC-Ka 
and ClC-Kb channel activity. Therefore, the renal phenotype of Bartter IV patients is more 
severe than with a loss of CLCNKA (nephrogenic diabetes insipidus) or CLCNKB (Bartter III), 
except when a BSND mutation elicits only a partial loss of function  (696, 769). Likewise, 
constitutive Bsnd-/- mice die within a few days after birth due to severe salt loss and 
dehydration (699), whereas Clcnk1-/- mice (532) and Clcnk2-/- mice (302, 336) survive with the 
renal phenotypes described above.  
In addition to the severe renal phenotype, Bartter IV patients (65, 444) and Bsnd-/- mice (699) 
display congenital deafness. The inner ear reacts more sensitively to a reduction of barttin 
function than the kidney, as revealed by non-syndromic hearing loss with mild BSND mutations 
(696, 769). As shown by in situ hybridization (65) and immunohistochemistry (222, 699), barttin 
localizes to the basolateral membranes of two types of K+-secreting epithelial cells, dark cells of 
the vestibular organ and marginal cells of the stria vascularis (Fig. 9). This highly vascularized 
multi-layered epithelium is found in the lateral wall of the scala media that contains the sensory 
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organ of Corti. By secreting K+ and generating a positive potential in the scala media, the stria 
generates an appropriate electrochemical potassium gradient to drive depolarizing K+ currents 
through mechanosensitive channels of sensory hair cells (940) (Fig. 9A). The passive apical 
uptake of K+ through mechanosensitive channels is matched by an equally passive basal efflux 
from hair cells mainly through KCNQ4 (Kv7.4) K+ channels (413, 436). This is possible because 
the base of hair cells is exposed to normal extracellular fluid. This purely passive K+ movement 
drastically lowers the need for metabolic energy in these sensory cells. The energy necessary 
for ion transport is provided by the ‘power station’ of the stria vascularis. If it fails, deafness 
ensues.  
Like the transport model for the TAL (see above), the model for potassium secretion by 
marginal cells of the stria vascularis is strongly supported by genetic evidence. Its feasibility has 
been tested by measuring intrastrial ion concentrations and by mathematical modeling (592, 
684, 685). Potassium is secreted across the apical membrane through the KCNQ1(Kv7.1)/KCNE1 
K+-channel. Both disruption of the α-subunit KCNQ1 (108, 448, 581) and of the β-subunit KCNE1 
(758, 858) entail deafness in mice and man. Potassium is taken up across the highly infolded 
basolateral membrane of marginal cells by the combined action of the Na+,K+-ATPase and the 
Na+K+2Cl--cotransporter NKCC1 (disruption of which leads to deafness in mice (182, 198, 253)). 
Akin to the need for K+ recycling of the apical NKCC2 in the TAL, NKCC1 needs recycling of Cl- 
across the basolateral membrane of marginal cells. This is accomplished by ClC-Ka/barttin and 
ClC-Kb/barttin channels which operate in parallel. Since deafness is not observed with single 
disruptions of either CLCNKA or CLCNKB (or their mouse orthologs), the function of either 
channel is sufficient for strial function. Only loss of both channels, either by a loss of function of 
their common β-subunit barttin (65, 699), or in rare patients by mutations in both channels 
(601, 748), impairs Cl- recycling to a degree that causes deafness. 
The impact of barttin on hearing has been studied in detail in mice with inner ear-specific Bsnd 
disruption (699). Similar to the congenital deafness observed with Bartter IV patients, these 
mice displayed a severe hearing loss that was already fully developed at the normal onset of 
hearing. Unexpectedly, disruption of barttin did not decrease the high K+ concentration in the 
scala media, but drastically reduced the endocochlear potential. This suggested the presence of 
another Cl- channel in marginal cells which is barely sufficient for strial K+-secretion, but not for 
generating the highly positive (~+100 mV) endocochlear potential. The collapse of this potential 
sufficed to impair the function of sensory outer hair cells which later also degenerated, without, 
however, compromising hearing further. Importantly, ClC-K proteins could no longer be 
observed by immunohistochemistry in the cochlea or vestibular organ, demonstrating that in 
vivo the stability of the ClC-K α-subunit depends on its β-subunit barttin. This excludes that ClC-
K1, which is not strictly dependent on barttin in heterologous expression systems, mitigates 
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symptoms in mice. Consistent with the expression of ClC-K/barttin in dark cells, subtle 
vestibular symptoms were also observed (699). 
Two additional Bsnd mouse models were described recently: a knock in mouse carrying the R8L 
mutation found in Bartter IV patients and, obtained as an intermediate step in its generation, a 
mouse expressing this mutant at very low levels (a hypomorph) (598). Whereas hypomorphic 
mice showed Bartter-like symptoms (but less severe than Bsnd-/- mice (699)), BsndR8L/R8L mice 
had a surprisingly mild phenotype which became apparent only under low salt diet (598). They 
also displayed a subtle hearing loss (597). Importantly, mutant R8L barttin and ClC-K 
immunoreactivity were shifted from the plasma membrane to the cytosol of kidney epithelial 
cells (598), consistent with the trafficking effect observed in cell culture (329). In proof-of-
principle experiments, treatment with an Hsp90 inhibitor slightly rescued the plasma 
membrane localization of R8L mutant barttin and of ClC-K in BsndR8L/R8L mice, corrected their 
metabolic alkalosis, ameliorated hypokalemia, and slightly amended the hearing loss (597).  
Many, if not most, pathogenic BSND mutations, like the R8L mutation (65) later studied in 
knock in mice (598), affect ClC-K function by decreasing the plasma membrane residence of the 
channel (329, 377, 696). Some BSND mutations, like G47R, seem to lead to a mild phenotype 
(555, 556), but this is not always the case (627). Of note, one particular mutation (I12T) 
underlies nonsyndromic deafness, i.e. without significant renal abnormalities, in four different 
pedigrees (696). Another BSND mutation (V33L) was associated with non-syndromic hearing 
loss in another family (769). Both mutants markedly reduce, but do not abolish, ClC-K/barttin 
currents in heterologous expression owing to reduced transport to the plasma membrane (696, 
825), suggesting that the inner ear reacts more sensitively than the kidney to a reduction in ClC-
K/barttin function.  
BSND mutations might cause disease not only because they impair the transport of ClC-K α-
subunits to the cell surface (329), but also by modulating the function of plasma-membrane 
inserted ClC-K channels (377). However, it may be difficult to extrapolate cell culture studies to 
the in vivo situation. For instance, using heterologous expression, Fahlke and coworkers 
reported that several pathogenic Barttin mutants including R8L reached the plasma membrane 
but failed to activate ClC-K currents (377). However, as mentioned above, BsndR8L/R8L knock in 
mice revealed that in vivo R8L mutant Barttin is largely retained intracellularly, resulting in a 
drastic overall decrease of ClC-K/barttin expression levels (598).  
 
 
F. Pharmacology of ClC-K channels 
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Before the molecular identification of ClC-K channels, Wangemann et al. screened hundreds of 
compounds for their ability to reduce the basolateral Cl- conductance of the thick ascending 
limb of Henle’s loop (TAL), and identified NPPB as one of the most potent compounds with an 
apparent affinity of  ~ 0.1 µM (885). However, subsequent studies on heterologously expressed 
ClC-K channels found only a weak block of rat and mouse ClC-K1 by this compound (441, 465). 
So far no functional data have been published for rat or mouse ClC-K2 channels, which are 
presumably underlying the basolateral Cl- conductance in the TAL, and the effect of NPPB on 
human ClC-Kb has not been reported in the literature. Screening several classical Cl- channel 
blockers and novel compounds, Liantonio et al. identified derivatives of CPP, in particular a 
bisphenoxy compound and 3-phenyl CPP, as rather potent inhibitors of ClC-K channels with 
affinities around 100 µM for rat ClC-K1 and human ClC-Ka (458, 465).  Interestingly, human ClC-
Kb was much less sensitive to 3-phenyl-CPP and also to DIDS, a non-specific anion channel 
blocker (648). The reason for this different pharmacological profile could be nailed down mostly 
to residues in the extracellular vestibule, which are negatively charged in the less sensitive ClC-
Kb and neutral in ClC-Ka: D/N68 and E/G72 (648). These results strongly suggest that the 
blockers are inhibiting ClC-K channels by directly binding to the external pore entry, in 
agreement with dependence of the affinity of the extracellular Cl- concentration (465). Matulef 
et al. found that polythiourea derivatives of DIDS, created by DIDS hydrolysis in aqueous 
solutions, bind to the same site with rather high affinity (533). Interestingly, the D68 residue 
was also found to be important for the gating of ClC-K channels (648), as in ClC-1 (233) and ClC-
0 (490). The same residue also affects gating relaxations in the Cl- / H+ antiporter ClC-5 (180).  
Subsequently, even higher affinity benzofuran derivative blockers were identified with IC50 
values < 10 µM (462, 464). Surprisingly, these compounds were practically equally effective on 
ClC-Ka and ClC-Kb. Two of these compounds have been found to slightly increase urine volume 
and to slightly reduce systolic blood pressure, without affecting electrolyte balance, in 
agreement with the presumed effect on kidney ClC-K channels (461, 462). These studies 
support the hypothesis that ClC-K channel inhibitors might be interesting alternative diuretics 
(257). However, the specificity of these compounds with respect to other targets, such as 
potassium channels or NKCC / KCC co-transporters, chloride-bicarbonate exchangers, or also 
regulatory proteins like WNK kinases, remains to be determined. Recently, Louet et al. used 
virtual screening, docking compound on a homology model of human ClC-Kb based on the 
bovine ClC-K structure to explore novel ClC-K ligands (486), using RT-93, one of the benzofuran 
derivative with highest affinity (464), as a reference point. However, testing about 40 
compounds resulting from the screening did not reveal any substance with higher affinity than 
RT-93 (486). Somewhat surprisingly, despite a very high sequence identity between bovine and 
human ClC-Kb, several helices in the model appeared to be oriented in significantly different 
directions compared to the experimental structure (486). Another disconcerting result was that 
the mutant D68N, which affects a residue that is critically involved in binding of various 
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inhibitors (648), was reported to not express functional currents (486), in contrast to the robust 
currents shown by Picollo et al. (648). Recently, testing FDA approved drugs for which Bartter 
syndrome like side-effects had been reported, the angiotension receptor 1 (AT1) blocker 
valsartan was found to rather specifically inhibit ClC-Ka (IC50 ~ 20 µM) but less so ClC-Kb (IC50 
>100 µM) (370). The difference in binding affinity suggests that the blocker binds to the same 
site as 3-phenyl-CPP (648), as also confirmed by docking studies (370).  A surprising finding was 
that niflumic acid (NFA), a common Cl- channel blocker, actually potentiated currents of human 
(but not rat) ClC-K channels expressed in Xenopus oocytes (463). For ClC-Ka the effect was 
biphasic with concentrations below 1 mM resulting in channel activation, whereas larger 
concentrations blocked the channel. In contrast, ClC-Kb currents were augmented at all 
concentrations with an up to fourfold potentiation (463). Interestingly, the chemically highly 
similar flufenamic acid (FFA) only led to channel block (463), an effect that could be pinpointed 
to the non-planarity of NFA compared to the more rigid planar structure of FFA (464). The NFA 
binding site is probably different from the 3-phenyl-CPP blocking binding site  in that mutations 
that affect 3-phenyl-CPP block only slightly affected potentiation and NFA potentiation was 
independent of the extracellular Cl- concentration (463, 647). However, a scanning mutagenesis 
study could not unequivocally identify the NFA binding site (962). More recently, two amino 
acids at the beginning of the I-J loop, close to the Ca2+ binding site, were shown to have a 
dramatic influence on NFA activation when mutated (295): In ClC-Ka, the mutation F256A 
dramatically augmented NFA mediated activation with almost 50-fold maximal activation. In 
contrast, the N257A mutation completely locked the channel open, probably by activation of 
the common gate, and introduced a high affinity NFA mediated block with an IC50 of ~ 1 µM 
(295). While these effects are dramatic, the molecular mechanisms underlying the complex 
interaction of ClC-K channels with NFA are still unclear. Furthermore, Imbrici et al. found that 
NFA has practically no activating effect on ClC-K channels expressed in HEK cells, probably 
because their open probability is constitutively high in these cells and cannot be increased 
further (368). Benzofuran blockers were equally effective in the two systems (368). The reason 




VIII. VESICULAR 2CL-/H+ EXCHANGERS 
For a long time, ClC-3 through ClC-7 were considered to be Cl- channels like ClC-0 and ClC-1, 
ClC-2 and ClC-K channels. Although predominently localized on endosomes, ClC-4 and ClC-5 
yielded plasma membrane currents upon heterologous expression and ion substitution 
experiments showed that these currents depend on the anion concentration. However, their 
extreme outward rectification precluded the determination of reversal potentials. Therefore, 
the coupling of anion movement to proton countertransport was missed until the discovery of 
2Cl-/H+-exchange in reconstituted EcClC-1 (5) prompted direct investigation of proton transport 
of ClC-4 and ClC-5 by two groups (651, 742). We now know that all vesicular CLCs, ClC-3 through 
ClC-7, function as Cl-/H+-exchangers. 
Vesicular CLCs are believed to assist the acidification of intracellular vesicles by electrically 
shunting the currents of the vesicular H+-ATPase (Fig. 10). Such a shunt is not only possible with 
chloride channels, but also with the highly electrogenic 2Cl-/H+-exchangers, even though one 
proton exits from the vesicle during one transport cycle. For electroneutrality, the three 
negative charges transferred by 2Cl-/H+-exchange have to be compensated for by three H+-ions 
pumped by the ATPase – hence, out of three protons, only one leaves the vesicle in this 
oversimplified model. Rather surprisingly, model calculations (372, 896) show that 2Cl-/H+-
exchange would achieve, together with the proton pump, a more acidic vesicular pH than a 
simple Cl- conductance. This can be attributed to a more inside-negative voltage obtained with 
an exchanger (896). In addition to a potential impact on luminal pH and luminal voltage, 2Cl-
/H+-exchange will also raise the vesicular Cl- concentration. The large transmembrane H+-
gradient of inside-acidic vesicles will raise luminal [Cl-] above the levels obtained with a 
shunting Cl- channel. 
As discussed for the individual vesicular CLCs below, the expected changes in luminal pH and 
[Cl-] were indeed observed in some of the knock out mouse models, which have been obtained 
for all mammalian vesicular CLCs. However, it remains unclear how these changes, and which 
ones, lead to the often severe pathologies of mice or human patients lacking functional 
vesicular CLCs. The strong outward rectification of ClC-3 through ClC-7 in heterologous 
expression at the plasma membrane poses another serious problem. Although model 
calculations predict a lumen-negative potential when 2Cl-/H+-exchangers operate in parallel 
with a proton pump (372, 896), endosomes/lysosomes are generally assumed to be inside-
positive. No methods are currently available to quantitatively measure this voltage. One may 
hypothesize that these CLCs display a different voltage-dependence when present in 
intracellular membranes, possibly owing to different lipid composition or posttranslational 
modification. Moreover, the voltage across endolysosomal membranes may show short 
excursion to negative voltages, for instance due to the opening of Ca2+-channels. The biological 
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role of vesicular CLCs may only be sufficiently understood once our picture of vesicular ion 
homeostasis in general is more complete. 
 
 
IX.  CLC-3 – A WIDELY EXPRESSED, MAINLY ENDOSOMAL CL-/H+ EXCHANGER  
ClC-3 (73, 410) is a widely, possibly even ubiquitously, expressed member of the second 
homology branch of the CLC family. Like its close homologues ClC-4 and ClC-5, ClC-3 is very 
predominantly expressed in membranes of the endolysosomal system (810). It may also be 
present on synaptic vesicles (729, 810) and synaptic-like microvesicles (SLMVs) (523, 729). 
Some ClC-3 splice variants may partially reach the plasma membrane upon heterologous 
overexpression (317, 609).    
Like its close congeners ClC-4 and ClC-5, ClC-3 is a strongly outwardly rectifying, electrogenic 
2Cl-/H+-exchanger (316, 651), although the stoichiometry of coupling has not yet been firmly 
established. Due to the difficulty of expressing ClC-3 at the plasma membrane, even upon 
heterologous overexpression, and owing to the apparently small transport rates of ClC-3 (316), 
many different, endogenous plasma membrane anion currents have been erroneously 
attributed to ClC-3 (153, 203, 360, 409, 410, 529, 554, 877, 881). This confusion has led to a 
large and still expanding body of literature purporting roles of ClC-3 in cell volume regulation 
(203, 342), apoptosis (306, 945), cell cycle regulation (152, 320, 520), cell migration (154, 279, 
311), cardiac function (77, 454, 921, 922), vasculature (279, 506, 960) and cancer (153, 348, 
871), among others. These publications will not be covered here. 
Like other vesicular 2Cl-/H+-antiporters, ClC-3 may assist in the acidification of endosomes and 
other compartments by shunting the electrical current of the vesicular V-type H+-ATPase (325, 
610, 810, 930). ClC-3 may also change the vesicular voltage or lead to luminal chloride 
accumulation, as directly shown for the lysosomal 2Cl-/H+-exchanger ClC-7 (895, 896). These 
parameters may impinge on various vesicular functions, including vesicle budding, fusion and 
trafficking and secondary active transport of ions and organic compounds across their limiting 
membranes. 
Important biological functions of ClC-3 are indeed indicated by the severe phenotype of ClC-3 
KO mice which eventually completely lose their hippocampus (Fig. 11) and show severe retinal 
degeneration (810). The neurodegeneration of these mice is not restricted to the hippocampus 
and Clcn3-/- mice appear systemically sick (194, 608, 810, 930). The mechanistic link between a 
loss of ClC-3 and the resulting pathology, however, remains obscure. So far, no human 




A. Basic properties of ClC-3 
ClC-3 migrates as a broad 95-155 kDa band in SDS PAGE (751, 810). Its size and migration 
behavior depend on apparently tissue-specific N-linked glycosylation (751) and the specific 
splice variant (317, 604, 609). These variants can add 58 amino acids to the amino-terminus, or 
42 amino acids to the carboxyterminus of the shortest 760 residue-long ClC-3a protein (317). 
Interestingly, a carboxyterminal variant (originally named ClC-3b) that replaces a short part of 
the ClC-3 C-terminus and adds a PDZ binding domain (604), was alternatively suggested to 
interact with EBP50 to yield plasma membrane localization  (604) or with GOPC to yield Golgi 
localization (286). Amino-terminal splice variants, which are differentially expressed across 
tissues (317), appear to change the subcellular localization of ClC-3 with ClC-3c reported to be 
localized to recycling rather than late endosomes (317). No differences in the biophysical 
transport properties of these splice variants were found (317, 609).  
ClC-3 may form heteromers with its close relatives ClC-4 and ClC-5, but not with ClC-6 or ClC-7 
(820). ClC-3 interacts with clathrin through an amino-terminal dileucine cluster (801, 958). 
Mutating this and other N-terminal motifs leads to slightly increased plasma membrane 
expression that facilitates the biophysical analysis of ClC-3 (316, 317, 958). In contrast to 
clathrin binding, the purported ClC-3 protein interactions with postsynaptic glutamate 
receptors and PSD-95 (881) or with CAMKII (153) should be viewed critically.  
 
B. Ion transport by ClC-3 
ClC-3 is a strongly outwardly-rectifying, electrogenic 2Cl-/H+-exchanger with biophysical 
properties that closely resemble those of its close homologues ClC-4 and ClC-5 which yield 
larger plasma membrane currents (269, 808). Upon overexpression, ClC-3 yields strongly 
outwardly-rectifying currents that are clearly different from background only at voltages more 
positive than +20 mV (316, 317, 456, 457, 531, 609, 651), display a Cl->I- conductance sequence 
(456, 531, 609), and are reduced by extracellular acidification (531). ClC-3 currents activate and 
deactivate almost instantaneously upon voltage steps. Rigorous experiments showed that ClC-3 
currents depend neither on intracellular, nor extracellular Ca2+ (609). Not only the strong 
rectification, ion selectivity and pH-dependence fit to the other vesicular CLCs, but importantly, 
also the effect of neutralizing mutations of the crucial ‘gating glutamate’ of ClC-3 that abolish 
the strong current rectification and result in an almost ohmic anion conductance (457, 531, 
609) just as observed for ClC-4 and ClC-5 (269, 651, 742), ClC-6 (576) and ClC-7 (453).  
Even though the more recent studies used ClC-3 splice variants or mutants which increased 
plasma membrane expression without detectably changing current properties (316, 317, 609, 
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958), ClC-3 plasma membrane currents are low and several groups were unable to detect novel 
currents upon ClC-3 overexpression (269, 902). It therefore remains difficult to directly show 
that ClC-3 is a Cl-/H+-exchanger. The strong rectification and almost complete absence of tail 
currents precludes measurements of reversal potentials as a function of chloride- and proton-
concentrations (609) (which were possible for the slowly gating ClC-7 (453) and a ClC-5 mutant 
(180)). One report (316), however, showed small voltage-dependent pHint changes with ClC-3 
expressing cells that are expected for a Cl-/H+-exchanger.   
In summary, there is no reasonable doubt that ClC-3 is a Cl-/H+-exchanger which may affect the 
ion homeostasis of intracellular vesicles. However, ClC-3 transport activity may be low 
compared to ClC-4 and ClC-5, even when corrected for the extent of plasma membrane 
expression (316). It was therefore suggested that the biological role of ClC-3 consists in 
providing increased membrane capacitance (which differed between splice variants) by 
performing ‘non-transporting cycles’ (316). These authors speculated that increased endosomal 
capacitance may facilitate the acidification of intracellular compartments by buffering the 
electric charge transported by the vesicular H+-ATPase, rather than by providing an ionic 
countercurrent. The model calculation used to demonstrate the feasibility of this concept, 
however, is based on the buffer capacity of pure water (316), which is orders of magnitude 
lower than that of endosomes or the cytoplasm. Therefore, a significant contribution of ClC-3 
capacitance to endosomal acidification seems excluded. 
 
C. Currents erroneously ascribed to ClC-3  
The field or ClC-3 research has been plagued by the fact that many different plasma membrane 
currents, which were probably endogenous to the expression system, have been mistakenly 
attributed to ClC-3. ClC-3 was first suggested to mediate time-independent, slightly outwardly 
rectifying currents that were strongly inhibited by PKC (410), but the same group later reported 
incongruent strongly rectifying single channel currents (100-140pS at positive potentials) that 
were directly inhibited by cytosolic Ca2+ (409). By contrast, others proposed that ClC-3 mediates 
outwardly rectifying anion currents with an I->Cl- halide selectivity that are activated by 
cytosolic Ca2+ through Ca2+/calmodulin-dependent protein kinase (CamKII) (153, 237, 279, 360, 
554, 706, 881). However, the single channels ascribed to CamKII-activated ClC-3 in hippocampal 
neurons (881) look suspiciously similar to ClC-2 (815, 834, 897). ClC-3 KO mice displayed 
unchanged Ca2+-activated Cl- currents in salivary glands (37), and currents from overexpressed 
ClC-3 are Ca2+-independent (609). 
ClC-3 had also been suggested (203, 342, 397) to encode the ubiquitously expressed Volume-
Regulated Anion Channel VRAC. This channel is slowly activated by hypotonic cell swelling and 
displays a I->Cl- permeability and outward rectification (635). This notion was even supported 
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by changed characteristics upon ClC-3 mutagenesis (202, 203, 575) and, although disproven, is 
still popular with some groups (311, 454, 871, 960). Three independent Clcn3 KO mouse models 
(194, 810, 930) revealed that typical ICl,vol VRAC currents are unchanged in hepatocytes and 
pancreatic epithelial cells (810), salivary gland cells (36), cardiomyocytes (291, 876, 926) and 
osteoclasts (610). The long search for the proteins constituting VRAC, which had yielded more 
than ten ‘candidates’ including ClC-3 (634), finally came to an end when two independent 
genome-wide siRNA screens identified LRRC8A as an indispensable VRAC subunit (681, 865). 
This subunit needs to assemble with other LRRC8 isoforms to form functional VRAC channels 
(865), which, depending on their subunit composition, also conduct various organic compounds 
(499, 662).  
Another probably ubiquitously expressed anion channel, the Acid-Stimulated Outward Rectifier 
ASOR (103), most likely underlies the currents ascribed to ‘uncoupling’ of ClC-3 Cl-/H+-exchange 
at strongly acidic external pH (529). ASOR probably also underlies the acid-activated currents 
ascribed to ClC-4 in skeletal muscle (408) and acid-activated currents observed upon ClC-7 
expression in Xenopus oocytes (195). ASOR, however, is definitely distinct from ClC-3 (609, 737) 
and LRRC8/VRAC channels (736). Moreover, a ClC-3 splice variant has been suggested to 
mediate CFTR-regulated outwardly-rectifying Cl- currents at the plasma membrane (604). For 
completeness, it should be mentioned that currents reported for a long amino-terminal variant 
of ClC-3 rather resemble swelling-activated VRAC/LRRC8 currents (772) and that strongly 
outwardly rectifying currents reported by Lamb et al. (531) show atypical slow activation by 
depolarization. 
 
D. Localization of ClC-3 
ClC-3 may be expressed in all mammalian tissues and cells. Northern blots found pronounced 
ClC-3 expression, for instance, in tissues as diverse as brain and kidney (73, 410, 810), results 
that were confirmed by Western blots (751). KO-controlled immunohistochemistry detected 
salient ClC-3 expression in neuroendocrine cells such as those of the posterior pituitary, 
pancreatic islets, and chromaffin cells of the adrenal medulla (523).  
 
ClC-3 resides on late endosomes 
ClC-3 is very predominantly expressed on intracellular vesicles (523, 729, 810). The 
identification of these vesicles by immunohistochemistry in native tissues has often been 
plagued by poor sensitivity and cross-reactivity of antibodies and a lack of controls in the form 
of tissue from Clcn3-/- mice. Subcellular fractionation by gradient centrifugation of liver 
membranes revealed that ClC-3 partially co-purifies with lamp-1, a marker of late endosomes 
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and lysosomes, and with rab4, an endosomal marker protein (810). The ‘purest’ lysosomal 
fractions (from brain), as identified by the presence of cathepsin D, however, did not contain 
ClC-3, but rather ClC-7 and small amounts of ClC-6 (663), suggesting a predominantly late 
endosomal rather than lysosomal localization of ClC-3. Interestingly, ClC-3 (and ClC-6) shifted to 
lysosomal fraction upon disruption of ClC-7 (663).  
A few knock out controlled immunolocalization studies of native tissues and cells also showed a 
late endosomal localization of ClC-3. Native ClC-3 co-localized with lamp-2 in cultured 
osteoclasts (610). Endosomal compartments of renal proximal tubules, which display 
particularly high rates of endocytosis, are nicely layered within the cell. In these cells, 
immunofluorescence localized ClC-3-positive vesicles below the apical brush border (523) 
between more apical ClC-5-containing (early) endosomes and more basal ClC-7-containing 
vesicles (mostly lysosomes) (888). KO-controlled immunohistochemistry (IHC) also revealed 
prominent ClC-3-positive vesicles in epithelial cells of the epidydimis, somata of CA3 
hippocampal neurons, various neuroendocrine cells and hepatocytes (523).   
Upon transfection, epitope-tagged ClC-3 also resides, at least partially, in vesicles positive for 
lamp-1 (316, 317, 457, 810, 820, 901), lamp-2 and cathepsin D (457) and the late endosomal 
rab7 (317), but also with the early endosomal marker EEA1 (820). A ClC-3 splice variant (ClC-3c) 
rather localized to rab11- and transferrin receptor-positive recycling endosomes (and partially 
to the plasma membrane) (317), and ClC-3-overexpressing vesicles were accessible to 
endocytosed transferrin (729). Inferring native subcellular localization from heterologous 
expression, however, is particularly problematic with ClC-3 because it artificially generates 
remarkably large vesicles with lysosome-like properties (317, 457). The generation of these 
vesicles depends on the transport properties of ClC-3 because it does not occur with the E224A 
mutant (457) that abolishes ClC-3’s voltage-dependence (457, 531, 609) and that most likely 
converts it from a 2Cl-/H+-exchanger into a pure Cl- conductance (as shown for ClC-4 and -5 
(651, 742)). Collectively, these results provide overwhelming evidence for a (most likely late-) 
endosomal localization of ClC-3.  
 
Evidence for presence of ClC-3 on synaptic vesicles and synaptic-like microvesicles 
Additionally, there is considerable evidence that ClC-3 is expressed on synaptic vesicles (SVs) 
(523, 729, 810), although the extent and functional relevance of this localization has been 
questioned (745). Likewise, ClC-3 has been localized by subcellular fractionation to synaptic-like 
microvesicles (SLMVs) in neuroendocrine cells (523, 729). By contrast, the postulated 
localization of ClC-3 to insulin-containing large dense-core secretory vesicles (LDCVs) (44, 188, 
455), which was based in part on IHC that lacked Clcn3-/- controls, is not convincing (390, 523). 
A presence of ClC-3 on SVs/SLMVs, and absence on LDCVs, fits to the difference in biogenesis 
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between SVs/SLMVs and dense core vesicles (290). Whereas the former are largely generated 
from endosomal intermediates (133, 729), secretory dense core vesicles rather form directly 
from the trans-Golgi network (TGN) (416).  
ClC-3 was present in a highly purified preparation of synaptic vesicles and was detected in both 
immuno-isolated GABA-ergic and glutamatergic vesicles (810). In the retina, KO-controlled IHC 
showed intense labeling for ClC-3 in the outer and inner plexiform layers (OPL and IPL, 
respectively) which contain the majority of retinal synapses (810) and where it (but only 
partially) overlapped with the SV marker synaptophysin (523). KO-controlled IHC of mouse 
brain revealed punctate/vesicular staining for ClC-3 in cell bodies and neurites of CA3 
hippocampal neurons. In neurites of the dentate gyrus it partially co-localized with 
synaptophysin (523). 
ClC-3 was present in synaptophysin-positive fractions upon fractionation of brain membranes 
using various protocols (523, 729). In both chromaffin cells and the INS-1 pancreatic β-cell line, 
ClC-3 co-purified with synaptophysin, but not with secretogranins or carboxypeptidase E as 
markers for secretory dense-core vesicles (523). The latter finding was supported by IHC of INS-
1 cells showing differential vesicular distribution of ClC-3 and insulin (523). Trafficking of ClC-3 
(and the zinc transporter ZnT3) to bona fide SVs and SLMVs in brain and PC12 cells depended 
on the adaptor complex AP3 (729), although ClC-3 appears not to bind AP3 directly (801). 
Functional data also seemed to indicate a presence of ClC-3 on SVs/SLMVs (729, 810): 
disruption of ClC-3 inhibited the ATP-dependent acidification of SV-enriched vesicles fractions 
(810) and co-targeting of ZnT3 and ClC-3 SLMV-like fractions increased intravesicular Zn-
accumulation (729). Both results were interpreted in terms of an anion conductance of ClC-3 
which neutralizes the electrical charge transferred by the H+-ATPase or the zinc transporter, 
respectively. However, for unknown reasons, expression of the glutamate transporter vGlut1 is 
strongly decreased in SVs of Clcn3-/- mice (810). Since vGlut1 is now known to also mediate a Cl- 
conductance, this secondary loss, and not directly a loss of ClC-3 on SVs, may explain the 
impaired SV acidification in Clcn3-/- mice (745). Another concern was raised by quantitative 
Western blots of purified SVs that seemed to indicate that only a very small fraction of SVs 
contains ClC-3 (745). However, the ClC-3 quantification used by Schenck et al. (745) has to be 
viewed with caution as it was based on a calibration of ClC-3 antibodies which used a C-
terminal epitope tag located close to the epitope on the native channel, the recognition of 
which might have been affected. A low abundance of ClC-3 on SVs is, on the other hand, 
consistent with the absence of ClC-3 in the published proteome of purified synaptic vesicles 
(824), although some other bona fide SV membrane proteins were also missed in that work.  As 
discussed below, effects of Clcn3 disruption on synaptic transmission are controversial. 
Although we believe that there are very good arguments for the presence of ClC-3 on 
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SVs/SLMVs, more work is needed to convincingly demonstrate a role of ClC-3 in these 
important organelles.  
E. Pathology from ClC-3 disruption and possible physiological roles 
Disruption of Clcn3 in mice entails severe neurodegeneration that, after a few months, leads to 
a conspicuous absence of the hippocampus (Fig. 11) and includes early blindness (810). These 
observations were reproduced in two other Clcn3-/- mouse models (194, 930). 
Neurodegeneration is also observed in several other brain regions including the cortex (194, 
608, 810, 930). Nonetheless Clcn3-/- mice, depending on the genetic background, survive for 
many months. Uchida and colleagues found some signs for lysosomal storage disease of the 
neuronal ceroid lipofuscinosis type in their mice (930) and that is accelerated by ischemia (608). 
However, lysosomal storage is much less pronounced in Clcn3-/- than in Clcn6-/- or Clcn7-/- mice 
(429, 663, 668). Lamb and coworkers reported a preferential predeliction for the GABAergic 
system (194). In accord with their neurodegeneration, Clcn3-/- mice, showed impaired motor 
coordination in rotarod tests, but could learn to improve their skills (810). The exact mechanism 
leading to neurodegeneration remains unclear and is difficult to ascertain like in other forms of 
neurodegeneration. It seems, however, likely that the pathology is a consequence of impaired 
vesicular trafficking or function. 
Further functional analysis of Clcn3-/- mice therefore focused on the possible roles of ClC-3 in 
endosomes, synaptic and other types of vesicles. The underlying hypothesis is that ClC-3, being 
possibly a Cl- channel or, as we now know, an electrogenic 2Cl-/H+-exchanger, would support 
their luminal acidification by supplying countercurrents for the vesicular H+-ATPase. Indeed, 
endosomal acidification and concomitant Cl- accumulation was impaired in hepatocytes from 
Clcn3-/- versus WT mice, and ClC-3 transfected CHO cells showed more acidic endosomal pH 
(325). Based on less reliable acridine orange staining, overexpression of ClC-3 also seemed to 
decrease vesicular pH (and increase drug resistance) in HEK293 and BON cells (901), and 
lysosensor staining suggested that intracellular vesicles of Clcn3-/- osteoclasts were less acidic 
than those in the WT (610). A role of ClC-3 in endocytosis, however, has not yet been 
demonstrated. Although ClC-3 is prominently expressed in apical endosomes of renal proximal 
tubules (523), proximal tubular endocytosis of luminal proteins was not affected in Clcn3-/- mice 
(700). This contrasts with the strong reduction of proximal tubular endocytosis upon disruption 
of ClC-5 (661, 700).  
Much work has focused on possible roles of ClC-3 in synaptic vesicles (314, 695, 745, 810), but it 
is fair to say that no definitive conclusions are possible to date. As mentioned above, the 
impaired acidification of synaptic vesicles of Clcn3-/- mice that was observed by Stobrawa et al. 
(810) might be owed to the loss of vGlut1 on SVs (810) because vGlut1 is now known to also 
provide a Cl- conductance (745). The impaired acidification of bona fide inhibitory synaptic 
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vesicles reported by Nelson and coworkers (695) is based to a large extent on a so-called ‘rat 
KO model’ in which vesicles fractions enriched for inhibitory SVs were depleted for ClC-3-
containing vesicles using antibodies coupled to magnetic beads. Of course, the resulting vesicle 
population is distinct from inhibitory SVs disrupted for Clcn3. ClC-3 might affect the loading of 
neurotransmitters into SVs since the respective vesicular uptake transporters are differentially 
driven by pH- or voltage gradients, which are expected to be increased and decreased, 
respectively, by the presence of ClC-3. Vesicular uptake of glutamate depends on the voltage 
rather than pH. Consistent with a role of ClC-3 in SV glutamate uptake, a slight increase in 
miniature synaptic currents (postsynaptic currents in response to presynaptic exocytosis of 
single synaptic vesicles, reflecting in part their glutamate content) was observed in 
hippocampal slice preparations of Clcn3-/- mice (810). However, even though these data were 
obtained before an onset of conspicuous degeneration, degenerative changes, which may 
include altered densities or localization of postsynaptic glutamate receptors, cannot be 
excluded. Miniature excitatory postsynaptic currents and action-potential induced excitatory 
potentials were also enhanced when comparing Clcn3-/- to WT neurons in culture (314). These 
authors also reported an increase in the volume of SVs from Clcn3-/- mice (314). Miniature 
inhibitory synaptic currents were unchanged in slice preparations of Clcn3-/- mice in one study 
(810), but reduced in another report (695). Together with a report claiming that ClC-3 is only 
expressed on a very minor fraction of SVs (745), these contradictory results do not yet allow to 
unambiguously establish a role of ClC-3 in SVs. 
Disruption of Clcn3 impairs the exocytosis of large dense core vesicles (188, 455, 523). This is 
probably an indirect effect because, as discussed above, IHC and subcellular fractionation 
revealed that ClC-3 is strongly expressed on SMLVs rather than on LDCVs, as observed both in 
chromaffin and β-cells (523). Moreover, the reported localization of ClC-3 to insulin granules 
(44, 188, 455) is not convincing (390). Exocytosis of catecholamine-containing LDCVs, as 
determined by capacitance changes or amperometry upon depolarization or intracellular Ca2+ 
release, was decreased in chromaffin cells from Clcn3-/- mice (523). These mice also displayed 
reduced serum insulin levels (523). However, this decrease may be owed to an indirect systemic 
effect, since Clcn3-/- are lean and have altered levels of other hormones such as leptin (523). A 
variable decrease in resting serum insulin concentration or insulin secretion from pancreatic 
islets was observed in two other studies (188, 455) which differ in several aspects (390). Given 
the systemic sickness and changed metabolism of Clcn3-/- mice, pancreatic β-cell specific 
disruption seems appropriate to better characterize the role of ClC-3 in insulin secretion (390).  
ClC-3 has also been localized to lamp-2 positive compartments in mouse osteoclasts (610). The 
acidity of these compartments seemed reduced in Clcn3-/- osteoclasts that were moderately 
impaired in their bone-degrading capacity as determined using in vitro pit assays (610). This 
effect was much less pronounced compared to Clcn7-/- osteoclasts (429). In contrast to ClC-3, 
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ClC-7 also localizes to the acid-secreting ruffled border and its disruption causes severe 
osteopetrosis (429). 
ClC-3 was also proposed to be present on secretory vesicles and phagosomes (vacuoles) of 
polymorphonuclear leukocytes, but the subcellular fractionation supporting this localization 
lacks essential controls for endosomes (570). Based on this assumed localization and the effect 
of (non-specific) inhibitors the authors suggested that ClC-3 provides a countercurrent for the 
phagosomal NADPH oxidase that is necessary for reactive oxygen species (ROS) generation in 
the oxidative burst. Indeed, ROS production appeared to be reduced in Clcn3-/- neutrophils 
(570, 571). The idea that ClC-3 neutralizes currents of the NAPDH oxidase in phagosomes is 
attractive, as the oxidase current, in contrast to the current of vesicular H+-ATPase, will render 
the compartment inside-negative (cytoplasmic positive) and thus open the strongly outwardly 
rectifying ClC-3 Cl-/H+ exchanger. The same group also suggested that ClC-3 is important for 
NADPH-oxidase function in smooth muscle cells, with an important effect on their migration 
(136), and that the activation of VRAC channels by tumor necrosis factor α requires ClC-3-
dependent ROS production (530). However, a more recent study found no change in vacuolar 
pH, nor in respiratory burst in  neutrophils from Clcn3-/- mice (260). The hypothesis that ClC-3 
supports NADPH oxidase function should therefore be viewed with due caution until other 
groups provide convincing evidence for this notion. 
 
X.  CLC-4 – A VESICULAR 2CL-/H+ EXCHANGER WITH SLOWLY EMERGING ROLES 
ClC-4 is a close homologue of ClC-3 and ClC-5 and is found in many tissues, including prominent 
expression in brain (389, 852). Like its homologues, ClC-4 is a strongly outwardly rectifying 2Cl-
/H+ exchanger (651, 742) and probably resides on endosomes (566, 820), although its 
heterologous overexpression can target it to the endoplasmic reticulum (611) and partially to 
the plasma membrane where it can be studied functionally (269). Its biological function may be 
related to the ion homeostasis, including acidification, of endosomes (566, 567). Although no 
obvious phenotype has been detected in Clcn4-/- mice (700), it is now clear from exome 
sequencing that mutations in human CLCN4 underlie particular forms of X-linked mental 
retardation (359, 620) sometimes associated with epileptic seizures (857). 
The CLCN4 gene localizes to the human X-chromosome (Xp22.2). While also present on the X-
chromosome in the wild Mediterranean mouse Mus spretus, Clcn4 is surprisingly located on 
autosomal chromosome 7 in the laboratory mouse Mus musculus (621, 713). This unusual 
situation, which contravenes ‘Ohno’s law’ (215), is of genetic interest (11, 585, 621). Crossing 
both mouse species can give mice lacking Clcn4 (11, 621). Like Clcn4-/- mice later generated in 
laboratory mice (700), Clcn4- mice resulting from such crosses lack obvious phenotypes except 




A. Basic properties of ClC-4 
Human full-length ClC-4 has 760 residues, but there may be shorter ClC-4 isoforms starting at 
later initiation sites and thus losing some of the amino-terminal residues. The NCBI-listed 
human short isoform 2 (NP_001243873), however, lacks essential parts of the protein (the first 
transmembrane helix B) and is predicted to be non-functional. The ClC-4 protein is about 80% 
identical to ClC-3 or ClC-5. It can interact with either of these proteins, but not with ClC-6 or 
ClC-7, and may therefore form functional ClC-3/4 or ClC-4/-5 heteromeric Cl-/H+-exchangers 
(315, 566, 820). The amino-terminus of ClC-4 interacts with clathrin, but this binding appeared 
weaker than that observed with ClC-3 and ClC-5 (801).  
 
Upon overexpression in Xenopus oocytes or in mammalian cells, a small portion of ClC-4 can 
reach the plasma membrane, thereby enabling its biophysical characterization.  Like ClC-3 and 
ClC-5, ClC-4 yields strongly outwardly rectifying currents with a NO3->Cl->I- conductance 
sequence (269). These currents, which are significant only at cytoplasmic potentials more 
positive than ~+ 20 mV, are inhibited by extracellular acidification. Like the other vesicular CLC 
proteins, ClC-4 is a Cl-/H+-exchanger (651, 742), and neutralization of its ‘gating glutamate’ by 
mutating it to alanine abolishes its rectification (269) and converts it into a pure Cl- 
conductance (651, 742). At first, a 3 pS ‘single channel’ conductance was ascribed to ClC-4 
(855), but noise analysis later indicated that ClC-4 displays much smaller ‘single channel’ 
amplitudes (~0.1 pS) (334). These are  similar to those later obtained for ClC-5 (~0.45 pS) and 
which likely represent the ‘gating’ of the 2Cl-/H+ exchange process (941).  
Currents mediated by ClC-4 expressed in oocytes are inhibited by extracellular Zn2+ and Cd2+ 
with an apparent affinity around 50 µM (613). However, the inhibition is not complete even at 
very high concentrations. The uncoupled gating glutamate mutation E224A was insensitive to 
Zn2+, suggesting that the cation binding interferes with the transport process. Mutating H493, 
which is located at the extracellular end of helix N, slightly reduced Zn2+ sensitivity (613). If, 
however, this residue is part of the binding site is unknown. 
The acid-activated currents with an I->Cl- selectivity ascribed to skeletal muscle ClC-4 (408) 
probably rather reflect activity of the widely expressed acid-activated ASOR channel (103).  
 
B. Localization of ClC-4 
ClC-4 is expressed in many tissues, including brain, skeletal muscle, liver, kidney, intestine and 
heart (389, 408, 564, 611, 852). There may be differences in the expression pattern between 
rodents and humans, but published Northern blots display disconcerting variability (11, 389, 
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408, 852). Part of the variability of tissue expression pattern may be owed to the different 
chromosomal localization and gene structure in rat and wild mice versus laboratory mouse 
strains (11, 585). In any case, ClC-4 is prominently found in brain, with particular high 
expression in pyramidal cells and dentate gyrus of the hippocampus (11, 810) and the Purkinje 
cell layer of the cerebellum (810).  
Although we favor the notion that ClC-4 resides on endosomes, there is currently no consensus 
on its native localization. This is largely owed to the lack of specific antibodies that work well in 
IHC with native tissues and cells, and to the lack of KO controls in several publications. 
Additionally, antibody cross-reactivity to ClC-3 and ClC-5 because of the high degree of 
homology between these transporter proteins must be addressed (374, 500, 523, 661). In IHC 
that lacked KO controls, Bear and coworkers described ClC-4 in apical brush border membrane 
of intestinal epithelia, where it seemed to co-localize with CFTR, and additionally in intracellular 
EEA1- and transferrin-positive endosomal compartments (564). These authors also found ClC-4 
in subapical vesicles of renal proximal tubules (566), resembling the localization of ClC-5 (661) 
and ClC-3 (523). Upon overexpression in HEK293 cells, epitope-tagged ClC-4 was targeted to 
endosomal structures where it co-localized with ClC-3 and partially with ClC-5 with which it 
might form heteromers (820). As described below, an endosomal localization seems to be 
supported by a few functional studies (566, 567). However, immunofluorescence and cell 
fractionation studies by Sardini and colleagues (611) suggested that ClC-4 rather localizes to the 
endoplasmic and sarcoplasmic reticulum when overexpressed either in HEK cells or in vivo in 
skeletal muscle fibers (where native ClC-4 appears highly expressed (611, 852)). This localization 
seemed to be supported by fractionation of brain membranes where ClC-4 overlapped with the 
ER marker SERCA2. Unfortunately, these experiments are not conclusive because subcellular 
fractions were not tested for endosomal marker proteins (611). Nonetheless, the authors 
identified an amino-terminal motif in ClC-4 that apparently directs ClC-4 specifically to the ER 
(611). 
 
C. Possible physiological roles of ClC-4  
The physiological role of ClC-4 remains largely enigmatic. Even if the questionable localization 
of ClC-4 to the intestinal brush border membrane (564) were correct, the strong outward 
rectification of ClC-4 (269) would preclude the postulated role in transepithelial transport (564). 
On the other hand, ClC-4 might have a role in endocytosis similar to that of ClC-5 (661). Indeed, 
Bear and co-workers reported reduced endosomal acidification and altered transferrin 
trafficking upon si-RNA mediated downregulation of ClC-4 (566), followed by a similar study on 
Clcn4- fibroblasts obtained by crossing Mus spretus with Mus musculus (567). However, their 
conclusion that ClC-4 is essential for transferrin endocytosis appears to conflict with the 
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apparently normal renal endocytosis in Clcn4-/- mice (700). Wang and Weinman (879) 
hypothesized that ClC-4 is important for neutralizing currents of the Cu2+-ATPase in the hepatic 
secretory pathway to explain their observation of increased copper loading of ceruloplasmin 
upon ClC-4 overexpression. However, this issue was not pursued further and unpublished work 
from the Jentsch lab found unchanged ceruloplasmin oxidase activity in liver extracts from 
Clcn4-/- mice (802). To add to the confusion, it has been reported that overexpression of ClC-4 
might contribute to tumor cell migration and metastasis  (373), to osteogenesis in an 
osteoprogenitor cell line (873), and to nerve growth factor-induced neurite outgrowth (363). It 
remains unclear how ClC-4 might exert these effects. 
 
D. ClC-4 in human disease 
Considering the likely effect of ClC-4 on endosomal ion homeostasis, and taking into account 
that disruption of ClC-5 leads to X-linked Dent’s disease (an inherited kidney stone disorder) 
(481) by impairing renal proximal tubular endocytosis (661), several groups sequenced the 
CLCN4 gene in patients with unclear forms of Dent’s disease. No mutations were found (494, 
836, 916). This agrees with the finding that, unlike Clcn5y/- mice (661), Clcn4-/- mice do not show 
proteinuria (700). The disruption of both Clcn4 and Clcn5 did not exacerbate the impairment of 
endocytosis caused by Clcn5 disruption (700).   
Unexpectedly, human genetics rather revealed an important, but poorly understood role of ClC-
4 in the brain. So far, two frameshifting mutations and >10 missense mutations in CLCN4 have 
been found in patients with mental retardation that was variably associated with behavior and 
seizure disorders as well as some facial abnormalities (359, 620, 857). Although mostly seen in 
males (359, 857) (who carry only one copy of the affected X-chromosome), less severe disease 
symptoms were also observed in heterozygous females (620) (expected to express mutated and 
WT ClC-4 in a mosaic manner). When expressed in Xenopus oocytes, the majority of the 
disease-associated missense mutations reduced or abolished the outwardly-rectifying ClC-4 
exchange currents (359, 620, 857). Of note, most of the missense mutations lie close to the 
interface of the two subunits of the ClC-4 protein (620).  
It remains unclear how ClC-4 loss of function mutations might cause these disease phenotypes. 
Hu et al. reported an impaired neurite branching of cultured hippocampal neurons upon Clcn4 
knock-down with shRNA, and a similar, but less pronounced effect was observed with neurons 
from Clcn4-/- mice  (359). Although this observation is consistent with a previous report (363), 
effects on neurite branching might be non-specific and can currently not be mechanistically 
linked to a loss of ClC-4. Moreover, no obvious morphological changes were observed in the 




XI. CLC-5 - A KIDNEY-SPECIFIC 2CL-/H+ ANTIPORTER INVOLVED IN RENAL 
ENDOCYTOSIS 
ClC-5 was identified independently by homology cloning (808) and by positional cloning as the 
gene being affected in Dent’s disease patients (251, 252). Dent’s disease, a renal Fanconi 
syndrome, is an X-linked renal tubular disorder characterized by low-molecular-weight 
proteinuria (LMWP), associated with hypercalciuria, nephrocalcinosis, and nephrolithiasis 
(kidney stones) (481, 743). The human CLCN5 gene is located on Xp11.22 and the gene is X-
linked also in rodents. ClC-5 shares about 80% sequence identity with ClC-3 and ClC-4. The 
protein is composed of 746 amino acids and has a calculated molecular mass of 83 kDa. It is 
glycosylated at Asn408 (401), a highly conserved glycosylation site in CLC proteins.  
ClC-5 is one of the best studied members of the mammalian CLC transporters. The 2Cl-/H+ 
antiporter is predominantly expressed in the kidney, where its transport activity in the 
endosomal membrane is essential for receptor mediated and fluid phase endocytosis, and the 
endocytosis of apical plasma membrane proteins, in the proximal tubule. Functional properties 
have been extensively studied in heterologous expression systems.  
 
A. Basic properties 
Even though in vivo ClC-5 is mostly localized in endosomes, it reaches the plasma membrane in 
a significant amount in heterologous expression systems and its functional properties can be 
studied using conventional electrophysiological techniques. A striking feature of ClC-5 mediated 
currents is their extreme outward rectification (corresponding to an inward movement of 
chloride) with currents being measurable only for voltages >20 mV (269, 808). Upon steps to 
positive voltages, a large proportion of the current activates instantaneously (as judged by the 
time resolution of the patch clamp technique), followed by a further increase with millisecond 
kinetics (269, 808, 941, 966, 967). Surprisingly, no inward tail currents can be resolved upon 
subsequent steps to a negative voltage (269). Importantly, the strong rectification of ClC-5 is 
preserved under a broad range of intracellular and extracellular pH and Cl- concentration values 
(787). These properties make it practically impossible to determine the reversal potential of 
ClC-5 mediated currents. Based on the magnitude of outward currents, a “conductivity 
sequence” of SCN->NO3->Cl->Br->I- was determined (269, 808, 941). These general properties of 
human and rat ClC-5 are qualitatively very similar in the species homologues from Xenopus 
laevis (559), pig (199), mouse (740), and guinea pig (148). 
After the landmark discovery that the bacterial EcClC-1 is a secondary-active 2Cl-/H+ antiporter 
and not a passive Cl- channel as previously assumed (5), two independent studies, using 
different methods to detect local H+ concentration changes, showed that also ClC-4 and ClC-5 
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are coupled chloride / proton antiporters (651, 742). As in EcClC-1, the “gating glutamate” is 
essential for proton transport (651, 742). Neutralization of the gating glutamate by mutation to 
alanine converts ClC-4 and ClC-5 to passive Cl- conductors (651, 742) that show an almost linear 
current voltage relationship, i.e. that permit inward currents that are not seen for the 
respective WT proteins (269, 651, 742). In addition, currents mediated by the gating glutamate 
mutant are completely time-independent, i.e. lack the millisecond time scale kinetics seen for 
WT ClC-5. Using concatemers of WT and gating glutamate mutations it could be demonstrated 
that  coupled Cl-/H+ transport is carried out by the individual subunits of the homodimeric 
protein (941). The transport stoichiometry of ClC-5 was determined as 2 Cl- : 1 H+ using a 
quantitative fluorescence transport assay (966). However, similar to what has been described 
for the bacterial EcClC-1, polyatomic anions like SCN- and NO3- lead to a partial (in the case of 
NO3-) or almost complete (in the case of SCN-) uncoupling of Cl- and H+ transport, i.e. these 
anions are transported without or with less counter-transport of protons (941). Interestingly, 
almost completely coupled 2NO3-/1H+ transport could be introduced into ClC-5 by mutating a 
highly conserved serine residue to a proline (60, 966), as found in the plant At-ClC-a transporter 
that performs coupled 2NO3-/1H+ transport (164), demonstrating the importance of the 
“central” anion binding site for the ion selectivity of CLC proteins. However, also mutations of 
the highly conserved lysine residue K210, which is localized in the extracellular pore entrance, 
slightly affected anion selectivity (179). 
Intracellular protons are assumed to access the transport pathway via the so-called proton 
glutamate that is localized “off-pore”, relatively close to the dimer interface (1). Mutating the 
proton glutamate in EcClC-1 led to a loss of H+ transport, but Cl- transport was fully preserved, 
similar to neutralizing mutations of the gating glutamate (9). Surprisingly, analogous mutations 
of the proton glutamate in ClC-4 and ClC-5 to alanine or glutamine completely abolished 
transport, even that of the uncoupling polyatomic SCN- or NO3- anions (941). Interestingly, 
transport was retained if the proton glutamate was replaced by the titratable residues Asp, His, 
and Tyr, but not by Arg (941). Additional neutralization of the gating glutamate restored Cl- 
transport but not H+ transport (941). 
While the proton glutamate mutant E268A does not exhibit steady-state transport, Smith and 
Lippiat found that upon voltage steps the mutant shows prominent “pre-steady state” or 
“transient” currents (788).  Such transient currents can be observed in response to voltage 
steps in a variety of electrogenic transporters, such as GABA transporters, or cistine 
transporters (132, 714). In these transporters, the transient currents are particularly evident in 
the absence of one of the substrates and generally reflect a combination of voltage-dependent 
binding of a charged co-transported substrate (e.g. sodium ions / protons) and conformational 
changes, associated with the partial completion of the transport cycle. Careful analysis of these 
transient currents can provide insights into some steps of the mechanism of transport. Full 
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completion of the transport cycle is impeded by the absence of an obligatory substrate. 
However, a combination of transient currents and steady transport currents is possible if the 
initial rearrangement of states caused by the voltage step is faster than the overall turnover. 
The fact that the transient currents in ClC-5 have been observed in the proton glutamate 
mutant E268A (788) suggests that a full transport cycle is inhibited because no protons can be 
supplied from the intracellular solution. Smith & Lippiat (788) suggested that the transient 
currents mainly reflect the voltage-dependent movement of an intrinsic “voltage-sensor” of the 
protein and that anions “modulate” this voltage-dependence. Zifarelli et al. could exclude H+ 
movement to be significantly involved in the generation of the transient currents (961). 
However, a detailed analysis of the Cl- dependence suggested that the movement of 
extracellular Cl- ions into the transporter contributes to the transient currents (961). The results 
could be well described by a three-state model predicting that, upon a step to a positive 
voltage, the first events in the transport cycle are the movement of the gating glutamate from 
Sext to Scen, accompanied by a movement of a Cl- ion from Scen to the inside, which is then 
followed by the binding of an extracellular Cl- ion to Sext (961). The direct involvement of the 
gating glutamate in the generation of the transient currents was further supported by analyzing 
the E211D mutant, in which the gating glutamate is substituted by an aspartic acid, which 
differs from a glutamate only by the lack of a single CH2 group. The E211D mutant showed no 
steady transport activity (961), similar to the analogous mutations in CmClC and EcClC-1 (243). 
Interestingly however, the E211D mutant displayed transient currents even with the proton 
glutamate being intact. The E211D transient currents were significantly smaller in magnitude, 
shifted to more negative voltages compared to those of the E268A mutant, and were almost 
independent of extracellular Cl- (961). These results strongly support the idea that the transient 
currents indeed reflect a movement of the gating glutamate in addition to Cl- ion movements.  
The voltage-dependence of the transient currents of the proton glutamate mutant E268A is 
characterized by a voltage of half-maximal activation beyond 100 mV (961). Grieschat & Alekov 
found that in the context of the mutation K210R, in which the lysine next to the gating 
glutamate is mutated to arginine, the voltage-dependence of the transient currents is shifted to 
more negative voltages (301). This leftward shift parallels the much less pronounced outward 
rectification of the currents mediated by the K210R mutation (179) and suggests that the 
outward rectification of ClC-5 and the activation of the transient currents by positive voltages 
reflect the same underlying  voltage-dependent process, i.e. the displacement of the gating 
glutamate.  The two components of the charge-voltage-relationship described by Grieschat & 
Alekov (301) confirm the three-state model proposed by Zifarelli et al. (961). However, the use 
of capacitance measurements to quantify the charge displacement (301) does not provide an 
accurate measurement if the kinetics of the charge movement are too slow to follow the 
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stimulating sine wave. Thus, the quantitative aspects of the work of Grieschat & Alekov (301) 
are questionable.  
Interestingly, ClC-3, when targeted to the plasma membrane by mutation of N-terminal sorting 
motifs, exhibits relatively large transient currents, even without mutating the proton glutamate 
(316). These authors even proposed that the transient currents could contribute to the charge 
compensation in vesicular acidification. This is however extremely unlikely since each CLC 
transporter would contribute only maximally 3 elementary charges. In fact, in the model 
proposed by Guzman et al. the buffer capacity of the vesicular lumen was not taken into 
account (316), completely invalidating this hypothesis. 
For ClC-4 and ClC-5, it was unclear if the extreme outward rectification reflects “instantaneous”, 
transport related rectification or a fast gating process because no inward tail currents could be 
detected that would reflect a deactivation of the gating process (180, 269, 808). However, a 
certain degree of current relaxation is visible for ClC-5 and ClC-4, which has been exploited to 
perform non-stationary noise analysis to estimate the single transporter turnover rate, resulting 
in surprisingly large numbers in the order of 105 s-1 (612, 941, 966, 967). Several mutations of 
ClC-5 led to significant kinetic alterations of these relaxations suggesting the presence of a 
gating mechanism (269). More recently, a point mutant (D76H) of ClC-5 was identified that 
showed reduced “instantaneous” currents, slowed activation kinetics, and inwardly directed Cl- 
/ H+ exchange currents at acidic extracellular pH (180), demonstrating for the first time 
unambiguously the presence of a gating process in ClC-5 that at least partially underlies the 
strong outward rectification. However, the interdependence of gating and permeation that 
plagues the biophysics of CLC channels, is even worse for CLC transporters and so far, we have 
no good understanding of the gating process in ClC-5. 
The dependence of endo/lysosomal transporters on pH is physiologically important because the 
luminal pH is acidic. ClC-5 is inhibited by acidic extracellular pH (269), in a manner that is 
compatible with a voltage-dependent binding from the extracellular solution (649). The 
dependence of transport on intracellular pH has been studied in inside-out macro-patches 
(966). Macroscopic currents increased at acidic pH with an almost voltage-independent 
apparent pK of around 7. Interestingly, at least for pH≤7.3, the single-transporter turnover 
estimated by noise analysis did not depend on pH, suggesting that intracellular pH mostly 
affects the gating process of ClC-5 (966). These results also suggest that H+ entry into the 
transporter from the cytosol is not rate-limiting in the turnover of the WT protein. 
Like all mammalian CLCs, the C-terminus of each ClC-5 monomer harbors two CBS domains. 
Wellhauser et al. provided biochemical evidence that isolated C-terminal fragments of the ClC-5 
Cl-/H+ antiporter bind ATP and other nucleotides (898), and small angle X-ray scattering 
indicated a compactation of the CBS domains upon ATP binding (899). The two full-length 
86 
 
structures of CBS domain containing CLC proteins, i.e. that of the red alga Cyanidioschyzon 
merolae  CmClC Cl-/H+ antiporter (242) and that of the bovine ClC-K channel (628), had no 
nucleotide bound in the CBS domain. Yet, the isolated ClC-5 C-terminus could be crystallized 
only in the presence of nucleotides and an ATP or ADP molecule was found in the crystal 
structure sandwiched in the cleft between CBS1 and CBS2, making contacts with the protein 
almost exclusively with the adenine moiety (542). This kind of interaction is consistent with the 
equal high micromolar binding affinity of AMP, ADP and AMP demonstrated by biochemical 
binding studies (542). Functional effects of nucleotide regulation have been studied in ClC-5 
using the inside-out patch clamp technique (967). Adenine nucleotides (ATP, ADP, AMP) 
increased currents mediated by the human ClC-5 Cl-/H+ antiporter almost two-fold (967). The 
effect of nucleotides on the currents could be well described by an allosteric model in which 
nucleotide binding stabilizes an active, transporting conformation, with apparent binding 
affinities of 0.9 mM for the inactive state and 0.4 mM for the active state (967).  Mutagenesis 
studies guided by the crystal structure of the ClC-5 CBS domain / ATP complex (542), are overall 
in agreement with the conclusion that the crystal structure faithfully reflects nucleotide binding 
in the full length proteins in that mutants Y617A and D727A were insensitive to nucleotides, but 
otherwise had functional properties that were similar to those of WT ClC-5 (967). 
 
B. Transcriptional regulation 
In general, the transcriptional regulation of ClC-5 in humans is little understood. The 5’ regions 
of mouse and human genes encoding ClC-5 are complex and not fully conserved between the 
two species (252, 261, 330, 481, 837), rendering an extrapolation of mouse data to humans 
difficult. However, Tanaka et al. (826) found that the transcription factor HNF1α 
(homeodomain-containing hepatocyte nuclear factor 1α), which is predominantly expressed in 
the proximal tubule, activates expression of mouse and human ClC-5 encoding genes, whose 5’ 
UTRs contain several predicted HNF1α binding sites. In HNF1α-null mice, expression of Clcn5 
was reduced in the proximal tubule but not in the collecting duct (826), where the closely 
related factor HNF1β might play an important role. HNF1α-null mice show low molecular 
weight proteinuria (831), caused by a down-regulation of the expression of the genes encoding 
cubulin and megalin (831), and probably by an indirect reduction of cubulin and megalin in the 
brush-border membrane due to reduced endocytic recycling caused by a reduced ClC-5 
expression, as seen in ClC-5 KO mice (see below). 
Interestingly, intron 3 of the human CLCN5 gene harbors several micro RNAs that play a role in 
lymphocytic leukemia (715). In chronic lymphocytic leukemia cells, interleukin-4 caused an up-
regulation of CLCN5 and a consequent induction of the expression of the miR-362, miR-500a, 
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miR-502, and miR-532 genes (715). A possible role of ClC-5 in this tumorigenic process is 
unexplored. 
 
C. Localization of ClC-5 and interacting proteins 
In the adult rat, ClC-5 mRNA is found most abundantly in the kidney but also in intestine, 
thyroid and to a smaller extent also in brain, liver, lung and testis (808, 850, 854). Using in situ 
hybridization, mRNA was localized in cortical medullary ray and outer medullary tubule 
epithelial cells (500). In the kidney, ClC-5 is expressed as early as E13.5 in mice and at 12 weeks 
of gestation in humans, i.e. at times when glomerular filtration starts (401). Interestingly, in the 
mouse embryo, ClC-5 mRNA is found not only in the kidney but also abundantly in other 
absorptive epithelia and even in skeletal muscle (826). 
In a landmark study, Günther et al. precisely localized the ClC-5 protein in several segments of 
the kidney tubule (307). In the proximal tubule, ClC-5 was found predominantly below the 
brush border, co-localizing with the H+-ATPase (307), which is present in the membrane of 
endosomes. In agreement with the localization of ClC-5 in the endosomal membrane, ClC-5 also 
co-localized with internalized proteins early after uptake (307). As ClC-5 was believed to be a Cl- 
channel, these results led to the hypothesis that ClC-5 plays a role in endocytosis by providing a 
shunting Cl- conductance to allow efficient endosomal acidification by the H+-ATPase (307). In 
addition to the proximal tubule (PT), ClC-5 protein was found in intercalated cells but not in 
principal cells of the collecting duct (307). Intercalated cells are most important for acid/base 
homeostasis. In acid secreting α-intercalated cells, ClC-5 again co-localized with the H+-ATPase 
in apical, sub-membranous vesicles (307). In acid resorbing β-intercalated cells ClC-5 was seen 
in the apical cytoplasm, whereas the H+-ATPase localized in the basolateral part of the cells 
(307). The expression of ClC-5 in PT and in the collecting duct was confirmed in independent 
studies (190, 603, 728) and additional expression in the thick ascending limb of Henle’s loop 
was found (190). 
Mechanisms involved in the membrane stability and subcellular targeting of ClC-5 are still little 
understood. The intracellular C-terminal region between the two CBS domains contains the 
amino acid sequence PLPPY, which is a putative “PY-motif” (660), and which is not conserved in 
the highly homologous ClC-3 and ClC-4. In vitro a ClC-5 derived peptide containing this 
sequence bound to fragments from the WW domain containing proteins WWP1 and WWP2 
(660). In support of a role of the PY motif in ubiquitin mediated degradation, in the 
heterologous Xenopus oocyte expression systems, currents mediated by ClC-5 were doubled by 
mutation of the motif or by overexpression of a dominant-negative mutant of the WWP2 
ubiquitin ligase (759). In addition, stimulation of endocytosis by co-expression of rab5 mutants 
decreased currents of WT ClC-5, but not ClC-5 with a mutated PY motif, and inhibiting 
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endocytosis had the inverse effect (759). Similar results were obtained in oocytes with the 
Nedd4.2, but not with the Nedd4, WW domain containing ubiquitin ligase, although both 
proteins bound to ClC-5 (355). In opossum kidney (OK) cells, a PT cell model that expresses ClC-
5 (735), ClC-5 biochemically interacted with other WW- and HECT-domain containing proteins, 
Nedd4 or Nedd4-2 (355). Knocking down Nedd4-2 activity in OK cells reduced albumin uptake 
but it is not clear if ClC-5 was involved in this effect (355). Despite the in vitro evidence the 
physiological role of the PY motif is still unclear as no effect on ClC-5 protein abundance or 
localization, or on proximal tubular endocytosis, was observed in a knock in mouse model in 
which the PY motif was disrupted (700). The possibility that heteromerization with the 
homologous ClC-3 or ClC-4 proteins could have masked a phenotype in this knock in model was 
excluded by showing that the combination of a disrupted PY motif in ClC-5 with knocking out 
ClC-3 or ClC-4 did not induce low molecular weight proteinurea or defective PT endocytosis 
(700).  
Several other proteins have been described to interact with ClC-5 and to be involved in the 
regulation of the transporter. For example, the actin depolymerizing protein clofilin was 
detected in a yeast-two-hybrid screen (357). However, the possible role of this interaction is 
obscure. The sodium hydrogen exchanger regulatory factors NHERF-1 and NHERF-2 and other 
PDZ domain containing scaffolding proteins are involved in the regulation of various transport 
processes in the PT (155). The PDZ2 domain of NHERF-2 was found to interact with ClC-5 (354) 
and silencing NHERF-2 in OK cells slightly reduced, and silencing of NHERF-1 slightly increased 
ClC-5 surface expression (354). The significance of these findings is unclear. Neither NHERF-1 
nor NHERF-2 knock out mice showed low-molecular proteinuria (156), a hallmark of ClC-5 
dysfunction. Again using yeast-two-hybrid screening, the KIF3B protein was reported to interact 
with a bait consisting of a C-terminal fragment of ClC-5 and the interaction was confirmed by 
pull-down and immunoprecipitation (693). KIF3B is a component of a heterotrimeric kinesin 2 
microtubule associated motor protein complex including also KIF3A and KAP3. Among other 
functions, kinesin-2 has been implicated in bidirectional transport of vesicles and organelles 
associated with both the secretory and endocytic pathways, moving towards the plus end of 
microtubules (753). Consistent with the idea that KIF3B containing kinesin 2 motors are 
involved in the regulation of ClC-5 in the plasma membrane, various maneuvers of up- and 
downregulation of KIF3B in HEK cells overexpressing ClC-5 or in polarized OK cells expressing 
ClC-5 endogenously resulted in the relatively small but predicted changes in ClC-5 mediated 
ionic currents and surface expression (693). However, effects resulting from the overexpression 
or suppression of a single subunit of a heterotrimeric complex are difficult to interpret and 
indirect effects on ClC-5 by a broad effect on intracellular trafficking are likely. Specificity should 
be demonstrated in future experiments by identification and subsequent modification of the 
KIF3B binding site on the ClC-5 protein. 
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Surprisingly, using a GST-fusion protein pulldown assay neither of the above mentioned 
proteins was identified as a binding partner of ClC-5 (447). Instead the cytosolic aspartyl 
aminopeptidase DNPEP was pulled down and direct interaction was confirmed by co-
immunoprecipitation in vitro and in rat kidney lysates (447). DNPEP overexpression in OK cells 
induced small effects on albumin endocytosis and ClC-5 plasma membrane expression (447). 
The overall physiological relevance of this interaction remains to be established. 
 
D. Dent’s disease mechanism revealed by knock out mouse models  
ClC-5 gained particular interest after it was shown that defects in the CLCN5 gene are 
underlying Dent’s disease (251, 252, 481). Dent’s disease (OMIM #300009), a type of renal 
Fanconi syndrome, refers to a group of closely related, previously distinctly defined X-linked 
diseases associated with malfunctions of the proximal tubule, including X-linked recessive 
nephrolithiasis, X-linked hypercalciuric hypophosphataemic rickets, and idiopathic low-
molecular-weight proteinuria with hypercalciuria and nephrocalcinosis (184, 191, 666, 744). 
The most common symptom present in practically all patients is low molecular weight 
proteinuria (LMWP), which is also seen in many female carriers (191). However, LMWP is 
clinically not the most important symptom. Patients often exhibit hyperphosphaturia and 
hypercalciuria which can result in rickets, nephrocalcinosis, and kidney stones, which can lead 
to progressive kidney failure (743, 915). Most male patients exhibit hypercalciuria, two thirds 
present with nephrocalcinosis, and about half of them develop kidney stones (112), the most 
relevant clinical symptom of the disease.  
More recently, a certain genetic variability of Dent’s disease has emerged. In fact, only about 
60% of patients with Dent’s disease carry mutations in CLCN5. In about 15% of patients, 
mutations were found in the X-chromosomal OCRL1 gene (349). Dent’s disease associated with 
OCRL1 mutations is now termed Dent’s disease 2 (175). OCRL1 encodes a phosphatidylinositol-
4,5-biphosphate-(PIP2)-5-phosphatase which hydrolyzes the signaling lipid PI(4,5)P2 in several 
cellular compartments (350, 956). OCRL1 is a membrane-associated protein localized to the 
Golgi apparatus and early endosomes (950), but also to lysosomes (168). The precise function 
of OCRL1 is not clear, but there is some evidence that the phosphatase is involved in endocytic 
megalin recycling through the effect of PI(4,5)P2 levels on actin polymerization (859). 
Previously, OCRL1 mutations had been exclusively associated with the oculocerebrorenal 
syndrome of Lowe, which is characterized by congenital cataracts, severe mental retardation 
and renal defects similar to Dent’s disease (39, 488). However, some OCRL1 mutations cause 
renal defects typical of Dent’s disease without other pathological manifestations (350). It is not 
clear why certain OCRL1 mutations only cause the renal symptoms and not the full spectrum of 
symptoms characteristic for Lowe syndrome. It has been suggested that the difference may be 
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related to the presence of OCRL1 splice variants and that some mutations only affect a limited 
number of variants (775). The lack of CLCN5 or OCRL1 mutations in patients with Dent’s disease 
suggests that at least one additional gene is associated with the disease (350, 916). 
For simplicity, hereafter, we will refer to Dent’s disease as the subtype caused by CLCN5 
mutations. Many Dent’s disease causing mutations cause a severe or total loss of function of 
the protein (see below). For such mutations, affected males will have a complete loss of ClC-5 
function, while female carriers will have a loss of function in approximately one half of cells due 
to X-chromosome inactivation. Two independent knock out mouse lines have been created to 
investigate the mechanisms underlying Dent’s disease (661, 878). The lines showed some 
interesting differences and for simplicity will be designated as the Jentsch mouse (661) and the 
Guggino mouse (878), respectively. Both lines were viable, had normal growth and were fertile. 
No gross anatomical changes were seen in either except that a small number of Guggino ClC-5- 
mice had deformities of the dorsal spine and backward growth of teeth but not osteopenia or 
rickets (878). Both KO lines showed prominent LMWP with an elevated loss of vitamin D 
binding protein (661, 878), retinol binding protein, PTH, injected beta2-microglobulin (661) (Fig. 
12 A-C) and Clara cell protein (878). Both mice exhibited polyuria and phosphaturia and the 
Guggino mouse had also glycosuria and aminoaciduria (which was not tested in the Jentsch 
mouse). Surprisingly, the Jentsch mouse did not exhibit hypercalciurea or nephrolithiasis, while 
the Guggino mouse had a more than doubled urine Ca2+ concentration and microscopic calcium 
deposits were found in the cortico-medullary junction. Possible reasons for this difference will 
be discussed below. Another mouse model in which ClC-5 was partially reduced with a 
ribozyme approach showed neither proteinurea nor phosphaturia and will not be discussed 
further (501). 
The LMWP in the KO mouse models was caused by a defective receptor mediated endocytosis 
process in the PT (661, 878). Injected horse-radish peroxidase was poorly endocytosed (Fig. 
12H) and was detected in distal segments in the Guggino mouse (878) and the accumulation of 
injected fluorescently labeled lactoglobulin accumulated in vesicles below the PT brush border 
was drastically reduced in the Jentsch mouse (661). In addition Piwon et al. exploited the fact 
that heterozygous female mice are mosaic knock outs because due to random X-chromosome 
inactivation about half of cells are ClC-5 knock out, whereas the other half express normal levels 
of ClC-5 (Fig. 12). Detecting fluorescent lactoglobulin at the single cell level and co-staining with 
ClC-5 antibodies, they could show that the defective receptor mediated endocytosis is seen 
only in the ClC-5- cells, i.e. it is a cell-autonomous defect (661) (Fig. 12). Very similar results 
were seen with FITC-dextran, a marker of fluid-phase endocytosis (661) (Fig. 12).  
An important finding was that megalin, the apical receptor for endocytosis of a broad range of 
luminal proteins which partially overlaps in localization with ClC-5 in WT mice (661), was 
significantly reduced in ClC-5- PT cells (661). Normally megalin is recycled to the plasma 
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membrane after discharging its endocytosed cargo in the endosomal lumen and the observed 
reduction of megalin in ClC-5- most likely reflects a defect in this recycling step. Later studies 
confirmed the reduction of megalin at the electron microscopic levels and additionally 
demonstrated that also the apical co-receptor cubilin is drastically reduced in the brush border 
in the PT of ClC-5- KO mice (135). The localization or abundance of the H+-ATPase was affected 
neither in the PT nor in α-intercalated cells in the collecting duct (661). 
Piwon et al. further studied in great detail the mechanisms of phosphate and calcium regulation 
in the ClC-5- mouse (661). A large proportion of phosphate is reabsorbed by the apical Na-
phosphate co-transporter Napi2 (also known as NaPi-2a or Npt2, encoded by the 
human SLC34A1 gene) (52). Napi2 is known to be regulated by endocytosis in PT, in response to 
parathyroid hormone (PTH). On a normal diet, WT mice showed an intense staining for Napi2 in 
the brush border, which was significantly reduced in ClC-5- mice (661). This is a priori surprising 
if ClC-5- mice have a defect in endocytosis. Importantly, exploiting mosaic female Clcn5+/- mice,  
it was found that the reduction of Napi2 was not a cell autonomous effect (661). In fact, Piwon 
et al. convincingly demonstrated that the Napi2 downregulation was secondarily caused by a 
defective endocytosis of the peptide hormone PTH that induces Napi2 endocytosis. The 
reduced Napi-2 expression most likely underlies the hyperphosphaturia seen in the knock out 
mice. Under a reduced phosphate diet, which is known to stimulate Napi2 expression (573), the 
presence of Napi2 was normalized in Clcn5- mice (661). To directly test the effect of PTH, the 
hormone was injected and kidney tissue was fixed at various time-points. 15 minutes after PTH 
injection Napi2 was internalized in a cell-autonomous manner in WT but not in ClC-5- mice, 
while 1 hour after injection Napi2 was internalized also in the knock out. Hence its endocytosis 
is reduced but not fully abolished (661). These results show that defective PTH uptake resulting 
in excessive Napi2 internalization underlies hyperphospaturia in Dent’s disease.  
Another transporter found to be disregulated in ClC-5- mice was the Na+/H+ exchanger NHE3, 
which is involved in Na and bicarbonate, and consequently, also water reabsorption. As Napi2, 
NHE3 is regulated by PTH-induced endocytosis. As found for Napi2, on a normal diet, NHE3 was 
internalized in a non-cell autonomous manner in ClC-5- mice, and dietary phosphate 
deprivation led to an increased plasma membrane expression (661). Similar to the observations 
made for Napi2, PTH-induced endocytosis of NHE3 was markedly slowed, but not abolished in 
ClC-5- mice. The decreased activity of NHE3 may contribute to increased volume of urine seen 
in both KO models (661, 878). The decreased protein abundance of NHE3 in ClC-5- mice was 
recently confirmed using transport activity measurements in kidney slices from the Guggino 
mouse (473). Acute dexamethasone stimulation, which is believed to augment NHE3 surface 
expression via exocytosis, increased NHE3 less in ClC-5- mice compared to WT mice (473). 
Further experiments in OK cells, in which endogenous ClC-5 was partially knocked-down by 
short hairpin RNA, suggested that PTH-induced endocytosis of NHE3 was not significantly 
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impaired by ClC-5 knock-down (473), in contrast to in vivo experiments with Clcn5- mice (661). 
However, the earliest time point at which endocytosis was assessed was 20’ after addition of 
PTH, such that a slowing of endocytosis might not have been detected.  Acute dexamethasone 
treatment led to a significantly smaller increase in NHE3 surface expression in OK cells in which 
ClC-5 had been knocked down, suggesting the possibility that ClC-5 is important for the 
exocytotic plasma membrane insertion of NHE3 (473). Contrasting with the decrease of 
megalin, Napi-2 and NHE3 in the apical membrane of PT cell lacking ClC-5, aquaporin 1 (AQP1) 
expression was reported to be rather increased in apical (but not basolateral) membranes of 
those cells (664). These results are in general agreement with the idea that ClC-5 is not only 
important for endocytosis but also for the recycling of endosomes (385), which in fact most 
likely underlies the decrease of megalin in the brush border (661).  
Reabsorption of Ca2+ in the kidney occurs via paracellular and transcellular pathways that most 
likely do not directly involve ClC-5 as an endosomal protein. Thus, the hypercalciuria seen in 
many Dent’s disease patients and in the Guggino mouse and the phenotypic differences 
between the two ClC-5- lines are most likely explained by a slightly different balance in the 
handling of calciotropic hormones and their effects in the kidney, as indeed strongly suggested 
by the investigations of Piwon et al. (661). It has to be remembered that the proximal tubule is 
the major site in the body for the enzymatic conversion of 25(OH) vitamin D3 to the active form 
1,25(OH)2 vitamin D3, a reaction performed by the mitochondrial α-hydroxylase, which is up-
regulated by PTH. Various effects of reduced endocytosis in the PT with opposite outcomes 
have to be considered. First, increased PTH should upregulate α-hydroxylase, as indeed 
observed  (308). This should stimulate the conversion of 25(OH) vitamin D3 to 1,25(OH)2 
vitamin D3 in the PT, leading to increased intestinal Ca2+ absorption. Also the urinary loss of 
phosphate could increase 1,25(OH)2 vitamin D3 as seen in Npt2+/- mice with a heterozygous loss 
of Napi2 (52). Indeed, increased 1,25(OH)2 Vitamin D3 concentrations are seen in Dent’s 
disease patients (743). On the other hand, the reduced endocytosis of Vitamin D binding 
protein leads to urinary loss of Vitamin D, i.e. a decreased availability of the precursor in the PT. 
In fact, both forms of vitamin D3 were decreased in the serum, with the ratio 1,25(OH)2 Vitamin 
D / 25(OH) Vitamin D being slightly increased (308, 661). Thus, a delicate balance between the 
supply of the precursor and the stimulation of the hydroxylase by PTH likely determines the 
presence or absence of hypercalciuria as seen in the Guggino mouse versus the Jentsch mouse 
and may underlie the phenotypic variability in Dent’s disease patients. In addition, alterations in 
the Ca2+ homeostasis of bone, another important vitamin D target organ, have to be 
considered. Indeed, an analysis of the Ca2+ handling in the Guggino mouse suggested that their 
hypercalciuria is of bone and renal origin instead of being caused by increased intestinal Ca2+ 
absorption (779). Especially the finding that the KO mice have elevated bone turnover markers 
points to a use of their bone Ca2+ stores. 
93 
 
Overall, the systemic effects induced by the dysfunction of ClC-5 show that the endocytosis of 
small proteins in the PT does not primarily serve to recover amino acids but has an important 
role in the control of hormone effects via their carrier proteins. An additional example regards 
retinol and its binding protein, which is lost in the urine in ClC-5- mice (661). This may underlie 
the upregulation or retinol target genes seen in ClC-5- mice (525) and may be the cause of night 
blindness reported in three Indian boys with Dent’s disease and mutations in CLCN5 (765). 
Gailly et al., using RT-PCR on cells from ClC-5- PT, found increased expression of various proteins 
linked to oxidative stress and an induction of type III carbonic anhydrase (CAIII) (278). The role 
of CAIII in Dent’s disease, however, remains elusive. More generally, 720 genes involved in 
various physiological processes are differentially expressed in ClC-5- mice (914).  
More recently, glomerular pathology, in particular focal glomerulosclerosis, focal interstitial 
fibrosis, interstitial lymphocyte infiltration and tubular damage, has been described in a 
considerable fraction of patients with Dent’s disease (147, 270, 880). While glomerulosclerosis 
is of clear pathological relevance, it remains to be understood if it caused secondary to the 
tubular phenotype or directly by ClC-5 dysfunction in glomerular cells, where the protein is 
expressed at a very small level (307).   
 
 
E. The function of ClC-5 as a 2 Cl-/H+ antiporter in proximal tubule endocytosis and recycling 
Assuming that ClC-5 is a passive Cl- channel like ClC-0 and ClC-1, the most parsimonious  
explanation of the phenotype of Dent’s disease, was that ClC-5 enables efficient endosomal 
acidification by providing an anion conductance necessary to neutralize the build-up of luminal 
positive charge by the V-type H+ ATPase (307, 661). This notion was bolstered by the co-
localization of ClC-5 with the H+-ATPase (307). The electrophysiological properties of ClC-5 did 
not provide any reason to doubt this hypothesis (269, 808). In agreement with this proposition, 
the rate of ATP-induced acidification of cortical endosomes from Clcn5- mice was significantly 
slowed compared to WT (308, 600). In agreement with Cl- ions playing an important role in ClC-
5 dependent  endocytosis, Wang et al. found that replacement of Cl- by the impermeable 
gluconate reduced receptor-mediated and fluid phase endocytosis in cultured PT cells from WT 
mice to the same level as in bafilomycin (284) treated cells and as in cells from Clcn5- mice 
(882). The residual endocytotic activity seen in cells from Clcn5- mice or in bafilomycin treated 
cells could be further reduced by the NHE3 inhibitor S3226 (882). Nhe3-/- mice display moderate 
proteinuria (285), but the precise role of NHE3 in PT endocytosis remains to be established. As 
expected, re-expression of WT ClC-5 but not of ClC-5 carrying Dent’s disease mutations restored 
endocytosis in cells from Clcn5- mice (882). 
After the discovery that the bacterial EcClC-1 is a transporter and not a channel (5), the 
properties of ClC-5 were reassessed and it was established that also ClC-5 is a secondary active 
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transporter that exchanges 2 Cl- ions for 1 H+ (651, 742, 966). This finding forced a revision of 
the physiological role of ClC-5, because the transport of protons directly impinges on 
endosomal pH. In this respect, a major unresolved question regards the direction of transport. 
The finding that ClC-5, like the other vesicular CLCs, shows extreme outward rectification is 
often interpreted as meaning that these transporters can only mediate transport of Cl- ions out 
of the lumen and protons into the endosomal lumen. However, if the voltage-dependence of 
the transporter is independent of the ion gradients, appropriate Cl- and H+-gradients would 
allow also net transport in the opposite direction if the cytoplasmic potential is positive enough. 
On the other hand, Lippiat and colleagues reported shifts in the voltage dependence of ClC-5 
with changes in pH and [Cl-] that conspire to only allow Cl- transport into the cytosol (787). This 
would mean that ClC-5 directly contributes to endosomal acidification (742), but in a manner 
that would actually exacerbate positive charge accumulation that should oppose sustained 
endosomal acidification. In line with such a hypothesis, Smith & Lippiat (787) found that 
overexpression of WT ClC-5 in HEK cells induced a component of endosomal acidification that 
could not be inhibited by the H+ ATPase blocker bafilomycin (787). This component was not 
seen after over-expression of mutants that are unable to transport protons, i.e. the uncoupled, 
passively Cl- transporting gating glutamate mutant or the non-transporting proton glutamate 
mutant (787). Furthermore, in OK cells, which endogenously express ClC-5, a bafilomycin-
independent component of endosomal acidification could be significantly reduced by knocking 
down ClC-5 expression (787). However, even though a direct contribution of ClC-5 to 
endosomal acidification cannot be safely ruled out as our knowledge of the native transport 
properties of endosomes is very limited, a few basic considerations render the hypothesis 
rather unlikely. Assuming that an endosome has to lower the pH from an initial value of 7.4 by 
at least 1.5 pH units, and assuming a pH buffer capacity around 30 mM / pH unit, a total of 45 
mM H+ have to be pumped into the lumen corresponding to about 90 mM equivalent Cl- ions to 
be pumped out assuming a 2:1 Cl-/H+ antiport stoichiometry. This figure, i.e. 90 mM Cl-, is above 
the initial value of Cl- which was measured to be less than 20 mM in endosomes after endocytic 
uptake (792). In fact, Sonawane et al. found that endosomal Cl- concentration increased during 
the acidification process (792), in contrast to the decrease predicted by Smith & Lippiat (787). 
Even ignoring this aspect, the total amount of charge to be neutralized amounts to 135 mM, 
which, based on the available ion species, can be realistically accomplished only by an outward 
movement of Na+ ions. Even assuming the existence of an endosomal Na+ channel, the overall 
process would lead to a dramatic reduction of endosomal osmolarity and consequent 
shrinkage, which is not observed experimentally.  
Important insight into to the role of ClC-5 was obtained by the study of mice in which ClC-5 
carried a mutation of the gating glutamate that uncouples Cl- and H+ transport rendering ClC-5 a 
pure anion conductance (600). Endosomes prepared from mice carrying this uncoupling 
mutation (ClC-5unc) exhibited practically normal ATP-dependent acidification, but, surprisingly, 
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endocytosis was severely impaired and the mice displayed a similar phenotype compared to 
ClC-5- mice KO (600). ClC-5unc mice even showed hypercalciuria and hyperphosphaturia (600). In 
agreement with these results from a mouse model, recently, Dent’s disease patients were 
shown to carry the uncoupling mutation E211Q (738, 764). These results show that defective 
endocytosis in Dent’s disease is not (or not only) the result of reduced ATP-driven acidification 
but is critically dependent on the coupling between Cl- and H+ transport (600). In fact, 
conceptually, a major difference between a passively shunting Cl- conductance and a secondary 
active Cl- / H+ antiport mechanism is that due to the strict transport coupling, the equilibrium 
values of the luminal Cl- concentration, the luminal pH and the endosomal membrane potential 
are intrinsically linked. This implies the somewhat counterintuitive result that 2Cl-/1H+ 
antiporter can sustain a more acidic luminal pH value compared to a passive Cl- conductance as 
shown in model calculations under simplifying assumptions (372, 896), even though 
acidification requires more metabolic energy because H+ are partially “wasted”. In these 
calculations the endosomal membrane potential reached rather negative (inside) potentials. A 
prediction of the antiport mechanism of ClC-5 (and all other intracellular CLCs) is that the 
luminal Cl- concentration is increased above the cytosolic Cl- concentration due to the pH 
gradient. In fact, based on the result from the Clcn5unc mice and similar Clcn7unc mice, Jentsch 
and colleagues proposed that this is the major function of endo/lysosomal CLCs (600, 896), 
implying that a high endosomal Cl- concentration is essential for endocytosis. In ClC-7unc mice a 
decreased lysosomal Cl- concentration could be measured using a ratiometric fluorescent Cl- 
sensor (896). 
 
F. Phenotype of Dent’s disease mutations 
A micro-deletion of less than 515 kb on Xp11.22 containing the CLCN5 gene led to the 
identification of ClC-5 as the causative gene of Dent’s disease (251, 252) and showed that a 
complete loss of function leads to the typical Dent’s disease phenotype. Subsequently, the first 
single-point mutations including nonsense, missense and donor splice site mutations were 
identified in Dent’s disease kindreds (481). Partial or complete loss of function was confirmed 
for 4 missense mutations in heterologous expression systems (481).  
Up to now, more than 190 CLCN5 sequence variants are known to cause Dent’s disease, 
including large  deletions, promoter mutations, splice site mutations, frameshift mutations, 
missense and nonsense mutations (519, 680). Most missense mutations that have been studied 
in heterologous expression systems lead to a lack of functional expression of the protein at the 
plasma membrane (161, 487, 680, 764, 802). The missense mutations are found all over the 
protein with a slight tendency to cluster at the dimer interface (487, 789, 917). If such 
mutations act by destabilizing biochemically or functionally the dimeric proteins, as seen e.g. 




Only a relatively small number of mutations has been characterized at the functional level, 
mostly in heterologous expression systems. Practically all mutations exhibit reduced or 
abolished ion transport ability at the plasma membrane. A limited number of mutations 
showed alterations of biophysical gating processes (21). In most cases, the loss of function is 
caused by impaired surface expression due to ER retention or altered redistribution between 
early and late endosomes (487, 519, 680). Surface expression is an indirect manner to assay 
ClC-5 function, whose physiological role is performed in the endosomal membrane. In this 
respect, a surprising finding was that two mutants (G57V and R280P) showed reduced surface 
expression, but unaltered (G57V) or even enhanced (R280P) endosomal acidification (789). 
However, results obtained in overexpressing heterologous systems have to be interpreted 
cautiously. A more physiological system was established by Gorvin et al. who obtained 
conditionally immortalized proximal-tubular epithelial cell lines (ciPTEC) from patients with 
Dent’s disease and studied the process of endocytosis (292). With this approach it was shown 
that all mutations studied reduced receptor mediated endocytosis as expected (292).  
Interestingly, in one of the mutant cell lines (harboring the 30:insH mutation) endosomal pH 
was unaltered compared to WT cells, suggesting that that the mechanism by which ClC-5 
mutations lead to Dent’s disease is not necessarily linked to defective endosomal acidification 
(292). Such patient-derived cell lines offer the opportunity to perform pharmacological tests 
aimed at correcting the functional defect. 
 
G. Role of ClC-5 in other organs 
In addition to kidney, ClC-5 is significantly expressed in intestine, thyroid and to a small extent 
also in liver and brain (148, 808, 850, 854). In the liver, no defect of endocytosis of asialofetuin 
could be detected in ClC-5- mice (661). In the intestine, using immunofluorescence, it was found 
that ClC-5 is concentrated in the cytoplasm above the nuclei of enterocytes and colon cells 
(854). Ulcerative colitis, one of the major forms of inflammatory bowel disease, is often 
associated with defects in intestinal ion and water transport and Alex et al. reported an 
increased susceptibility to dextran sulfide sodium induced colitis in Clcn5- mice (23). However, 
whether this was associated with altered intestinal fluid and salt handling was not investigated. 
Thus, the physiological role of ClC-5 in the intestine remains essentially unknown. An altered 
immune response at the basis of the increased susceptibility to colitis would be consistent with 
microarray data from intestine showing differences in genes implicated in the immune system 
(525). 
The quite significant expression of ClC-5 in the thyroid (524, 850) led to the suggestion that it 
might be involved in the megalin-mediated endocytosis of iodinated thyroglobulin from the 
follicular lumen, similar to megalin-mediated endocytosis in the kidney. Consistent with a role 
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of ClC-5 in the thyroid, the Guggino Clcn5- mice indeed show a thyroid phenotype with mice 
developing a goiter, i.e. an increased size of the thyroid gland, at 5 months of age (850), 
whereas this was not observed in the Jentsch mouse (524). Importantly, both mouse models 
had normal levels of thyroid hormones and normal endocytosis, and no reduction in megalin 
was seen in the thyroid of Jentsch mice (524). The goiter of the Guggino mouse was associated 
with a reduced expression of the apical I- / Cl- exchanger pendrin involved in apical I- efflux 
(850). However, the mechanistic link to ClC-5 dysfunction is not resolved (258).  
 
H. Pharmacology of ClC-5 
Several classical Cl- channel blockers including DIDS, 9AC, NPPB, DPC, NFA, CPP have been 
tested on ClC-5, but none of these has any appreciable effect (675, 808). The only small 
molecule compound reported to reduce ClC-5 is RT-93 with a reported IC50 value of ~ 200 µM 
(464). This low affinity and the hydrophobic nature of RT-93 render this compound rather 
useless for practical applications. High affinity ligands are of considerable interest in particular 
as experimental tools to interfere acutely with ClC-5 function in physiological experiments. 
From a therapeutic perspective, “correctors” that help to reduce mutation induced misfolding, 
could help in a significant number of patients.  
 
XII. CLC-6 – A LATE ENDOSOMAL CL-/H+ EXCHANGER OF NEURONS 
Together with ClC-7, ClC-6 forms the third branch of the mammalian CLC gene family (79). In 
spite of a wide expression of the CLCN6 mRNA across many human tissues (79), the ClC-6 
protein appears to be rather specific for the nervous system (663). ClC-6 resides predominantly 
on late endosomes (663) and mediates voltage-dependent electrogenic Cl-/H+-exchange (576) 
like the other vesicular CLC proteins. Disruption of Clcn6 entails a peculiar form of neuronal 
lysosomal storage disease in mice that resembles mild forms of neuronal ceroid lipofuscinosis 
(663) (Fig. 13) and is distinct from that observed with a loss of Clcn7 (407, 668). As yet, no 
convincing disease-causing mutations have been identified in human patients. ClC-6 is one of 
the less studied mammalian CLCs. 
 
A. Basic properties of ClC-6 
ClC-6 is a glycosylated (366) ~97 kDa protein of 869 amino-acids that shares ~45% sequence 
identity with ClC-7 (79, 663) with which it forms an own branch of the gene family. In contrast 
to members of the second CLC family branch (ClC-3 through ClC-5), which could be co-
immunoprecipitated and may form heteromeric transporters (820), ClC-6 appears not to 
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interact with ClC-7, nor with other CLCs (820). Both the N- and the C-terminus of ClC-6 can bind 
to the adaptor complex AP3 (801). Several CLCN6 splice variants have been identified by RT-PCR 
from a human cell line (213) but their significance is questionable as they predict severely 
truncated, non-functional proteins.  
For more than ten years, attempts to determine the transport properties of ClC-6 were 
unsuccessful (79, 92) because of its targeting to endosomes. Mutating AP3-binding sites and 
other consensus sorting motifs failed to bring sufficient amounts of ClC-6 to the plasma 
membrane (801), but for unknown reasons fusion of GFP to the N-terminus of ClC-6 finally 
allowed a small fraction of ClC-6 to reach the outer membrane (576). GFP-ClC-6 mediates small, 
strongly outwardly rectifying currents in CHO cells (576) which lack significant ClC-5 expression 
(808) and display minimal Cl-/H+-exchange background activity. These currents activated almost 
instantaneously upon depolarization, were inhibited by extracellular acidification, and displayed 
the NO3->Cl->I- conductance sequence that is typical for mammalian CLC exchangers (576). Cl-
/H+-exchange activity could be ascertained by voltage-dependent changes of intracellular pH in 
GFP-ClC-6 expressing Xenopus oocytes (576). Like in other mammalian CLC exchangers, 
mutations in the ‘gating’ glutamate of GFP-ClC-6 abolished proton coupling and converted ClC-6 
to an almost ohmic anion conductance. This conductance could be increased 3-fold by mutating 
a Cl- coordinating tyrosine (576) which is thought to represent an internal gate in the E. coli 
exchanger EcClC-1 (378). As further proof for ClC-6 mediating these rather small currents, 
mutating the Cl- coordinating serine to proline increased its preference for NO3-, just as 
observed in ClC-4 and -5 (60, 966),  ClC-0 (60) and EcClC-1 (650). Although expression levels did 
not allow to determine the stoichiometry of Cl-/H+ coupling, there is little doubt that ClC-6 is a 
2Cl-/H+-exchanger with transport properties that strongly resemble those of ClC-4 and ClC-5.  
 
B. Localization of ClC-6 
Although Northern blots (79) and NCBI expression databases show a nearly ubiquitous 
expression of ClC-6 transcripts, Western blots revealed that the ClC-6 protein was expressed in 
brain, but not in liver, kidney and heart (663). Immunohistochemistry detected ClC-6 in the 
hippocampus and all cortical layers of adult mice (663) and in situ hybridization of mouse P0 
embryos revealed strong signals in brain, spinal cord, trigeminal and dorsal root ganglia and the 
eye (663). In situ hybridization of adult mouse tissue sections (414) found impressive Clcn6 
signals in the testis and in epithelial cells of the lung, trachea, pancreas, and intestine, but failed 
to detect Clcn6 transcripts in the brain. The reason for the discrepancy between the wide 
mRNA- and restricted protein-expression is unclear. It seems possible that it involves tissue-
specific translational control, or rather a neuron-specific interaction partner that stabilizes the 
ClC-6 protein.  
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Like all other vesicular CLC proteins, ClC-6 is found on vesicles of the endolysosomal system 
(663). Knock out controlled IHC revealed that native ClC-6 partially overlapped with the late 
endosomal/lysosomal marker lamp-1 in somata of cortical, thalamic, and dorsal root ganglia 
neurons (663). When brain membranes were fractioned on Percoll gradient, ClC-6 partially co-
migrated with ClC-3 and ClC-7, and, less than ClC-7, with the lysosomal enzyme cathepsin D 
(663). In Clcn7-/- brain, ClC-6 shifted partially to the lysosomal fractions (663). ClC-6 could 
functionally complement the gef1 phenotype of yeast (414) which results from disruption of 
the single S. cerevisiae CLC Gef1p (299), a protein located in the yeast Golgi and pre-vacuole 
(81, 760). In conclusion, native ClC-6 resides in late endosomes, partially overlapping with late 
endosomal ClC-3 and with late endosomal/lysosomal ClC-7.   
Consistent with a late endosomal localization, native ClC-6 also co-localized with lamp-1, but 
not with EEA1 or the transferrin receptor in the human neuroblastoma cell line SH-SY5Y (366). 
However, when overexpressed in the same cell line or in HeLa or COS cells (where the authors 
had previously found an ER localization (91)), ClC-6 was rather found in early or recycling 
endosomes as indicated by co-localization with EEA1 and transferrin receptors, respectively 
(366). Upon expression in HEK cells, ClC-6 partially co-localized with EEA1 and lamp-1 (820). The 
co-localization of ClC-6 with the transferrin receptor in transfected HeLa cells could not be 
changed by mutating a confirmed AP3-binding site, even when done in combination with 
mutations in several other putative sorting signals (801). By contrast, mutating a stretch of 
basic amino-acids in the ClC-6 amino-terminus that is involved in the incorporation of ClC-6 into 
detergent resistant membranes shifted ClC-6 into a ‘later’, ClC-7 positive compartment (366), 
but the biological significance of this finding is unclear. In spite of the uncertainties concerning 
the mechanisms of ClC-6 sorting (801), it seems obvious that native ClC-6 resides 
predominantly in late endosomal compartments. 
 
C. Possible physiological roles of ClC-6 and involvement in pathologies 
The loss of ClC-6 leads to moderate lysosomal storage in neurons (663) (Fig. 13), but the 
mechanism underlying this pathology and the precise physiological role of ClC-6 remain 
unknown. Most likely, ClC-6 is involved in the ion homeostasis, possibly including pH-regulation, 
of late endosomes. Measurements of lysosomal pH of cultured hippocampal neurons with 
ratiometric dyes indicated that this parameter is not changed by Clcn6 disruption (663). In 
contrast to similar negative results for lysosomal ClC-7 (407, 445), however, these results may 
just reflect the fact that ClC-6 has its major role in late endosomes, and not lysosomes, into 
which the indicator had been chased after endocytosis.  
Clcn6-/- mice are viable, fertile, and lack an immediately obvious phenotype (663). However, 
they display lysosomal storage in neurons that develops over the first few months after birth. 
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Autofluorescence is seen in initial axon segments that are often ballooned and contain storage 
material positive for lysosomal proteins such as lamp-1, cathepsin D and ClC-7 (Fig. 13). It was 
also labeled with antibodies against subunit c of the mitochondrial ATPase which is a marker for 
neuronal ceroid lipofuscinosis (NCL). The relatively mild pathology, localization of storage 
material to initial axon segments, and virtual absence of neurodegeneration markedly differ 
from the severe lysosomal storage and neurodegeneration observed with a loss of ClC-7 or its 
β-subunit Ostm1 (407, 445, 668). The strong accumulation of storage material in dorsal root 
ganglia neurons  (see Fig. 13) probably explains the reduced pain sensitivity of Clcn6-/- mice in 
tail flick assays (663). In addition, Clcn6-/- mice displayed mild cognitive abnormalities (663).  
The phenotype of Clcn6-/- mice prompted Poët et al. to search patients with mild forms of NCL 
for CLCN6 mutations (663). This included patients with Kuf’s disease who typically accumulate 
storage materials in initial axon segments (61). However, although two out of 75 patients 
displayed heterozygous CLCN6 missense variants, no convincing disease-causing mutations 
were found (663).  
In inconclusive studies, CLCN6 sequence variants were identified in patients with epilepsy (883, 
927), but the Glu178Ala CLCN6 variant reported by Wang et al. (883) is questionable as there is 
no Glu178 in ClC-6. Sequence variants in the CLCN6 gene were also linked to lower blood 
pressure levels (932) and to coronary heart disease (949). These results need confirmation in 
other cohorts.  
 
 
XIII. CLC-7 - A LYSOSOMAL CL-/H+ ANTIPORTER MUTATED IN OSTEOPETROSIS 
AND NEURODEGENERATION 
ClC-7 is a 89 kD protein with 803 amino acids in rat (805 amino acids in humans) that is 
ubiquitously expressed (79). It conforms to the overall CLC structure with a large 
transmembrane domain and two C-terminal CBS domains, even though the stretch between 
the CBS1 and CBS2 domains is shorter compared to the other CLCs. Together with ClC-6, with 
which it shares about 45% sequence identity, it forms the third branch of mammalian CLCs (79). 
It has only low sequence similarity with the other mammalian CLC-proteins but is rather closely 
related to the plant homologues At-ClCa-d (335, 428, 510). ClC-7 is strictly associated with the 1 
TMD protein Ostm1 (445) and the protein complex functions as a 2Cl-/H+ antiporter in 
lysosomes and in the ruffled border of osteoclasts (298, 407, 429, 445, 453, 802, 888). ClC-7 
lacks any N-glycosylation site, while Ostm1 is heavily glycosylated (79, 445), a property which 
could be important for protein stability in the acidic, protease rich lysosomal lumen. Mutations 
in the genes encoding ClC-7 and Ostm1 cause osteopetrosis and neurodegeneration (116, 429). 
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In the ruffled border of osteoclasts, ClC-7/Ostm1 is most likely essential for the acidification of 
the resorption lacuna (the sealed extracellular space contacting the bone) and consequent 
osteoclast mediated bone resorption (429). In lysosomes, the 2Cl-/H+ antiporter might be 
important for the regulation of the luminal Cl- concentration (896).  
 
A. Localization and transcriptional regulation of ClC-7 
ClC-7 mRNA is expressed in practically all tissues examined and expression starts early in 
development being detectable already at embryonic day 7 (79). Using in situ hybridization, high 
Clcn7 mRNA expression was found in brain, eye, spinal cord, dorsal root ganglion, and 
trigeminal ganglion in mouse embryos (429) and in various CNS neurons, hepatocytes, kidney 
outer medulla, lung, pancreas and testis in adult mice (414). These sites of expression were 
confirmed by studies of ClC-7 KO mice in which β-galactosidase was expressed under the 
control of the endogenous Clcn7 promoter (429). X-gal staining in these mice further revealed 
expression in osteoclasts, lens, retinal pigment epithelium and cells of the neuroretina (429), as 
well as in all regions of the adult kidney (888). Using antibodies that had been controlled on 
knock out tissue, immunohistochemical staining demonstrated the presence of ClC-7 in neurons 
(407), in microglia and in cortical kidney segments including the proximal tubule (888). 
Regarding the subcellular localization, ClC-7 shows a high degree of overlap with the late 
endosomal / lysosomal marker lamp-1 in all reported cell types, including mouse fibroblasts 
(429), hippocampal neurons (407), and proximal tubule cells (888). Immunoelectron microscopy 
confirmed the lysosomal localization in cortical neurons (407). The lysosomal localization of ClC-
7 was also shown by subcellular fractionation of brain (429, 663) and subsequently of liver and 
HeLa cells (298). Cell fractionation showed that ClC-7 is the only lysosome-resident CLC (298, 
663). In the brain of Clcn7-/- mice, ClC-3 and ClC-6 are partially shifted into the lysosomal 
fractions (663). Collectively, these studies provide overwhelming evidence for a lysosomal 
localization of ClC-7 in most tissues, but additional localization to late endosomes or 
phagosomes is likely. In quiescent cultured microglia ClC-7 and Ostm1 are predominantly found 
in the ER but can be shifted to lysosomes by treatment with macrophage colony-stimulating 
factor (514). The subcellular localization of ClC-7/Ostm1 in microglia in situ remains to be 
determined.  
ClC-7 is targeted to lysosomes also in heterologous expression systems (445, 801, 820). Stauber 
& Jentsch found that both the N- and the C-terminus of ClC-7 interacted with members of the 
adaptor protein complex (AP) and identified regions of amino acid residues in the N-terminus 
that mediated this  binding (801).  In addition, the N- terminus also pulled down members of 
the Golgi-localized, γ-ear-containing, Arf-binding (GGA) family (801). Mutating the leucine 
residues of the putative GGA binding motif (DDELL69) indeed abolished the interaction with 
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GGA proteins, but did not affect AP binding. Conversely, mutating the two leucine residues of 
the potential AP binding (DE)XXXL(LI) motif EAAPLL24 to alanine abolished pulldown of APs but 
not of GGAs (801). Interestingly, in chimeric constructs, the N-terminus of ClC-7 was sufficient 
to target the plasma membrane channel ClC-0 to lysosomes. However, the combined disruption 
of the two above mentioned leucine-based sorting motifs in the context of the chimera did not 
abolish lysosomal targeting (801). An additional putative AP binding (DE)XXXL(LI) consensus 
motif (EETPLL37) was then found to be critical for lysosomal targeting of the chimera. In the full 
length ClC-7 protein, mutating the leucines of the two AP motifs to alanines (L23A, L24A, L36A, 
L37A) was sufficient to redirect ClC-7 and also the ClC-7/Ostm1 complex partially to the plasma 
membrane (801). This construct is also called ClC-7PM and has been used for extensive 
electrophysiological characterization of ClC-7/Ostm1 mediated currents and for the functional 
characterization of osteopetrosis-causing mutations (453).  
In osteoclasts, ClC-7 is not only present in lysosomes, but also in the ruffled border, a 
specialized plasma membrane region that is sealed on the bone surface defining the sites 
where osteoclasts reabsorb the bone material (429). The delivery of ClC-7 and the V-type 
ATPase to the ruffled border occurs via lysosomal exocytosis, which also delivers acid 
hydrolases to the so-called “resorption lacuna” or “extracellular lysosome”.  
Transcriptional regulation of ClC-7 and Ostm1 is little understood. A putative promoter 
fragment of mouse Clcn7 showed a high G/C content and lacked apparent TATA boxes, 
consistent with an ubiquitous expression pattern as seen for many housekeeping genes (428). 
In addition two “E-boxes” were identified in the promoter region (428). In osteoclasts, the 
genes encoding ClC-7 and Ostm1 are both regulated by the transcription factor microphthalmia, 
which controls several genes in osteoclast function (536). 
Pattern discovery analysis on 96 known lysosomal genes led to the identification of a 
palindromic 10 bp promoter motif that was enriched in 68 out of the 96 genes and included 
CLCN7 but not OSTM1 (733). This motif is recognized by the TFEB transcription factor that 
appears to act as a master regulator of lysosome biogenesis (733). 
 
B. Ostm1 is an obligatory ClC-7 β-subunit 
Ostm1 was identified (116) as the gene mutated in the spontaneous mouse mutant “grey 
lethal” (gl) (304). Grey lethal mice exhibit severe osteopetrosis characterized by defective 
osteoclast maturation and function and die at 3-4 weeks of age (689). A further characteristic of 
gl mice is a grey coat color in an agouti background, being caused by a malfunction of pigment 
forming granules in melanocytes (304). The genetic defect underlying the gl phenotype was 
found to be a 460 bp insertion in the gene encoding the Ostm1 protein (116). Ostm1 RNA was 
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found to be widely expressed in osteoclasts, brain, kidney, spleen, thymus, testis, heart, liver 
and primary osteoblasts and in fetal tissues at E12.5 (116, 445). The open reading frame 
encodes 338 amino acids with a single predicted transmembrane domain. Evolutionary, Ostm1 
homologues are found in multicellular animals like C. elegans but not in yeast (116, 622). The 
lack of an Ostm1 homologue in yeast may underlie the finding that ClC-7 could not functionally 
complement the yeast CLC (414). The importance of Ostm1 in humans was confirmed by the 
finding that a mutation in the OSTM1 gene at a donor splice site caused recessive osteopetrosis 
in an Italian patient (116), followed by the identification of additional mutations in other 
patients (624, 690). 
However, the function of Ostm1 and the mechanisms leading to osteopetrosis were completely 
unclear until Lange et al. discovered that Ostm1 is an essential β-subunit of ClC-7 (445). The two 
proteins could be co-immunoprecipitated from brain tissue and co-localized in late endosomes 
and lysosomes in mouse fibroblasts (445). Immunohistochemistry showed co-localization also 
in neuronal cell bodies in lysosomal structures and in osteoclasts in the ruffled border (445). In 
the absence of ClC-7, Ostm1 showed an ER-like distribution in transfected cells, and Ostm1 
staining was very weak in Clcn7-/-  mice, suggesting that association with ClC-7 is needed for 
Ostm1 protein stability (445). Conversely, staining of ClC-7 was greatly reduced in gl mice (445). 
Importantly, the transcript levels of Clcn7 were unchanged in gl mice and those of Ostm1 were 
unchanged in Clcn7-/-  mice (445). 
These data firmly established that Ostm1 serves as an essential β-subunit of ClC-7 and that the 
two proteins mutually stabilize each other. Lysosomal targeting of Ostm1 is fully dependent on 
ClC-7 with Ostm1 “following” the α-subunit (801). The interdependence of the two proteins is 
also reflected in the very similar phenotype of the respective knock out models. For example, 
Clcn7-/- mice have grey fur in an agouti background and retinal and hippocampal 
neurodegeneration was detected in gl mice (445). It closely resembles the neurodegenerative 
phenotype of Clcn7-/- mice (407, 668, 888). 
Lange et al. also obtained important information on the biochemical properties of Ostm1. The 
authors firmly established the topology of the protein as a type I transmembrane protein with 
extracellular, highly glycosylated N-terminus and a short cytoplasmic C-terminus mice (445). In 
addition the protein bears a proteolytic cleavage site in the N-terminus. The fragments created 
by the cleavage are probably kept together by disulfide bonds (445). The topology was fully 
confirmed in a later study (622). However, the results concerning subcellular localization and 
putative protein interaction partners of that study (622) are questionable because most 
experiments were performed overexpressing Ostm1 in the absence of ClC-7, a condition known 
to destabilize the protein (445). The established topology of Ostm1 ruled out a previous 
hypothesis according to which Ostm1 is a RING finger containing cytosolic ubiquitin ligase (250). 
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Another report suggested a role of Ostm1 in Wnt/β-catenin signaling (241), but experiments 
with Clcn7-/- and Ostm1-/- fibroblasts and melanocytes contradicted this notion (895). 
C. General biophysical properties of ClC-7/Ostm1 mediated transport 
Due to its strict intracellular localization, functional characterization of ClC-7 using standard 
electrophysiological techniques had not been possible for a long time (79, 407, 429, 445). An 
antiporter instead of channel function was suspected because ClC-7 carries a “proton-
glutamate” (E312) as other CLC exchangers (9, 383, 941). A first characterization of endogenous 
lysosome Cl- / H+ antiport activity was performed on native lysosomes prepared from rat liver 
(298). Using sophisticated flux measurements, Graves et al. showed that the major endogenous 
lysosomal Cl- transporting pathway has 2Cl-/H+ antiport characteristic, with a typical CLC anion 
preference of NO3- > Cl- ≥ Br- > I- (298). Since ClC-7 is the only lysosomal CLC protein (407, 429, 
888) and because ClC-7 was the only CLC that co-purified with the lysosomal preparation (298), 
the transport activity was likely mediated by ClC-7. This notion was ascertained by Weinert et 
al. who studied the response of luminal pH to Cl- gradients with lysosomal preparation from WT 
and Clcn7-/- mice (896). Interestingly, transport activity was enhanced in acidic pH (298) similar 
to the bacterial EcClC-1 (5).  
A breakthrough allowing functional analysis of ClC-7 came from a systematic study by Stauber & 
Jentsch who discovered that N-terminal leucine based sorting motifs are critically involved in 
the lysosomal targeting of ClC-7. They found that mutating 4 leucine residues (L23, L24, L36, 
L37) to alanines resulted in partial membrane localization of the protein (801) (see above).  
Using this “ClC-7PM” variant, Leisle et al. performed a detailed electrophysiological 
characterization of heterologously expressed ClC-7 (453). Importantly, Ostm1 “followed” ClC-7 
(801), being co-localized with ClC-7PM at the plasma membrane (801). Interestingly, the N-
terminus of Ostm1 was not essential for co-localization of the two proteins but, together with 
the transmembrane domain, it was required for functional activity, while the C-terminus could 
be exchanged by that of the CD4 protein (453). In voltage-clamp experiments in Xenopus 
oocytes as well as in transfected mammalian cells, ClC-7PM/Ostm1 mediated currents slowly 
activated at positive membrane potentials with kinetics in the seconds range. These currents 
deactivated with a time constant of the order of hundreds of ms upon repolarization to 
negative voltages (453). Currents of rat and human ClC-7 clones were indistinguishable. The 
very slow activation of ClC-7PM/Ostm1 mediated currents at positive voltages clearly reflects a 
“gating” phenomenon, i.e. a conformational change of the protein from an inactive, non-
transporting state to an actively transporting state. In agreement with this interpretation, 
gating kinetics showed a relatively large temperature dependence characterized by a Q10 of ~ 3 
(453). Activation kinetics were so slow and activation occurred at such positive voltages that no 
true equilibrium could be achieved. Measuring currents from the “fast” mutant R762Q (see 
below), and using classical protocols to assess steady-state voltage dependence, a voltage of 
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half-maximal activation of ~80 mV and an apparent gating valence of 1.3 was determined (453). 
The mechanism of the gating of ClC-7 is little understood. It appears to involve both the 
transmembrane part as well as the cytoplasmic CBS domains because mutations in both regions 
strongly affected gating kinetics (453), suggesting that the gate could bear similarity to the 
common gate of CLC channels that depends of both subunits of the homodimer. This 
hypothesis was tested by Ludwig et al. using a clever co-expression approach that exploited the 
transport deficient proton glutamate mutant E312A (493). Currents mediated by WT ClC-
7PM/Ostm1 were accelerated by co-expression with gate-accelerating mutations in the 
background of E312A, and conversely, fast mutants were slowed down upon co-expression with 
the transport deficient E312A demonstrating that the non-transporting subunit influences the 
speed of the conformational change of gating (493). Such a dominant acceleration of gating 
may underlie the dominance of several gate-accelerating osteopetrotic mutations (453). 
The currents mediated by ClC-7PM/Ostm1 showed a Cl- >Br- > NO3- > I- conductivity sequence. 
Similar as for all mammalian CLCs, iodide was less conductive, but somewhat surprisingly also 
NO3- was conducted less efficiently than Cl-. This contrasts with ClC-4 and ClC-5 exchangers 
(941, 966, 967) and with what had been reported for endogenous lysosomal flux activity (298). 
Mutating the highly conserved pore serine 202 to proline, as found in the plant At-ClC-a NO3-/ 
H+ antiporter (164), greatly enhanced NO3- conductance of ClC-7PM/Ostm1 (453), similar to 
what had been described for ClC-5 (60, 966), and demonstrating that the fundamental 
mechanisms of ion selectivity and transport coupling are conserved in ClC-7. The presence of 
inward tail currents allowed Leisle et al. to determine the transport stoichiometry by measuring 
the reversal potential upon changing pH and Cl- concentration. They consistently found a 2Cl-
/1H+ stoichiometry when changing both ion species (453). Proton transport was also directly 
detected by fluorometrically measuring intracellular pH changes upon current stimulation 
(453). As for ClC-5 (269, 649), ClC-7PM/Ostm1 mediated outward currents were slowed down 
and their magnitude was decreased by acidic extracellular pH (453). Such inhibition is possibly 
of physiological relevance as the lysosomal luminal pH is highly acidic. In this respect it is 
interesting to note that the endogenous lysosomal Cl-/H+ antiport was actually enhanced by 
acidic pH (298).  Furthermore, the activity of heterologously expressed ClC-7PM/Ostm1 was very 
low at negative or slightly positive membrane potentials (453). For these reasons, it will be 
interesting to characterize the voltage- and pH-dependent biophysical properties of ClC-
7/Ostm1 in their native membrane environment.  
The functional properties of ClC-7PM/Ostm1 are very different from those of acid -induced anion 
currents reported in Sertoli cells (40), acid-induced currents in ClC-7 expressing oocytes (195) or 
acid-induced currents in mouse osteoclasts (606). The anion currents reported in these studies 
are most likely unrelated to ClC-7. Indeed, Capurro et al. found that acid induced anion currents 




D. Gating of ClC-7 and osteopetrosis 
The gating of ClC-7 is likely of physiological relevance because several osteopetrosis mutations 
led to a significantly accelerated gating kinetics (453). Human mutations with accelerated gating 
include residues in the transmembrane part, some of which in regions close to the dimer 
interface, and several residues in the cytosolic CBS domains (453). Accelerated activation 
kinetics is, a priori, a gain of function, at least at positive voltages. However, osteopetrosis is 
clearly due to a loss or reduction of function of ClC-7/Ostm1 as demonstrated by the presence 
of disease causing deletion and truncation mutations (e.g. (181, 429)) and missense mutations 
that reduce functional expression (453). It cannot be excluded that the gating phenotype seen 
with ClC-7PM/Ostm1 in heterologous expression is an epiphenomenon and that the mutations 
induce, for example, a reduction of protein expression in vivo. This has indeed been described 
for the gate accelerating mutation R762Q, for which less protein was found in Western blots 
from patient-derived fibroblasts (429). However, detailed in vivo studies are difficult to perform 
for human mutations. Recently, a cattle model of osteopetrosis shed light on this issue (734). 
Animals carrying the Y750Q mutation (affecting a conserved tyrosine in CBS2) had severe 
osteopetrosis and blindness that was associated with high perinatal lethality. Importantly, the 
mutations did not affect protein abundance and preserved lysosomal localization (734). In the 
background of the plasma membrane targeted ClC-7PM/Ostm1, the mutation significant 
accelerated gating kinetics (734), which was thus the only detectable functional effect of the 
mutation.  
 
E. ClC-7, bone resorption and osteopetrosis 
The importance of ClC-7 for osteoclast mediated bone resorption was revealed by the 
phenotype of ClC-7 KO mice that displayed severe osteopetrosis, a disease characterized by 
dense and fragile bones (429). Even though ClC-7 is expressed early in the embryo (429), birth 
rate of knock out pups was Mendelian and heterozygous mice were at first undistinguishable 
from WT. Later Clcn7-/-  mice were smaller, their teeth failed to erupt and they died after 6-7 
weeks even if fed liquid diet (429). Analysis of bones of Clcn7-/-  mice revealed shortened long 
bones, absence of bone marrow cavity, disorganized trabecular structure, fibrosis and absence 
of a regular corticalis, while osteoblast mediated bone apposition rate was unaltered (429).   
Osteopetrosis in Clcn7-/- mice is not caused by a lack of osteoclasts but by their inability to 
reabsorb calcified bone, as shown by the inability of in vitro differentiated cultured osteoclasts 
to excavate pits on dentin substrate, even though the H+ ATPase was normally expressed in 
osteoclasts (429, 580). In addition, osteoclasts were abnormally large in Clcn7-/- mice (429, 580). 
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Importantly, no resorption lacuna was formed by Clcn7-/- osteoclasts in culture even though the 
osteoclasts firmly attached to bone and osteoclast from Clcn7-/- are able to degrade decalcified 
bone (580).  
The inability to resorb dentin was associated with an apparent inability to acidify the resorption 
lacuna as assayed by acridine orange fluorescence (429). However, as no clear resorption 
lacuna was actually formed by knock out osteoclasts, it is difficult to distinguish an acidification 
defect from a maturation defect of the ruffled membrane. Indeed, the intracellular punctate 
pattern of acridine orange fluorescence, reflecting likely acidic lysosomes of the osteoclasts, 
was preserved in Clcn7-/-  mice, suggesting that lysosomal acidification was not affected (429), 
in agreement with quantitative measurements of lysosomal pH in cultured neurons (407) and 
fibroblasts of Clcn7-/-  mice (445, 896).  
The critical role played by ClC-7 in bone resorption was confirmed by the finding that CLCN7 
mutations cause osteopetrosis in a significant number of patients (429, 791). The first 
mutations were found in a compound heterozygous patient who carried a nonsense (Q555X) 
mutation on one allele and a missense (R762Q) mutation on the other allele (429). No RNA was 
detected for the Q555X transcript. Interestingly, no ClC-7 protein was found in patient derived 
fibroblasts, suggesting that the R762Q mutation, which alters a charged residue in CBS2, leads 
to protein instability (429). However, large currents of the R762Q mutant in the background of 
plasma membrane redirected ClC-7 construct could be measured in heterologous expression, 
and the mutant displayed faster gating kinetics (453).  
Osteoclast-rich autosomal recessive osteopetrosis had been previously associated with 
mutations in the a3 subunit of the H+ ATPase (266, 430). It is also one of the symptoms in 
carbonic anhydrase deficiency syndrome (786). However, while the phenotypes caused by 
these genetic defects are overlapping, symptoms and treatment options differ in detail and are 
clonically important (46). Since the defective osteoclasts are of hematopoietic origin, bone 
marrow transplantation can often be curative (791). However, the severe neurological 
symptoms associated with homozygous CLCN7 loss-of-function mutations will not be corrected 
by this treatment.  
Over the years, a large number of osteopetrosis causing CLCN7 mutations has been identified 
(70, 141, 183, 429, 442, 623, 659, 791, 943, 959). Osteopetrosis caused by CLCN7 mutations is 
classified as infantile malignant CLCN7-related recessive osteopetrosis (ARO), intermediate 
autosomal osteopetrosis (IAO), and autosomal dominant osteopetrosis type II (ADOII, Albers-
Schönberg disease) (141, 791). The recessive forms of the disease are generally much more 
severe with clinical symptoms that include fractures, poor growth, optic nerve compression, 
absence of the bone marrow cavity resulting in anemia and thrombocytopenia, dental 
abnormalities, and various other secondary symptoms (791). Children with ARO rarely survive 
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to adulthood. Onset of the dominant form of osteopetrosis is in late childhood or adolescence 
and symptoms are much milder. The dominant inheritance of certain CLCN7 mutations is most 
likely caused by a dominant negative effect of the mutated allele on the dimeric complex, 
similar to what is occurring in dominant myotonia congenita (679). Among the dominant 
mutations, several lead to a faster gating kinetics, including L213F (453, 867), R286Q (267, 453), 
P619L (453, 644), Y7050Q (in cattle) (734), and R762L (453, 867). Since the gating of ClC-7 
involves both subunits of the dimeric transporter (493), it is tempting to speculate that in many 
cases the dominant imposition of accelerated gating on ClC-7 dimers underlies the dominant 
inheritance pattern. In principle, a dominant negative effect may also be observed if a mutated 
subunit impairs the trafficking of both mutant/mutant and mutant/WT ClC-7 dimers.  
A different mechanism of dominance underlies the G215R mutation (141). Osteoclasts derived 
from patients carrying this mutation could degrade bone only to 10-20% of the level in controls 
(337). In vitro, the mutation led to a retention of the protein in the ER, being, however, 
functional in a supported bilayer assay (757). The equivalent mouse mutation G213R was used 
to generate a mouse model of dominant osteopetrosis (19). Homozygous G213R knock in mice 
showed severe osteopetrosis and in general a phenotype similar to Clcn7-/- mice (19). 
Heterozygous mice had only a very mild phenotype without neurological symptoms that was 
highly variable depending on the genetic background, but structural bone parameters were 
significantly altered and a higher number of osteoclasts was observed (19, 20). In a proof-of-
principle gene therapeutic approach, treatment of heterozygous G213R knock in mice by 
repeated intravenous injection of conjugated G213R specific small interfering RNA led to a 
significant amelioration of various disease markers (102). However, the mechanism underlying 
the dominant inheritance of the G215R mutations remains unknown. The G213R knock in 
mouse model has also been used to test pharmacological interventions indicating that 
interferon gamma, but not calcitriol might be helpful in dominant osteopetrosis (18). Another 
more recent mouse model for dominant osteopetrosis carrying the ClC-7 F318L mutation (94) 
displays a similar phenotype. Crossing these mice with the G213R mice to generate double-
heterozygous Clcn7F318L/G213R mice showed that the mutant alleles do not complement each 
other and likely result in loss of function (94). 
The impact of disease-causing CLCN7 or OSTM1 mutations on osteoclast function can be 
studied in patient-derived, in vitro differentiated osteoclasts using resorption assays. These 
showed reduced osteoclast activity in all cases (129, 337, 338, 819). Interestingly, for several 
missense mutations (associated with recessive or dominant osteopetrosis) no reduction of ClC-
7 protein abundance or localization was found, suggesting that these  mutations affect the ion 
transport properties of the transporter (819). A notable exception were osteoclasts from a 
heterozygous patient carrying the P470L and the R762Q mutations, which showed significantly 
reduced ClC-7 protein expression (819). In order to obtain insight into the phenotypic 
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variability, Supanchart et al. analyzed several transgenic mouse lines that expressed TRAP 
promoter-driven ClC-7 in a Clcn7-/- background to different levels, and estimated that a 
reduction of ClC-7 activity by 70-80% impaired osteoclast resorption capability to a degree seen 
in dominant osteopetrosis (819). Furthermore, it was found that ClC-7 is not critically involved 
in gastric acid secretion, in agreement with the absence of osteopetrorickets in patients with 
mutations in CLCN7 (819).  
Teeth of Clcn7-/- mice do not erupt due to the severe osteopetrosis (429). Impaired tooth 
eruption, root and enamel formation was also reported for patients with CLCN7-related 
osteopetrosis (924). Two groups (309, 900) studied the role of ClC-7 on teeth formation in more 
detail, using Clcn7-/- mice of Kornak et al.  (429). They concluded that ClC-7 is crucial for tooth 
eruption and root development by enabling osteoclasts to remove craniofacial bone, with only 
minor effect or no effect on dentin mineral density and enamel, respectively. By contrast, 
changes in enamel were observed in another study using local application of Clcn7 siRNA in 
mice (874).  
Clcn7-/- mice not only show osteopetrosis, but also severe neurological defects and blindness, 
which will be discussed below. A common symptom also seen in non CLCN7 associated 
osteopetrosis is visual impairment caused by compression of the optic nerve by osteopetrotic 
narrowing of the optical canal (809). Several lines of evidence show that the retinal 
degeneration of Clcn7-/- mice is nevertheless a primary defect caused by photoreceptor 
degeneration. First, the number of retinal ganglion cells, the first cell type affected by optic 
nerve compression, is not reduced at 4 weeks of age (430), Secondly, “curing” osteopetrosis of 
Clcn7-/- mice by expression of ClC-7 under the TRAP promoter did not prevent retinal 
degeneration (407).  
All reported human OSTM1 mutations predict a truncated protein (116, 341, 521, 624, 683, 
690, 793). As expected from the phenotype of gl mice (116), targeted Ostm1-/- mice (632) and 
the role of Ostm1 as ClC-7  β-subunit (445), patients carrying such mutations on both alleles 
exhibit severe osteopetrosis with strong neurological symptoms that cannot be cured by bone 
marrow transplantation (615).  
 
F. Role of ClC-7 in lysosomes in neurons and in the renal proximal tubule  
Kasper et al. (407) and Wartosch et al. (888) studied in detail the mechanisms underlying 
neurodegeneration in ClC-7 deficient mice. First, using a lacZ fusion protein under the control of 
the endogenous ClC-7 promoter, expression was found in practically all neuronal cell types and 
in glia (407). Immunostaining revealed punctate patterns in neuronal cell bodies in almost 
perfect co-localization with the lysosomal marker lamp-1 (407). Loss of ClC-7 led to wide-spread 
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neurodegeneration which was most evident in the CA3 region of the hippocampus (407). It was 
associated with the appearance of electron-dense osmiophilic material in hippocampal and 
cortical neurons at P40 with ultrastructural characteristics of lysosomal storage disease of the 
neuronal ceroid lipofuscinosis (NCL) type (407). In agreement with NCL, autofluorescent 
punctae were observed in Clcn7-/- brains as early as P20. Storage material was also seen in the 
kidney proximal tubule (407). Somewhat surprisingly, the abundance and the in vitro activity in 
lysates of several tested lysosomal enzymes was markedly increased in Clcn7-/- mice (407), 
possibly reflecting a compensatory increase of enzymes which are, however, to a large degree 
inactive in vivo because of their localization in storage material. In fibroblasts, however, the in 
vivo activity of the β-hexosaminidase and tripeptidyl peptidase I (TPP1) was unchanged. No  
neurodegenerative symptoms were observed in parallel experiments of osteosclerotic oc/oc 
mice that lack the a3 subunit of the V-type ATPase, demonstrating that the neurodegeneration 
of Clcn7-/- mice was not secondary to osteopetrosis (407). Further proof that the 
neurodegeneration and osteopetrosis are independent outcomes was obtained by investiging 
Clcn7-/- mice that transgenically expressed ClC-7  under the control of the tartrate-resistant acid 
phosphatase (TRAP) promoter, which is nearly exclusively active in osteoclasts and 
macrophages (761). These mice had no osteopetrosis but lived only about 3 weeks longer than 
Clcn7-/- mice and had severe retinal and CNS degeneration similar to the full knock out (407). 
Similarly, ClC-7 targeted mice which expressed an alternate ClC-7 transcript in bone exhibited 
neurodegeneration but no osteopetrosis (688). Very similar neurodegeneration was also seen 
in gl mice (339, 445, 668), most likely reflecting the decrease of ClC-7 protein caused by the 
absence of Ostm1 (445, 888). Surprisingly, osteopetrosis of gl mice was not cured by transgenic, 
TRAP promoter-driven expression of Ostm1 (631). Transgenic Ostm1 expression in myeloid 
progenitors using a construct containing PU.1 regulatory sequences could instead rescue the 
bone phenotype (631). This suggested that Ostm1 has additional functions beyond stabilization 
of the ClC-7 protein in the osteoclast lineage or in other hematopoietic cell types indirectly 
affecting osteoclast function (631). However, in the transgenic TRAP promoter Ostm1 
expressing gl mice, the expression of Ostm1 protein in osteoclasts was not ascertained to be of 
the same level as in WT mice (631).  
ClC-7, like other CLC proteins, had been proposed to provide a shunting conductance to allow 
efficient lysosomal acidification by the H+ ATPase (392). However, using a ratiometric, dextrane-
coupled lysosomally targeted pH indicator, the average lysosomal pH was unchanged in 
lysosomes of cultured neurons and fibroblasts from KO compared to WT mice (407, 445, 895, 
896). By contrast,  lysosomal Cl- concentration was significantly decreased (896). A role of ClC-7 
in neutralizing the currents of the NADPH-oxidase in the phagocytic vacuole of neutrophils has 
also been excluded (260). 
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The severe phenotype and early death of Clcn7-/- and gl mice provide severe obstacles in 
studying the mechanisms underlying the observed neurodegeneration. These problems were 
overcome by Wartosch et al., who developed and studied mouse models that allowed to follow 
neurodegeneration and lysosomal biology in long lived mice (888). In the first model, floxed 
Clcn7 was specifically disrupted in hippocampal and forebrain structures of the cortex, sparing 
parvalbumin positive interneurons (888). These mice lived to the same age as WT without 
osteopetrosis or change in size. However, some behavioral abnormalities became apparent at 
4-5 months of age (888). There was a massive loss of cortical neurons that was confined to 
regions that did not express ClC-7. Neurodegeneration started in the CA3 region of the 
hippocampus as in constitutive Clcn7-/- mice, showing that neurodegeneration occurs in a cell- 
autonomous manner (888).  At 1.5 years of age the cortex and the hippocampus had almost 
disappeared (888). The distribution of the late endosomal / lysosomal marker lamp-1 was more 
diffuse in neurons from constitutive Clcn7-/- mice and in ClC-7-lacking neurons from the 
forebrain specific knockout (888). The neurodegeneration was associated with typical feature 
of NCL such as the presence of storage material in the somata of cortical neurons at P37. 
Astrogliosis and activation of microglia, which is also seen in constitutive Clcn7-/- mice (407, 
668) and which is a typical feature of NCL and other neurodegenerative pathologies, was 
restricted to those brain regions where ClC-7 had been disrupted  (888). As the EMX1 promoter 
used to drive Cre expression in the forebrain-specific KO is not active in astrocytes and 
microglia, this result strongly suggests that astrogliosis and microglia activation represent a 
secondary response to the primary neurodegeneration.  
In order to investigate in more detail the role of ClC-7 in lysosomal biology, Wartosch et al. 
concentrated on the kidney as a model for endocytosis and lysosomal dysfunction. ClC-7 was 
found to be highly expressed in all parts of the kidney, co-localizing with Ostm1 and lamp-1, and 
large amounts of lysosomal storage material and of the autophagy marker LC3-II were seen in 
proximal tubular cells (PTCs) of Clcn7-/- and gl mice (888). It is not clear if the accumulation of 
LC3-II reflects increased autophagy or reduced degradation. Lamp-1 positive structures were 
enlarged and distributed more broadly in PTCs from Clcn7-/- mice, resembling somewhat the  
pattern seen in neurons (888). The morphology of ClC-3-positive late endosomes or ClC-5-
positive early endosomes was unchanged. In vivo pulse-chase endocytosis experiments 
revealed that the enlarged lysosomal structures are connected to the endocytic system (888). 
Crossing the floxed Clcn7 mice with mice expressing Cre recombinase in renal cortex led to a 
mosaic disruption of ClC-7 in PTC, allowing to compare endocytosis in ClC-7 expressing and 
Clcn7-/- PTCs side by side (888) (Fig. 14). In essence, it was found that in Clcn7-/- PTCs, 
endocytosis per se is not affected, endocytosed material is delivered to the enlarged lamp-1 
positive vesicles, but degradation is significantly slowed (888). Importantly, the enlargement of 
the lysosomal structures probably does not depend on an accumulation of endocytic cargo 
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because it was not abolished by additional disruption of ClC-5 that greatly diminished 
endocytosis (888). 
  
G. The role of ClC-7 as a lysosomal Cl- / H+ antiporter 
Early on, endosomal and lysosomal CLC proteins had been proposed to function as Cl- channels 
that provide a charge compensating conductance necessary for the efficient luminal 
acidification by the electrogenic H+ ATPase (307, 392). Indeed, ATP dependent acidification of 
renal cortical endosomes is significantly slowed in ClC-5 knock out mice (308, 600). Surprisingly, 
and conflicting with the idea that ClC-7/Ostm1 is essential for lysosomal acidification, pH was 
normal in lysosomes of cells from Clcn7-/- and Ostm1-/- mice (407, 445, 896). The report by 
Graves et al. that siRNA-mediated down-regulation of ClC-7 leads to an alkalinization of 
lysosomes in HeLa cells (298) needs to be interpreted with caution, because their assay was 
based on a non-ratiometric fluorescent dye and on poorly effective siRNAs. Working with 
permeabilized cells and ratiometric measurements of lysosomal pH, Steinberg et al. found that 
cations contribute in a significant manner to support lysosomal acidification (803). Different 
results have also been reported for cultured microglia in which full lysosomal acidification could 
only be achieved if ClC-7/Ostm1 had been upregulated by treatment with macrophage colony-
stimulating factor (514). As primary cultures of microglia not always faithfully reflect the in vivo 
situation (509), it will be important to confirm these results, for example in brain slices or using 
a conditional knock out model. The same caution should be maintained interpreting recent 
results reporting a reduction of Ostm1 expression and an alkalinization of lysosomal pH in 
cultured microglia treated with Alzheimer disease related A-β peptides (312).  
A clearly diminished acidification in Clcn7-/- mice has been observed for the osteoclastic 
resorption lacuna (429). It might be that the highly specialized acid-secreting ruffled border, in 
contrast to lysosomes, lacks a parallel cation conductance. Alternatively and more likely, the 
lack of ClC-7 interferes with vesicular trafficking and the build-up of the acid-secreting ruffled 
border by exocytic insertion of lysosomal membranes. Indeed, electron microscopy shows that 
the ruffled border of Clcn7-/- osteoclasts in situ is underdeveloped (429, 895).  
The interpretation of the role of ClC-7 in lysosomal biology changed significantly after it had 
become likely (383) and later established that ClC-7 is not a Cl- channel, but a coupled 2Cl-/1H+ 
antiporter (298, 453, 896). Intuitively, such a transport mode might not seem well suited to 
provide a Cl- based shunting permeability for the H+ ATPase as the required inward movement 
of Cl- ions into the lumen is accompanied by an outward movement of protons, leading thus to 
a waste of pumped protons, increasing thereby the metabolic expense of the acidification 
process. However, model calculations show that under certain conditions the presence of a 2Cl-
/1H- exchanger results in a more acidic luminal pH compared to the presence of a Cl- 
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conductance (372, 522, 896). Under these conditions, the voltage across the lysosomal 
membrane would become negative inside, a situation that would be actually in harmony with 
the strongly outwardly rectifying electrophysiological phenotype of CLC exchangers. However, 
little is known about the actual voltage across endo/lysosomal membranes. 
The physiological relevance of the 2Cl-/1H- exchange mechanism for lysosomal and osteoclast 
biology was tested using a knock in mouse model in which the gating glutamate neutralizing 
E245A mutation was introduced into the Clcn7 gene (896). The equivalent mutation abolishes 
H+ transport in bacterial and plant CLCs (5, 60) and in ClC-4 and ClC-5 (651, 742), converting the 
transporters to uncoupled and voltage-independent Cl- conductances, as later verified directly 
for ClC-7 (453). Similar to Clcn7-/- mice, the so-called Clcn7unc/unc (for “uncoupled”) mice had a 
severe phenotype with growth retardation and they died within 5 weeks (896). ClC-7 was 
normally expressed in lysosomes and also the abundance and localization of Ostm1 were 
unchanged (896). Similar to mice lacking ClC-7 (888) or Ostm1 (445), Clcn7unc/unc mice 
developed retinal degeneration and lysosomal storage disease associated with 
neurodegeneration and signs of NCL (896). Mice also developed osteopetrosis (896), which 
was, however, less severe compared to Clcn7-/- (429) or gl (116) mice. Interestingly, on an 
agouti background the fur was brownish in Clcn7unc/unc mice as in WT mice (896) and not grey as 
in gl (116) or in Clcn7-/- mice (445). The less severe osteopetrosis was associated with a slightly 
more developed ruffled border and improved osteoclast function in a pit assay (896) compared 
to cells from Clcn7-/-  mice (429). 
Lysosomal pH measurements in cells from WT, Clcn7-/- and Clnc7unc/unc cells and application of a 
proton ionophore indicated that lysosomes must have a sizeable cation conductance and that 
the luminal Cl- concentration in Clcn7unc/unc mice is lower than in WT lysosomes (896). In 
agreement with a large cation conductance, ATP driven lysosomal acidification was similar in all 
genotypes (896). A lower lysosomal Cl- concentration was directly confirmed using a ratiometric 
lysosomal targeted Cl- sensor, although the saturation of this sensor at high Cl concentrations 
required a preincubation of cells in Cl--depleted medium (896). 
Clearly, the physiological roles of endo/lysosomal CLC exchangers are far from being 
understood. The simple idea of a Cl- shunting conductance certainly does not hold true. Indeed, 
if ClC-7 were the only or rate-limiting pathway to shunt the H+ ATPase, its knock out would be 
expected to be embryonically lethal. Based on the combined results from the various mouse 
models, Jentsch and co-workers proposed the hypothesis that the major role of ClC-7 (and of 
other endo/lysosomal CLCs) is not to provide a shunting conductance for efficient acidification, 
but to exploit the pH gradient created by the H+ ATPase to increase the luminal Cl- 
concentration (383, 600, 800, 896). Surprisingly, lysosomal chloride concentrations were 
recently found to be reduced in C. elegans and mammalian cell models of several lysosomal 
storage diseases unrelated to primary defects in lysosomal Cl- transport (115), raising questions 
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about the underlying mechanism. It is not clear why a high Cl- concentration could be 
important. In principle, a chloride gradient across the lysosomal membrane could be used by 
(unknown) secondary active transporters. Furthermore, several degradative enzymes, like e.g. 
cathepsin C are directly regulated by Cl- (138).  The slower degradation in ClC-7-deficient PTCs 
(888) would be consistent with this hypothesis. However, the enlargement of lysosomal 
structures in PTCs was independent of endocytic cargo (888). Interestingly, the enlarged 
structures were enriched for the late endosomal marker lysobisphosphatidic acid (LBPA), raising  
the possibility of defective endosomal-lysosomal trafficking (888). A trafficking effect could also 
underlie the underdevelopment of the ruffled border in osteoclasts. However, it is unknown if 
luminal Cl- concentration affects endosomal-lysosomal trafficking. The Cl- concentration, and 
consequently also the membrane voltage, might affect fusion and fission of organelles, which 
have been proposed to be associate with the release of luminal Ca2+. In this respect, it is 
interesting to note that an endosomal Ca2+ channel has been reported  to be regulated by 
luminal Cl- (727). 
Additional, ion transport-independent roles for ClC-7/Ostm1 are suggested by the phenotype of 
a ClC-7 knock in mouse model in which the transport deficient “proton-glutamate” mutation 
had been introduced (895). The proton glutamate is essential for the shuttling of intracellular 
protons to the gating glutamate (9, 468) and its mutation to alanine or glutamine abolishes Cl- 
and H+ transport activity in ClC-7 (453) as it does in ClC-4 and ClC-5 (941). As expected for a 
non-functional mutant, the Clcn7td/td (transport deficient) knock in mice exhibited an 
osteopetrosis phenotype that was as severe as that of Clcn7-/- mice (895). Surprisingly however, 
fur color in an agouti background was not affected (895), suggesting that the relevant activity of 
ClC-7/Ostm1 in melanocytes was maintained. This led to the suggestion that ClC-7/Ostm1 might 
have functions beyond its transport activity, for example by directly interacting with other 
proteins. However, it cannot be fully excluded that some residual transport activity, not 
detectable in heterologous expression systems is maintained in the proton glutamate mutant 
(895), as is the case in the bacterial EcClC-1, which exhibits uncoupled Cl- transport (9).  
 
H. Pharmacology of ClC-7 
ClC-7 has been suggested as a target for the treatment of osteoporosis since its activity in 
osteoclasts is essential for bone resorption. Schaller et al. reported that the compound NS3736 
inhibits acidification in resorption compartments and osteoclastic resorption in vitro and 
prevented bone loss in a rat model of osteoporosis (741). Analogs of NS3736 have similar 
effects (406). However, it remains to be shown that these compounds act directly on ClC-7. 
Several classical Cl- channel blockers and inhibitors of ClC-K channels have been tested on the 
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open “gating glutamate” mutation E245A. However none of these compounds showed 




XIV. CLCs IN OTHER ORGANISMS 
CLCs have been studied in various model organisms like yeast, C. elegans, zebrafish (642), 
Drosophila (849) and plants (335). We will restrict the review on those organisms which have 
been investigated in more detail, i.e. yeast, C. elegans and Arabidopsis. 
A. Yeast 
The yeast (Saccaromyces cerevisae) genome encodes a single ScCLC also called Gef1p because it 
was identified as one of the genes underlying the GEF (glycerol/ethanol, Fe-requiring) 
phenotype (299), which is characterized by a loss of high affinity iron uptake, reduced 
resistance to toxic cations and sensitivity to alkaline pH (281, 282, 299, 760). Gef1p has been 
implicated in Cl- transport in a late secretory compartment where Cl- ions are needed for the 
maturation of the Fet3p multi-copper oxidase (163). A unique feature of this CLC protein is a 
proteolytic processing in the secretory pathway in the first extracellular loop (866). So far, 
Gef1p not be functionally expressed in heterologous systems. Based on the presence of the 
proton glutamate, Gef1 is probably an anion/H+ exchanger and not a channel.  Accordingly, the 
uncoupling mutation of the gating glutamate, E230A, could not complement the GEF 
phenotype and resulted in the acidification of the Gef1 containing compartment (81). 
Furthermore, the GEF phenotype can be easily complemented by CLC antiporter homologues 
such as ClC-6 (414) or the fish OmClC-3 and OmClC-5 (558), but not by ClC-0 (B. Schwappach, 
personal communication). However, ClC-2 was reported to rescue the GEF phenotype when 
overexpressed together with Kha1p (254), a putative yeast cation/H+-exchanger that co-
localized with ClC-2 in the same Golgi to prevacuolar compartments that normally express the 
yeast CLC protein. Interestingly, similar to the role of Gef1, mammalian ClC-4 has been 
implicated in cellular copper/iron transport (567, 879). However, it is unclear if the underlying 
mechanisms are similar and the effect of ClC-4 on liver copper metabolism have been 
questioned (see above). 
 
B. Plants  
Anion transport in plants is important for many physiological processes including nutrient 
uptake, salt stress, turgor/osmo regulation, stomatal opening, and in photosynthesis (for 
reviews see: (42, 165, 433, 965). The first plant CLC homologues have been identified in 
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Arabidopsis thaliana (335) and in Tobacco (498) and genome sequencing revealed their 
presence in all investigated plant species. Most information has been obtained for CLCs from 
the model flowering plant Arabidopsis and we will restrict the present review to these. The 
Arabidopsis genome encodes 7 members called AtClC-a through AtClC-g. They can be 
phylogenetically grouped into two classes (502): AtClC-a to -d and AtClC-g form one group, 
which is relatively closely related to the bacterial EcClC-1, whereas AtClC-e and -f have very low 
similarity with EcClC-1 or mammalian CLCs even in the key ion binding regions (502). Direct 
functional data are available only for AtClC-a and AtClC-b (see below) and most information has 
been obtained from knock out, GUS reporter and protein/RNA localization studies. None of the 
AtCLCs is expressed in the plasma membrane. AtClC-a, -b, -c, and -g are localized to the 
vacuolar (tonoplast) membrane (164, 584, 863, 893). AtCLC-d is found in the trans-Golgi 
network co-localizing with a V-type ATPase (864). Also AtClC-f is localized to the Golgi (527), 
and both Golgi localized isoforms are able to complement the yeast Gef1 phenotype (527, 864). 
AtClC-e is localized to thylakoid membranes in the chloroplast (527), where its absence affects 
the proton motive force (340). 
After the initial finding that the loss of AtClC-a function reduces the capacity to accumulate 
NO3- by 50% (283), in a landmark paper De Angeli et al. discovered that AtClC-a is a vacuolar 
2NO3-/1H+ antiporter using patch-clamp recordings on isolated vacuoles from WT and AtClC-a 
knock out plants (164). The preference for NO3- over Cl- was unprecedented for CLC proteins 
and was later pinpointed to the presence of a proline residue in the selectivity filter (60, 863, 
893, 966). Physiologically, AtClC-a is assumed to accumulate NO3- in vacuoles, exploiting the 
proton gradient (164, 165). More recently Wege et al. discovered that AtClC-a activity is 
regulated by the OST1 protein kinase via phosphorylation of Thr-38 in response to abscisic acid 
(ABA) stimulation and proposed that the transporter is also able to release NO3- from the 
vacuole in stomatal guard cells (892). Like AtClC-a, also the highly homologous AtClC-b carries a 
proline residue in the selectivity filter and is a vacuolar NO3-/H+ exchanger, as demonstrated by 
heterologous expression in Xenopus oocytes (863). However, knocking out AtClC-b had not 
detectable phenotype (863). Interestingly, Carpaneto et al. recently discovered that 
endogenous AtClC-a mediated vacuolar currents are inhibited by the low-abundance signaling 
lipid phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2), and that the inhibition resulted in 
enhanced vacuolar acidification (106). It will be interesting to identify the binding site of 
PI(3,5)P2 in AtClC-a and to find out if other CLC proteins are modulated by phosphoinositides. 
The other two vacuolar AtCLCs, AtClC-c and AtClC-g, which are ~ 60% homologous to each 
other, carry a serine residue in the selectivity filter and are  thus probably Cl-/H+ exchangers. 
Both AtClC-c and AtClC-g are involved in salt tolerance (400, 584) and AtClC-c is additionally 
important for stomatal opening (400). There are still many open questions regarding the 





C. Caenorhabditis elegans 
The nematode Caenorhabditis elegans is a widely used simple model organism which has a 
number of experimental advantages compared to more complex organisms (82). Its genome 
encodes 6 different CLCs, called CeClC-1 to -6 (755). CeClC-1 to -4 are similar to mammalian 
plasma membrane CLC channels, but no clear correspondences can be identified. CeClC-5 is 
distantly related to mammalian ClC-3 to -5, whereas CeClC-6 falls in the same class as human 
ClC-6 and ClC-7. The nematode has no homologue of the accessory proteins barttin, Ostm1 or 
GlialCAM. CeClC-4 shows a rather specific expression in the large H-shaped excretory cell, co-
expressing with CeClC-3, which has, however, a relatively broad expression in neurons, muscle 
and epithelia (755). Also CeClC-2 is broadly expressed in several neurons, intestinal cells and in 
vulval muscle (755). CeClC-5 is ubiquitously expressed (578), whereas CeClC-6 is predominantly 
neuronal (578), and appears to be specifically expressed in two GABAergic RME neurons (63). 
Functional electrophysiological data are available for CeClC-1,-2 and -3 (578, 755). All three 
isoforms exhibit strongly inwardly rectifying currents with some similarity to mammalian ClC-2 
when expressed in Xenopus oocytes or mammalian cell lines (578, 755). Very recently, CeClC-1 
has been reported to be permeable to HCO3- and to contribute to the pH homeostasis in 
amphid sheath glia (297). However, due to the extreme inward rectification of currents 
mediated by CeClC-1, reliable reversal potential measurements are difficult to obtain using 
standard IV pulse protocols, as employed by Grant et al.  (297). Specific tail current protocols 
with careful leak subtraction are necessary to accurately obtain reversal potential 
measurements from channels whose steady state open probability is very low in the voltage 
range of the expected reversal potential. 
The CeClC-3 channel has been studied in most detail. Two predominant splice variants, called 
CeClC-3a and CeClC-3b, have been described. They differ at their N-terminus and in the C-
terminus, mostly regarding the loop between CBS1 and CBS2, and the part downstream of 
CBS2, including the last residues of the CBS2 domain CBS2 (162, 185).  CeClC-3b exhibits simple 
inwardly rectifying currents similar to mammalian ClC-2, albeit with faster kinetics (578). Gating 
of the CeClC-3a splice variant is more complex with an additional gating process induced by 
“conditioning” pulses to positive voltages (185, 331, 755). Interestingly, exchanging parts of 
CBS2 between the two isoforms could interchange the gating phenotypes, suggesting that the 
differences reflect properties of the common gate (162).  
In general, C. elegans cells are difficult to assess with electrophysiological recording techniques. 
A notable exception are oocytes which can be released from the animals. Using this approach, 
Rutledge et al. discovered that C. elegans oocytes exhibit swelling activated inwardly rectifying 
Cl- currents carried by CeClC-3 (716). The physiological signal for channel activation is the 
induction of oocyte meiotic maturation and the current was proposed to modulate ovulatory 
contractions of gap junction–coupled gonadal sheath cells (716). Swelling-induced activation 
does not appear to be direct but rather mediated by the action of type CeCLC-7-α or -β 
phosphatases (717). The kinase underlying the corresponding phosphorylation was identified as 
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the GCK-3 kinase, a member of the Ste20 family of kinases that are involved in osmosensing in 
mammals (186). Denton et al. found that GCK-3 directly binds to the channel and that 
heterologous co-expression reduced currents (186). Regulation in vivo was shown by GCK-3 
knockdown (186). The specific sites phosphorylated by GCK-3 were identified as S742 and S747 
in the CBS1-CBS2 linker (235). The single mutants S742E and S747E were still regulated by 
volume and phosphorylation, whereas the double mutant was constitutively active (557). The 
CBS1-CBS2 linker is unstructured and the mechanism underlying the gating effects of 
phosphorylation / dephosphorylation was described as a “catch and fish” mechanism (816). The 
phosphorylation effects on external Zn2+-block described by Yamada et al. (925) are consistent 
with an involvement of the common gate in these regulatory processes, and in general 
agreement with the close apposition of the C-terminus with the membrane domain as seen in 
the CmClC crystal structure (242). In addition to the well-studied role of CeClC-3 in oocytes, 
Branicky et al. found that the channel modulates electrical activity of HSN neurons which 
control egg laying (80). 
In summary, while the role of CeClC-3b is relatively well understood in oocytes, in general the 
physiological roles of CLC proteins in C. elegans remain largely unexplored. 
 
XV. SUMMARY AND OUTLOOK 
The molecular identification of ClC-0 (393), the apparently ‘strange’ double-barreled channel 
form Torpedo electrical organ (905), led to the identification of a gene family of Cl- channels and 
Cl-/H+-exchangers with members in all phylae. Human genetic diseases and mouse models 
yielded many, and often very surprising, insights into their diverse physiological functions. 
Other model organisms such as yeast, C. elegans, and Arabidopis, revealed roles in other 
phylae. Structure-function analysis, first limited to biophysical analysis of mutants but now 
firmly based on several crystal and cryo-EM structures, revealed fascinating insights into the 
mechanism of ion transport that is strikingly different from those of Kv-related cation channels. 
The presence of anion channels and cation/anion exchangers within the same gene family is 
particularly intriguing.  
Although the field has come of age, we expect that exciting discoveries on the biological roles 
of CLC proteins will continue to be made, as suggested by the only recent discovery of 
activating CLCN2 mutations in primary aldosteronism (246, 747). Many physiological aspects 
remain enigmatic, in particular concerning the roles of CLC 2Cl-/H+-exchangers in the 
endosomal-lysosomal pathway, synaptic and possibly other types of vesicles. Key aspects of 
ther structure-function relationship remain poorly understood, as exemplified by the common 
gating of both ion translocation pathways, the roles of CBS domains, and the mechanism 
underlying the strong influence of amino-terminal residues on ClC-2 gating. Very little is known 
about the interaction between CLCs and their accessory subunits, including the interaction 
stoichiometry. Furthermore, the regulation of CLC proteins by post-translational modifications 
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needs to be ascertained and put on a more solid basis. Also, the functional properties of 
endo/lysosomal CLC exchangers have yet to be explored in their native endomembrane 
environment. Finally, CLC proteins remain interesting putative targets for pharmacological 
interventions in a variety of pathological conditions, but so far no useful high-affinity blockers 






We use the most widely accepted CLC nomenclature in this review. As a generic name, CLC with 
three capital letters are used, with individual proteins using lower case l (for Cl) and a dash to 
connect to the number or letter specifying the individual isoform, e.g. ClC-1 (as originally 
proposed by Steinmeyer et al. (807)). Species specifiers are added at the beginning, for example 
EcClC-1 for Escherichia coli (210, 335), AtClC-a for Arabidopsis thaliana (335), or hClC-1 and 
mClC-1 for the human and mouse ClC-1 channels. The corresponding human and mouse genes 
are e.g. CLCN1 and Clcn1, respectively, according to the genome nomenclature.  
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Figure 1.  
The family of mammalian CLCs and associated proteins.  In mammals, three homology 
branches can be identified (shown in dendrogram at left). Whereas members of the first branch 
function as plasma membrane voltage-gated anion channels like the Torpedo channel ClC-0 
(most closely related to ClC-1), proteins of the two other branches are rather 2Cl-/H+ 
exchangers that reside predominantly on endosomes and lysosomes. ClC-1 and the two ClC-K 
isoforms show highly specific tissue expression patterns, whereas ClC-2 and the vesicular Cl-/H+ 
exchangers (with the exception of ClC-6) are widely and probably even ubiquitously expressed 
across tissues. Both ClC-K isoforms and ClC-7 need specific auxiliary proteins (‘β-subunits’) for 
functional expression and protein stability (222, 445). ClC-2 can function without a β-subunit, 
but associates with the cell adhesion molecule GlialCAM in glia, which changes its localization, 
stability and biophysical properties (346, 395). These differential requirements for ancillary 
proteins are symbolized by ‘/’ and ‘±’, respectively. The main phenotypes of Clcn mouse models 
or human diseases caused by CLCN mutations are indicated. The loss of the common β-subunit 
barttin (65, 222), or the loss of both ClC-K isoforms (748), leads to a combination of severe renal 





Double-barreled CLC Cl- channels with independent pores. Panel A shows a recording of a 
single Torpedo Cl- channel incorporated into a lipid bilayer before the application of DIDS (upper 
trace) and after addition of 10 mM DIDS (lower traces). Note the grouping of openings in bursts 
during which two equally spaced conductance levels are visible, being caused by the opening of 
two independent pores. After DIDS addition, first one and later both pores stop opening, 
suggesting that both pores are physically distinct. Figure taken from (549). Panel B shows a 
recording of a single concatemeric channel composed of one subunit of ClC-0 and the other 
subunit of ClC-2. The observed conductance levels are fully consistent with the linear 
superposition of a larger ClC-0 and a smaller ClC-2 pore, demonstrating that pore properties are 








Structure and membrane topology of CmClC. Panels A and B show the crystal structure of 
CmClC (pdb entry 3ORG) in a lateral view in cartoon representation with the approximate 
position of the membrane indicated by brown lines. The view in panel B is rotated by ~90o with 
respect to that of panel A. The membrane embedded parts of the two subunits are shown in 
light blue and green, respectively. The intracellular CBS domains are colored in yellow (CBS1) 
and red (CBS2) in one of the subunits and in gray for the other subunit. Bound chloride ions are 
shown as pink spheres. Panel C, partially adapted from (210), illustrates the complex toplogy of 
the CLC structure with the α-helices (A-R) shown as cylinders. The two halves of the 
transmembrane part of each subunit are differently colored. Partial positive charges in Cl- ion 
binding regions are schematically shown in red.  
 
Figure 4. 
The Cl- transport pathway and Cl- binding sites. Key amino acids involved in gating and anion 
selectivity and pore-bound Cl- ions are shown for three different crystal structures that are 
assumed to represent different conformations during the transport cycle of CLC exchangers. A: 
WT EcClC-1 (pdb entry 1OTS); B: Mutant E148Q of EcClC-1 (pdb entry 1OTU); C: WT CmClC (pdb 
entry 3ORG). Positions of anion binding sites are indicated by dashed lines. The gating 
glutamate (and Q148 in B) is shown in red stick. The pore serine (S107 in EcClC-1) and the pore 
tyrosine (Y445 in EcClC-1) are shown in green stick. The external site is occupied by the side-
chain of the gating glutamate in A, and by a Cl- ion in B and C. The side-chain of the gating 




Different models of the transport cycle of CLC exchangers. In all three models the anion 
binding sites correspond to those illustrated in Fig. 4 with Cl- ions indicated as green spheres. 
The side chain of the gating glutamate, acting in all models as the external gate, is highlighted in 
red. The conserved tyrosine (Y445 in EcClC-1), suggested to play a role as internal gate (1, 47) is 
shown in violet in panel B and the proton glutamate is shown in orange in B (model in B 
adapted from (1, 47)).  The model in A was suggested by Feng and MacKinnon and incorporates 
only the external gating glutamate as a structural gating element (242). Here, the negatively 
charged side chain of the gating glutamate, EGate occupies Sext in state 1, which corresponds to 
the crystal structure of WT EcClC-1. In the clockwise direction, the first transport event is a 
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downward movement of the side chain of EGate from Sext to Scen, pushing the Cl- bound in Scen to 
Sint and the ion bound in Sint into the cytoplasm, followed by rapid binding of an extracellular Cl- 
ion into Sext (state 2). A proton arriving from the cytoplasm protonates EGate, neutralizing its 
electrical charge (state 3). The Cl- ion that previously occupied Sext has to leave again its binding 
site towards the outside to allowing the EGate side chain to reorient towards the outside (state 
4). Thus, in these first events, extracellular Cl- binding / unbinding does not correspond to net 
transport, but extracellular Cl- exerts a modulating function, controlling access of EGate to the 
outside. From state 4, binding of two extracellular Cl- ions results in state 5. Deprotonation of 
EGate and release of the proton to the outside results in a state that corresponds to the E148Q 
mutant of EcClC-1 (state 6), from which the transporter returns to state 1 by the downward 
movement of EGate accompanied by the release of a Cl- ion into the inside. All transitions are 
reversible and the transport cycle can be operated in the reverse order. In this model, states 4-
6 are conductive for Cl- ions, i.e. allow Cl- transport that is uncoupled from H+ movement. Panel 
B shows an alternative model proposed by Basilio et al. (1, 47), in which strict coupling is 
ensured by an additional intracellular gate formed (in part) by the conserved tyrosine residue 
(Y445 in EcClC-1), as suggested by various pieces of experimental evidence (see main text). 
Panel C shows a modified version of the kinetic model shown in A, which eliminates the 
modulatory Cl- binding/unbinding step by introducing a hypothetical transition during which the 
protonated side chain of EGste the Cl- ion bound in Sext swap their position and the side chain of 
the gating  glutamate EGate moves further out (state 4 in panel C). In models A and C, 
approximate 2:1 Cl- : H+ transport coupling is achieved by “kinetic” gating that ensures that the 
conductive states are short-lived (242). However, preliminary model simulations using the 
parameters employed by Feng and MacKinnon ((242), personal communication) show that at 
acidic pH values (<3) with the model shown in panel A the transporter becomes almost 
completely uncoupled, because the conductive states 4 and 5 are highly populated. This is in 
contrast to the experimental observation that EcClC-1 remains fully coupled for pH values as 
low as 3 (1, 3, 5). This behavior is partially remediated in the model shown in C, using similar 
parameters. The qualitative reason for this difference is that in model C the non-conductive 
state 3 is more highly populated at acidic pH and because of the different Cl- ion occupancy of 
the various states (unpublished result).   
 
Figure 6. 
Shift of ClC-1 voltage-dependence by dominant myotonia mutant I290M. A, typical voltage-
clamp traces from individual oocytes injected with RNA coding for WT ClC-1 (left), mutant 
I290M (right) or co-injected with these RNAs (middle) elicited with the voltage-clamp protocol 
shown in the inset (holding potential -100 mV). The co-injection mimics the genotype of a 
heterozygous patient. B, apparent open probability obtained from the normalized initial tail 
currents measured at the -80 mV tail pulse (WT: black; I290M: red; WT/I290M: pink) together 
with the fit of a Boltzmann distribution (black lines) from which the voltage of half-maximal 
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activation, V1/2, was obtained. The dashed line was obtained by the average of the Boltzmann 
fits of WT and mutant I290M, which is less steep than the Boltzmann fit obtained for the co-
injected oocyte, indicating that heteromeric WT/I290M channels gate with a dominantly shifted 
voltage-dependence. In particular, the Cl- conductance in the physiological (negative) voltage-
range is significantly reduced in the co-injected oocyte. C, shift of V1/2 induced by mutations of 
I290 by the indicated amino acids. Figure adapted from (679). 
 
Figure 7. 
CLCN2 gain-of-function mutations lead to primary aldosteronism. A, typical hyperpolarization-
activated currents of ClC-2 in the Xenopus oocyte expression system. Currents slowly activate 
upon hyperpolarization beyond approximately – 60 mV, leading to inward rectification of 
steady-state currents. B, currents from the G24D mutant identified in a patient with primary 
aldosteronism (246). It affects a residue in an amino-terminal ‘inactivation domain’ previously 
identified to be crucial for the activation of ClC-2 by hyperpolarization and cell swelling (303, 
399). It results in a large increase of ClC-2 currents that then almost totally lack voltage-
dependent gating. C, model for the mechanism by which activating CLCN2 mutations lead to 
hyperaldosteronism. In normal adrenal glomerulosa cells, binding of angiotensin II to its G-
protein coupled receptor leads to an increase of IP3 which releases Ca2+ from the ER, as well as 
to an inhibition of plasma membrane K+ channels that largely determine the resting potential of 
these cells (794). This inhibition leads to a depolarization, which opens voltage-dependent Ca2+ 
channels, leading to a further increase of cytosolic Ca2+. A rise in extracellular K+ concentration 
can also directly depolarize glomerulosa cells. The large chloride currents observed with 
activating CLCN2 mutations identified in patients with aldosteronism (246, 747) lead to 
constitutive depolarization of glomerulosa cells, Ca2+-influx, and increased aldosterone 
production by increased transcription of aldosterone synthase (red arrows). Figure panels 




Clustering of ClC-2 at cell junctions and change of rectification properties of ClC-2 currents by 
GlialCAM in heterologous expression systems. A, in transiently transfected HeLa cells, ClC-2 is 
diffusely localized to the plasma membrane. Upon co-expression of GlialCAM, the channel is 
localized at long (B) or short (C) cell contact processes, or in extensive contact regions (D) (see 
arrows). E, in the absence of GlialCAM, ClC-2 currents activate slowly at negative voltages (left) 






Function of ClC-K/barttin channels in the cochlea. A, model for K+ recycling in the inner ear. 
Activation of outer (green) and inner (red) sensory hair cells by sound opens ciliar 
mechanosensitive cation channels leading to hair cell depolarization via K+ influx driven by the 
high K+ concentration in the endolymph and the large voltage gradient between the endolymph 
and the hair cell cytoplasm (100 mV). The composition of the endolymph and the positive 
extracellular voltage are established by the stria vascularis, a highly vascularized epithelial layer  
composed of primarily three epithelial cell types (marginal, intermediate, and basal cells) 
(colored in blue). K+ released by hair cell at their basal end is shuttled to the stria via a system of 
gap junctions (884), taken up by marginal cells by the basolateral  Na+K+2Cl--cotransporter 
NKCC1 and extruded through apical KCNQ1/KCNE1 K+ channels into the endolymph. Chloride 
ions needed by the NKCC1 co-transporter are recycled by ClC-K1/Ka-barttin and ClCK-2/Kb-
barttin channels at the basolateral membrane. Panel B shows immunofluorescence labelling of 
stria vascularis sections from WT and inner ear-specific barttin knock out mice with antibodies 
against KCNQ1 (green), barttin (a, b, d, e; red) and ClC-K (c, f; red). It demonstrates the co-
localization of ClC-K with barttin in basolateral membranes of marginal cells, contrasting with 




Approximate subcellular distribution of CLC 2Cl-/H+-exchangers in the endosomal-lysosomal 
system. Vesicular CLCs are differentially localized on various endosomal and lyosomal 
compartments, where they are co-expressed with V-type H+-ATPases. The currents of these 
highly electrogenic CLC exchangers may help in the acidification of these compartments by 
neutralizing currents of the proton pumps, as has been shown for ClC-3 (325) and ClC-5 (308, 
600). However, no change in lysosomal pH is observed upon loss of ClC-7/Ostm1, probably 
owing to the presence of cation conductances in lysosomes (803). Proton-driven Cl- transport is 
predicted to increase vesicular Cl- concentration (383), as experimentally verified for ClC-7 using 
mouse models (896). The conversion of ClC-5 and ClC-7 into pure Cl- conductors by point 
mutations in knock in mice demonstrated that the exchange activity of vesicular CLC is 
biologically important (600, 896). This suggested that an increase of luminal Cl- concentration 
has an important, though unknown, function in endosomes and lysosomes. CLCs of early and 
recycling endosomes, such as ClC-5 and possibly ClC-4, might be found to a small extent also at 
the plasma membrane. However, their extreme outward rectification seems to exclude that 






Loss of hippocampus in Clcn3-/- mice. Nissl stained frontal sections of adult WT (A) and Clcn3-/- 
(B) mice illustrates the almost complete degeneration of the hippocampal formation caused by 
the lack of ClC-3. Figure taken from (810). 
 
Figure 12. 
Role of ClC-5 in proximal tubule endocytosis. A amounts of injected radioactive β2-
microglobulin lost in the urine (left) or retained in the kidney (right) in WT mice and male mice 
lacking ClC-5. B, C, audioradiographs of kidneys 7 mins after injection of radioactive β2-
microglobulin show that the small protein had accumulated in the cortex, which consist mostly 
of proximal tubules, in WT kidneys, but is found in deeper, probably pelvic regions in ClC-5- 
kidneys. D - F, endocytosis of fluorescently labeled β-lactoglobulin (in blue) is severely impaired 
in Clcn5- proximal tubules (E) compared to WT (D). In heterozygous Clcn5+/- females (F), which 
express normal ClC-5 levels in some cells and lack ClC-5 in others, display normal endocytosis in 
exactly those cells that do express ClC-5, as highlighted by antibody staining (panel G, red). 
Panel H shows reduced receptor mediated uptake of horseradish peroxidase only in some cells 
in a heterozygous Clcn5+/- female. Panels I and J illustrate that also fluid phase endocytosis of 
FITC-labeled dextran (I, red) is impaired only in ClC-5 lacking cells (ClC-5 stained in red in J) in a 
heterozygous Clcn5+/- female. Figure taken from (661).  
 
Figure 13. 
Storage material and axonal swelling in Clcn6-/- mice. A, B, autofluorescence, reflecting the 
presence of lysosomal storage material, in hippocampal sections reveals the accumulation of 
storage material in 3 months old Clcn6-/- mice (B) compared to WT littermates (A) and 
localization in the initial axon segment (arrow). C, Golgi staining shows proximal axonal swelling 
in cortical neurons from Clcn6-/- mice (6 months). D, electron microscopy picture showing 
similar swelling of a hippocampal axon because of material accumulation (arrow). The plasma 
membrane of the neuron is highlighted by a dashed line; n, nucleus. E, presence of lipofuscin-
like lipopigment associated with lipid droplets in a cortical neuron of a Clcn6-/- mouse. F, G, 
Presence of storage material in DRG axons ClC-6 knockout (G) but not in WT (F). Figure taken 








Localization and functional role of ClC-5 and ClC-7 in renal proximal tubules. Confocal light 
microscopical image of proximal tubules from a female Clcn5+/-;Clcn7lox/lox;ApoE-Cre mouse that 
had been injected intravenously 1 hour before fixation with fluorescently-labelled β-
lactoglobulin (red in right panel) to reveal the fate of proteins that pass the glomerular filter. 
Sections were stained with antibodies against ClC-7 and ClC-5 (green and blue, respectively, in 
right panel). Because ClC-5 is encoded on the X-chromosome, which shows random inactivation 
in females, some cells of the proximal tubule shown in the center express ClC-5, whereas others 
do not. The Clcn7 gene was also disrupted in a mosaic manner by using ‘floxed’ Clcn7lox/lox mice 
and ApoE-Cre mice which leads to incomplete, random Clcn7 disruption in proximal tubular 
cells (888). Hence, endocytosis and degradation of proteins can be compared side-by-side in the 
same tubule as a function of all combinations of expression of ClC-5 and ClC-7. One hour after 
injection of β-lactoglobulin, the protein is only seen in cells lacking ClC-7, highlighting its role in 
lysosomal protein degradation. At that time point, β-lactoglobulin has already been degraded in 
WT cells. Impairment of apical endocytosis by ClC-5 disruption (661) prevents its accumulation 
in cells lacking ClC-7.  Note that in proximal tubular cells early endosomal ClC-5 is located more 
apically than lysosomal ClC-7, consistent with the high rate of apical endocytosis in the cells. 
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